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ABSTRACT 
 
 
The  AS/AGU  rat  originated  as  a  recessive  mutation  (agu)  in  a  closed  colony  of 
Albino Swiss (AS) rats.  The mutation is in the gene coding for the gamma isoform of 
protein  kinase  C.  It  is  characterized  by  movement  impairments  and  progressive 
dysfunction of the nigrostriatal dopaminergic (DA) and raphe striatal serotonergic (5 
HT)  systems.  The  movement  impairments  including  rigidity  of  the  hind  limbs,  a 
staggering gait, a tendency to fall over every few steps, a slight whole body tremor 
and  difficulty  in  initiating  movements.  The  dysfunction  in  both  systems  is 
characterised by a failure to release DA or 5 HT within the striatum and cell loss 
within the substantia nigra pars compacta (dopaminergic cells) and the dorsal raphe 
nuclei (5 HT+ve cells). 
 
In this study, three experiments were carried out to examine the possible pathological 
responses of midbrain cell groups to the agu mutation in the gene coding for protein 
kinase C gamma (PKC γ). 
 
Experiment 1 was carried out to examine levels of two groups of molecules in the 
midbrain  cell  groups  using  quantitative  immunofluorescence  microscopy  of  cell 
bodies or their surrounding neuropil (a) those molecules giving information about the 
capacity  of  midbrain  aminergic  cell  bodies  to  synthesis  transmitters;  tyrosine 
hydroxylase  (TH)  in  the  dopaminergic  neurons  and  serotonin  (5 HT)  in  the 
serotonergic  neurons  (b)  those  which  have  been  found  to  occur  in  human 
neurodegenerative conditions such as Parkinson’s disease: ubiquitin, parkin and α 
synuclein (Lewy body proteins). Immunofluorescence levels of tyrosine hydroxylase 
(in dopaminergic cells of the SNC) and serotonin (in 5HT+ve cells of the dorsal raphe 
nuclei) were both significantly increased in AS/AGU (mutant) compared to the AS 
(control) rats aged 6 months and older. TH and 5 HT immunofluorescence levels were 
both significantly decreased in the striatum in the AS/AGU (mutant) compared to the 
AS  (control)  rat  aged  12  months.  Ubiquitin  immunofluorescence  show    a  gradual 
increase with age in AS and AS/AGU rats and the increase was much greater in the 
mutant  in  every  region  except  the  oculomotor  and  pontine  nuclei.    Parkin 
immunofluorescence show increases in the mutant within the SNC and  the dorsal 
raphe nucleus and this increase was significant at older ages. Alpha synuclein does 
not occur in the cell bodies of the substantia nigra or VTA but outside in the neuropil. 
Alpha synuclein immunofluorescence levels progressively increased with age in both 
strains  in  the  SN  and  VTA  and  were  higher  in  the  mutant.  The  levels  of  those 
molecules  (ubiquitin,  parkin  and  alpha synuclein)  do  not  differ  in  the  striatum  of 
mutants compared to controls. 
 
Experiment 2 examined SNC cell bodies to look for possible strain differences in cell 
size or ultrastructure or any sign of cell death using light and transmission electron 
microscopy. The diameter (maximum and minimum) of the SNC cells and nuclei 
were measured in toluidine blue paraffin wax and immunoperoxidase DAB staining 
for TH sections. Cell diameter was reduced in the AS/AGU mutant compared to the 
AS control. No obvious ultrastructural differences were seen in nigrostriatal neurons                                                                                                                             Abstract                
 
vi 
of  both  strains.  The  volume  fractions  of  mitochondria  and  rough  endoplasmic 
reticulum were significantly higher in the mutant. No Lewy bodies were present. 
 
Experiment 3 examined TH+ve nigrostriatal dopaminergic terminals in the dorsal 
caudate putamen to determine whether there are (a) differences in the percentages and 
numbers of TH+ve terminals and (b) differences in synaptic vesicles numbers. In 12 
month AS/AGU mutant, there are reduction in TH+ve terminals (40%) together with 
a reduction in vesicle numbers (40%) in such terminals where in 3 month AS/AGU 
mutant, the reduction in TH+ve terminals was more (50%) and a reduction in vesicles 
numbers by three quarters. TH ve terminals are also reduced in numbers in 12 months 
aged  AS/AGU  mutant  rats.  In  12 month  AS/AGU  rats,    there  were  significantly 
reduced numbers of synaptic terminals in the striatum compared to AS controls. This 
applied to both dopaminergic terminals (which make up 15% of the total) and to non 
dopaminergic terminals. In 3 month AS/AGU rats, there is a reduction in terminal 
numbers, but this is restricted to the dopaminergic terminals only: non dopaminergic 
ones are unaffected.                                                                                                                             Chapter1 
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              GENERAL INTRODUCTION 
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2 
1.1   Overview 
This study was designed to take advantage of a unique mutation in a population of 
Albino Swiss (AS) rats. The mutant AS/AGU rat has a stop codon in the gene for 
expression of protein kinase C gamma (Craig et al., 2001) which lead to disordered 
movement, a major loss in dopamine and serotonin release in the striatum and, with  
time, a loss of midbrain aminergic neurons (Campbell et al., 1997, 1998; Al Fayez et 
al., 2005). 
Many  aspect  of  human  conditions  such  as  Parkinson’s  disease  (PD)  can  not  be 
properly assessed until after the death of patient, and many Laboratory models of PD 
have  therefore  been  introduced  to  mimic  the  disorder.  However,  since  the 
neurological events leading up to symptomatic PD are unknown, these models rely on 
hypotheses  which  remain  unproven.  By  contrast,  the  AS/AGU  rat  is  a  naturally 
occurring model (Payne et al., 2000) which is under  examination.  
This study is designed to explore three aspects of the AS/AGU rat which have not 
been examined before: 
I.  Do midbrain neurons show changes in molecules which are elevated in human 
PD? 
II.  What are the morphological changes in the midbrain aminergic neurons in the 
mutant. Can these changes point to a particular pathology? 
III.  What changes occur in the synaptic terminals of these cells within the caudate 
putamen?      
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1.2  The Basal ganglia 
 
The term basal ganglia has no precise definition but, in general, the basal ganglia are a 
group of subcortical nuclei located bilaterally in the inferior cerebrum, diencephalon, 
and  midbrain.  They  appear  in  a  fifth  week  of  development  in  the  floor  of  the 
telencephalic vesicle (FitzGerald and FitzGerald, 1994; Carlson, 2004). The basal 
ganglia play a prominent role in the planning, initiation and execution of movement 
(Albin et al., 1989). 
The term basal ganglia is currently used to describe the large nuclear masses in the 
deep forebrain and midbrain that (a) share a similar motor function and (b) which are 
connected to the cerebral cortex and thalamus by various loops. These include the 
caudate, putamen,  globus pallidus, subthalamic nucleus, and substantia  nigra.  It is 
convenient to describe these components initially before discussing their functional 
circuitry.  
 
1.2.1  Compartmental organization of the  basal ganglia 
 
Two levels of compartmental organization have been deduced by using techniques 
such  as  retrograde  tracing,  histochemistry,  immunohistochemistry,  and 
histopharmacology. 
Striatal  patch matrix  systems  have  been  demonstrated  by  specific  neurochemical 
markers.  The  patch  compartment  is  defined  by  areas  of  dense    opiate  receptor 
binding (Herkenham and Pert, 1981), and by low expression of acetylcholinesterase 
(Butcher  and  Hodge,  1976).  Graybiel  and  Ragsdale  (1978)  was  used  the  term 
striosome to describe these areas of low cholinesterase activity. Five nucleotidase was Chapter 1                                                                                      General Introduction 
 
4 
also found to be an excellent marker for striosome in the rat (Schoen and Graybiel, 
1992).          
The striatal matrix compartment can be detected by positive staining for the calcium 
binding  protein  calbindin,  and  by  the  somatostatin  immunoreactive  positive  fibers 
(Gerfen and Baimbridge, 1985).  Patch matrix organization is mainly found in the 
caudate putamen, extending into the dorsolateral and ventromedial areas.   
In the rat, the compartmental organization of cortico striatal afferent was related to 
their lamina of origin rather than to their cortical areas of origin (Gerfen, 1989). 
The striatal medium spiny neurons can be arranged into separate populations to form 
patch and matrix compartments that have their  connections related to the laminae 
(Gerfen, 1989) and regional (Donoghue and Herkenham, 1986) organization of the 
cortex, and they can be also categorized by their projections to the globus pallidus, 
entopeduncular nucleus (EPN) and substantia nigra, with two type of neurons: the 
striatopallidal  neurons  within  the  globus  pallidus,  and  the  striatonigral  neurons 
extending to EPN and substantia nigra (Parent et al., 1984). 
Striatopallidal projections to many cholinergic and substance P expressing areas of 
the ventral pallidum arise mainly from patch areas, whereas matrix neurons tend to 
project mainly to the GABAergic enkephalin areas of the dorsal pallidum (globus 
pallidus) (Gerfen, 1992). 
In the rat both types of neurons project to the substantia nigra, patch neurons project 
to  the  dopaminergic  cells  in  the  SNC,  and  cell  islands  in  SNR,  whereas  matrix 
neurons project to areas containing GABAergic neurons in the SNR (Gerfen, 1984; 
1985). 
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1.2.2  Striatum 
 
The striatum or neostriatum is the largest component of the basal ganglia and the 
major receiving area (Parent, 1990). It receives a glutamatergic projections from the 
whole cerebral cortex (McGeorge and Faull, 1989), from the intralaminar nuclei of 
the thalamus (Berendse and Groenewegen, 1990), and from dopaminergic neuron 
from substantia nigra pars compacta (SNC). It receives smaller projections from the 
globus pallidus (GP), the subthalamic nucleus (STN), the serotonergic dorsal raphe 
nucleus and the pendunculopontine tegmental nucleus (PPN) (Parent, 1990). 
The striatum sends projections to the globus pallidus (GP) and substantia nigra pars 
reticulata (SNR) (Parent and Hazrati, 1995). 
The  striatum  generally  refers  to  both  the  putamen  and  caudate  nucleus  that  are 
separated by the internal capsule in primates but united in rodents. 
In man, the caudate nucleus is a large C shaped mass of gray matter that form the 
floor of the lateral ventricle, lies lateral to the thalamus, and lies medial to the internal 
capsule. It is divided into a head that is large, rounded and forms the lateral wall of the 
anterior  horn  of  the  lateral  ventricle,  and  a  body  and  tail  that  terminates  in  the 
amygdaloid nucleus.  
The  putamen  is  a  large,  dark  mass  of  gray  matter  and  both  putamen  and  globus 
pallidus called the lentiform nucleus. 
The striatum is composed of a large number of medium spiny projection neurons, 
which use γ amino butyric acid (GABA) as a neurotransmitter (Kita and Kitai, 1988; 
Parent  and  Hazrati,  1995a)  and  a  small  number  of  large  and  medium  sized 
interneurons (Wilson and Groves, 1980). 
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1.2.3  Globus pallidus 
 
The globus pallidus represents the principal efferent side of the basal ganglia. 
The  globus  pallidus  (GP)  can  be  subdivided  into  internal  (medial)  and  external 
(lateral) segments, separated by an internal lamina of myelinated fibers. The GP also 
contains  a  ventral  subcommissural  portion  termed  the  ventral  pallidum  (GPv) 
(Heimer et al., 1982). 
In  rodents,  the  entopeduncular  nucleus  (EPN)  represents  the  internal  segment  of 
globus  pallidus  (Morgan,  1927).  The  GP  receives  afferent  projections  from  the 
striatum and subthalamic nucleus and it sends efferent projections to the thalamus, 
subthalamic  nucleus,  SN  and  pedunculopontine  nucleus  (Parent  and  Hazrati, 
1995b). The principal neurons of GP are large cells with long, thick and generally 
smooth  dendrites    (Fox  et  al.,  1974;  DiFiglia  et  al.,  1982)  and  they  use  γ 
aminobutyric acid (GABA) as a neurotransmitter (Oertel and Mugnaini, 1984). 
 
1.2.4  Substantia nigra 
 
The  substantia  nigra  (SN)  is  a  layer  of  grey  matter  containing  numerous,  deeply 
pigmented, multipolar nerve cells and extending throughout the whole length of the 
midbrain, (i.e from the rostral end of the pons to the subthalamic region) and it is 
considered part of the basal ganglia due to its close ties with the striatum. In sections 
of the midbrain in human, it is easily recognized by the black pigment from which its 
name derives. It is semilunar on transverse section; its concave surface being directed 
toward the tegmentum  and its convex surface  direct toward the  crus  cerebri; it is 
thicker medially than laterally. Chapter 1                                                                                      General Introduction 
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Classically, the SN has been divided into (a) a dorsal pars compacta (SNC) composed 
of numerous medium sized dopaminergic neurons (A9), containing large amounts of 
melanin  pigament–with  a  few  non dopaminergic  neurons;  and  (b)  a  ventral  pars 
reticulata (SNR) composed of fewer neurons, some of which are also dopaminergic 
and contain small amount of melanin pigament (Fallon and Loughlin, 1995), though 
the majority are GABAergic neurons (Oertel and Mugnaini, 1984; Parent, 1990). 
 A lateral extension of the SNC is called the pars lateralis (SNL). It is insignificant in 
man (Huber and Crosby, 1933) and has a variety of  neurons, some of which are 
dopaminergic (Fallon and Loughlin, 1995).  
The SN has extensive connections with the cortex, spinal cord, hypothalamus, and 
basal ganglia (Table 1.1). Medial to the substantia nigra is the ventral tegmental area 
(VTA)  composed  of  dopaminergic  neurons  (A10)  and  non   dopaminergic  neurons 
(Fallon and Loughlin, 1985;1995): their terminations are shown in Table 1.1. 
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  INPUT  OUTPUT 
SNC   ● Striatum (GABAergic) (human, 
primate,  rat) 
 
● Globus pallidus  (GABAergic) 
(human, primate,  rat) 
 
● SNR (GABAergic) (rat) 
 
● Cerebral cortex (glutamatergic) 
(human, primate,  rat)  
 
● Subthalamic nucleus (glutamatergic) 
(human, primate,  rat) 
 
● Pedunculopontine nucleus 
(glutamatergic and Cholinergic) (human, 
primate,  rat)  
 
● Dorsal raphe (serotonergic) (human, 
primate,  rat) 
 
● Striatum  (A9 dopaminergic) (mainly) 
(human, primate,  rat) 
 
● Subthalamic nucleus  (A9) (sparse) 
((human, primate,  rat) 
 
● Globus pallidus  (A9) (sparse) 
(human, primate,  rat) 
 
● Amygdala (dopaminergic) (a few) 
(human, primate,  rat)  
 
● Cerebral cortex (dopaminergic) 
(a few) (rat) 
 
● Striatum (GABAergic) (a few) (rat) 
 
SNR   ● Striatum (GABAergic) (human, 
primate,  rat) 
 
● Globus pallidus (GABAergic) (rat) 
 
● Accumbens nucleus (GABAergic) 
(rat) 
 
● Ventral pallidum (GABAergic) (rat) 
 
● Subthalamic nucleus (glutamatergic) 
(rat) 
 
● Cerebral cortex (glutamatergic) (rat) 
 
● Amygdala (rat) 
 
● Striatum (A9 dopaminergic) (a few) 
(rat) 
 
● VA VL thalamus (GABAergic) 
(human, primate,  rat) 
 
● Superior colliculus (GABAergic) 
(human, primate,  rat) 
 
● Pedunculopontine nucleus 
(GABAergic) (human, primate,  rat) 
 
 
SNL   ● Amygdala (rat)  ● Striatum (A9 dopaminergic) (a few) 
(rat) 
 
● Amygdala (dopaminergic) (rat) 
 
● Inferior colliculus (non dopaminergic 
(rat) 
 
 
 
VTA  ● Accumbens nucleus (GABAergic) 
(rat) 
 
● Locus coeruleus (noradrenergic) (rat) 
 
● Dorsal raphe (serotonergic) ((human, 
primate,  rat) 
 
 
● Ventral striatum (A10 dopaminergic) 
((human, primate,  rat) 
 
● Amygdala (A10) (human, primate,  
rat) 
 
● Cerebral cortex (A10) (rat) 
 
● Visual cortex  (non dopaminergic) 
(rat) 
 
● Pedunculopontine nucleus (non 
dopaminergic) (rat) 
 
 
Table 1.1 : Inputs and outputs connections of the substantia nigra 
(SN) and the ventral tegmental area (VTA). (from Fallon and Loughlin, 
1985;1995; Flaherty and Graybiel, 1994; Blandini et al., 2000). 
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1.2.5  The subthalamic nucleus 
 
The subthalamic nucleus (STN) is a small, densely populated and highly vascularized 
structure located dorsomedial to the junction between the crus cerebri and the internal 
capsule, ventral to the thalamus. The STN receives projections from both the frontal 
cortex and GPe and sends projections back to GPe and GPi. 
The STN consists of a multitude of medium sized and densely packed neurons with 
long, sparsely spiny dendrites radiating from the cell body (Chang et al., 1983; Kita 
et al., 1983). The subthalamic nucleus is the only glutamatergic nucleus of the basal 
ganglia circuit (Smith and Parent, 1988) and most of their neurons are projection 
neurons (Van der Kooy and Hattori, 1980a). 
 
1.3  Basal ganglia circuitry (See figure 1.1) 
 
Early studies using autoradiography suggested that cortical afferents arising from the 
somatomotor  cortex  preferentially  innervate  the  putamen  (Kunzle,  1977),  while 
association  cortex  afferents  innervate  the  caudate  nucleus  (Goldman  and  Nauta, 
1977).  Different  areas  of  cerebral  cortex  reach  the  striatum  by  excitatory 
glutamatergic projection (Young et al., 1981). The subthalamic nucleus is the only 
other structure in the basal ganglia receiving direct afferents from the premotor and 
motor cortices (Afsharpour, 1985; Stanton et al., 1988). The basal ganglia are not 
isolated structures but form part of neural circuits organized in parallel called cortico 
striato thalamo cortical loops. Five such loops have been described (Alexander and 
Crutcher., 1990). 
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Figure 1.1  Basal ganglia circuitry in normal people, showing the direct 
and  indirect  pathways  of  basal  ganglia.  Excitatory  projections  are  shown  in  green; 
inhibitory projections are shown blue; dopaminergic nigrostriatal projections are shown 
red. (CM/PF: centromedian/farafasicular nucleus of thalamus; D1: dopamine receptor 
1;  D2:  dopamine  receptor  2;  DA:  dopamine;  Enk:  enkephalin;  GABA:  gamma 
aminobutyric acid; GLU: glutamate; Gpe: external segment of globus pallidus; Gpi: 
internal  segment  of  globus  pallidus;  SNC:  substantia  nigra  pars  compacta;  SNR: 
substantia  nigra  pars  reticulata;  STN:  subthalamic  nucleus;  SP:  substance  P;  VL: 
ventrolateral  thalamus)  (Partially  adapted  from  Alexander  and  Crutcher,  1990; 
Blandini et al., 2000). 
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1.3.1 Motor circuit or loop 
The motor circuit is the loop most related to general movement. In the motor circuit 
information is somatotopically organized into distinct zones representing the leg, face 
and arm (Kunzle, 1975; Crutcher and DeLong, 1984; Alexander and DeLong, 
1985). The premotor cortex, the supplementary motor area and the somatosensory 
cortex all send excitatory information to the putamen (Kunzle, 1977; Selemon and 
Goldman Rakic,  1985),  which  projects  topographically  to  specific  areas  of  the 
internal  and  external  segment  of  globus  pallidus  and  the  substantia  nigra  pars 
reticulata  (Johnson  and  Rosvold,  1971;  Parent  et  al.,  1984).  Topographic 
projections  reach  thalamic  nuclei  including  nucleus  ventralis  lateralis  pars  oralis, 
lateral nucleus ventralis anterior pars parvocellularis, lateral nucleus ventralis anterior 
pars magnocellularis and the centromedian nucleus (DeVito and Anderson 1982; 
Kinsky et al., 1985). The motor loop ends with thalamo cortical projections to the 
premotor  and  the  supplementary  motor  cortical  area  (Wiesendanger  and 
Wiesendanger, 1985; Matelli et al., 1989). There are two main pathways through the 
basal ganglia.  
a)  The direct pathway is an inhibitory efferent pathway which projects from 
the striatum to the output nuclei (the internal segment of globus pallidus and 
the  substantia  nigra  pars  reticulata).  The  direct  pathway  contains  GABA, 
substance P (Albin et al., 1989), and dynorphin (Vincent et al., 1982) and 
expressed D1 dopamine receptors.  
b)   The indirect pathway projects from the striatum to the external segment of 
the globus pallidus; this in turn projects to the subthalamic nucleus through 
purely GABAergic neurons (Albin et al., 1989; Hamani et al., 2004) and Chapter 1                                                                                      General Introduction 
 
12 
from  the  subthalamic  nucleus  to  the  output  nuclei  through  an  excitatory 
glutamatergic projection (Nakanishi et al., 1987; Smith and Parent, 1988). 
The direct and indirect pathways have opposite effects on the output nuclei (Their 
connections  to  the  thalamus)  via  an  inhibitory  GABAergic pathway  (Penney  and 
Young, 1981; Chevalier et al., 1985) (Figure 1.1).                
 
 
1.4 Extrinsic monoaminergic system   
 
Monoaminergic pathways which originate in the midbrain project rostrally and make 
contact with key components of basal ganglia loops or circuits. Even though they are 
not  part  of  the  loop,  they  may  exert  a  considerable  effect  on  its  activity  and 
disturbances in their input underlie common motor disorders.        
 
1.4.1 Dopamine 
Dopamine (DA) is a member of the catecholamine family and was found in the brain 
in 1959. It has many functions around the body but has an especially important role as 
a neurotransmitter in the brain. 
The  existence  of  dopaminergic  innervation  within  the  brain  was  suggested  by 
biochemical studies (Thierry et al., 1973 a,b) and confirmed by anatomical work 
utilizing  glyoxylic acid induced histofluorescence (Lindvall and Bjorklund, 1974 
a,b), histofluorescence in combination with tract tracing (Tork and Turner, 1981), 
autoradiography  (Descarries  et  al.,  1987),  immunohistochemistry  against  the 
synthesizing  enzyme  tyrosine  hydroxylase  (TH)  (Berger  et  al.,  1985)  and Chapter 1                                                                                      General Introduction 
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immunohistochemistry  with  antibodies  against  dopamine  (DA);  the  problem  of 
distinguishing between DA and NA in these studies is acknowledged (Papadopoulos 
et al., 1989).  
The amino acid tyrosine is the starting point for dopamine synthesis. It is converted 
into dihydroxyphenyalanine (dopa) by the rate limiting enzyme tyrosine hydroxylase, 
after which dopa can be converted to dopamine by the enzyme dopa decarboxylase. 
Dopamine  synthesis  is  modulated  by  the  end  product  inhibition  of  tyrosine 
hydroxylase  (TH)  through  negative  feedback;  in  addition,  depolarization  of 
dopaminergic cells results in TH activation, thus maintaing the balance between DA 
synthesis and release (Joh et al., 1978) (Figure 1.2). 
Dopamine  can  be  taken  back  up  into  presynaptic  terminals  via  the  dopamine 
transporter (Hitri et al 1994), or catabolized by monoamine oxidase (MAO) to 3,4, 
dihydroxyphenylacetic  acid  or  to  3 methoxytyramine  by  Catechol O 
methyltransferase (COMT). 
 Dopamine receptors can be divided into five subtypes (D1 to D5) all of which belong 
to the G protein coupled type (for review, see Wolfarth and Ossowska, (1995). 
 The  vast  majority  of  all  the  brain  dopamine  (some  80%)  is  found  in  the  corpus 
striatum (Coyle and Snyder, 1981). 
The midbrain dopaminergic neurons form three groups of cells A8, A9, and A10 and 
three major dopaminergic pathways arise from them.  This classification groups the 
cells according to the transmitter (class “A”  cells contain dopamine or norepinephrine 
while class “B” contain serotonin) while numbers (e.g. 8,9,10) represent regions: thus, 
A9 is a group of cells containing dopamine in the SNC (Dahlstrom and Fuxe, 1964). 
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Figure 1.2  Biosynthetic pathway of catecholamine synthesis.  The 
enzymes  needed  for  this  pathway  are  shown  in  yellow  rectangles.  The 
feedback  regulation  by  the  end  product  on  TH  is  shown  in  red.  (TH 
requires cofactors  pteridine or tetrahydrobiopterin (BH4) and molecular 
oxygen and Fe
+2) partially adapted from Kumer and Vrana (1996).    
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The A9 cell group in the SNC, the A8 cell group in the retrorubral region, and the 
A10 cell group in the medial region of the ventral tegmental area are the main sources 
of dopamine for the ventral striatum, cerebral cortex and limbic system although these  
regions also receive some connections from the medial SNC (Fallon and Loughlin, 
1995). 
The  most  important  dopaminergic pathways  are  the  nigrostriatal,  mesolimbic,  and 
mesocortical pathways. These all originate from the dopaminergic cells (A9, A8, and 
A10) so, neurons of the A9 and A8 groups supply the nigrostriatal system whereas 
A10 supplies the mesolimbic and mesocortical systems (Prensa and Parent, 2001) 
(see Table 1.2). 
 
Cell groups  Regions  Pathways  Targets 
A8  Retrorubral field (RRF)  Mesostriatal 
Mesolimbic 
Caudate putamen (human, 
primate, rat) 
 
Amygdala (human, primate,  rat) 
 
A9  SNC ventral tier 
(lateral) 
Nigrostriatal  Caudal  putamen  (striosome) 
(human) 
A9  SNC ventral tier 
(medial) 
 
Nigrostriatal  Dorsal  caudate  nucleus 
(human) 
A9  SNC dorsal tier 
 
Nigrostriatal  Rostral putamen (human) 
Caudate  nucleus  (matrix) 
(human) 
 
A9  SNR  Nigrostriatal  Caudate putamen (human, 
primate,  rat) 
 
A9  SNL  Nigrostriatal 
Mesolimbic 
Caudate putamen (rat) 
Amygdala (rat) 
A10  VTA  Mesolimbic 
Mesocortical 
Ventral striatum (human, 
primate,  rat) 
 
Amygdala (human, primate,  rat) 
 
Prefrontal/Anterior  cingulate 
cortices (rat) 
Table  1.2:  Dopaminergic  cell  groups  in  the  midbrain  and  their 
targets.  (from  Dahlstrom  and  Fuxe,  1964;  Fallon  and  Loughlin,  1985;1995; 
Gibb and Lees, 1994; Prensa and Parent, 2001). Chapter 1                                                                                      General Introduction 
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1.4.2  Dopamine interactions 
Dopamine interacts with many other neurotransmitters in the basal ganglia circuitry. 
In particular, the interaction of dopamine with glutamate has an important excitatory 
effect on the neostriatum (Shimizu et al., 1990; Garcia Munoz et al., 1991) from the 
converging of glutamatergic and dopaminergic afferents onto the same striatal GABA 
neuron (Bouyer et al., 1984).  Changes in dopamine and other transmitters during cell 
stress  may  be  due  to  a  global  response,  or  may  signal  a  true  interaction.  Thus, 
ischemia and hypoxia have been found to produce an increase in the concentration of 
dopamine, glutamate and aspartate in the neostriatum of rat (Globus et al., 1988; 
Damsma  et  al.,  1990;  Akiyama  et  al.,  1991),  while  dopamine  depletion  and 
glutamatergic receptor blockade have both been shown to attenuate neuronal death 
following hypoxic and ischemic injury (Weinberger et al., 1985; Gill et al., 1987; 
Clemens and Phebus, 1988). Conversely, increasing dopamine concentration may 
lead to the release of glutamate and aspartate as a toxic cascade (Barbeito et al., 
1989; Carlsson and Carlsson, 1990), while the inhibitory amino acid GABA and 
taurine are thought to exert a protective role during a hypoxic and ischemic insult 
(Sternau et al., 1989).    
There  are  also  important  interactions  between  acetylcholine  and  dopamine.  The 
striatum has very high expression of acetylcholine receptors and enzymes needed for 
the synthesis or metabolism of acetylcholine such as Choline acetyltransferase and 
acetylcholinesterase within pedunculopontine afferents and cholinergic interneurons 
in  the  striatum.  In  normal  conditions  there  is  a balance between  the  inhibition  of 
acetylcholine  release  by  dopamine  receptor  D2  and  excitation  of  it  by  dopamine 
receptor D1 (Jabbari and Pazdan, 2005). Chapter 1                                                                                      General Introduction 
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A further important  interaction is between DA and 5 HT. There are projections from 
the serotonergic dorsal raphe nucleus to dopaminergic (DA) cell bodies and dendrites 
in  the  substantia  nigra,  ventral  tegmental  area  and  striatum  (Van  der  Kooy  and 
Hattori, 1980b; Steinbusch et al., 1981; Herve et al., 1987; Nedergaard et al., 
1988;  Corvaja  et  al.,  1993).    Moreover,  dopamine  from  the  SN  and  VTA  may 
increase 5 HT release in the DRN (Ferre and Arigas, 1993). Other studies show that 
dopamine release is facilitated by serotonin (Benloucif and Galloway, 1991) and the 
regulation of serotonin in the DRN is mediated by dopamine D2 receptor (Ferre et 
al., 1994).     
 
1.4.3  Serotonin 
The midbrain raphe nuclei came to attention in the time of Cajal who described the 
cells in that area as large multipolar neurons with uncertain projections. 5 HT was 
considered  as  a  CNS  neurotransmitter  when  it  found  in  significant  but  varying 
quantities in different regions of brain. 5 HT cell bodies and their axon terminals have 
been  visualized  by  different  methods  including  autoradiography  using  light 
microscopy (Conrad et al., 1974; Bobillier et al., 1976; 1979; Azmitia and Segal, 
1978;  Moore  et  al.,  1978),  electron  microscopy  (Aghajanian  and  Bloom,  1967; 
Descarries  et  al.,  1990),  histochemistry  (Ungerstedt,  1971)  or 
immunohistochemistry with antibodies against 5 HT (Steinbusch et al., 1978; Lidov 
et al., 1980; Lidov and Molliver, 1982a,b). 
The 5 HT cell bodies in the brain are located in the raphe nuclei groups in the brain 
stem (Morgan et al., 1987; Jacobs and Azmitia, 1992; Chojnacka Wojcik, 1995). 
The  areas  are  classified  into  nine  regions  (B1 B9)  (Dahlstrom  and  Fuxe,  1964; Chapter 1                                                                                      General Introduction 
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Steinbusch, 1981; Tork, 1990). Serotonin receptors are currently classified into 7 
types (5HT1 5HT7) (Boess and Martin, 1994; Wesolowska, 2002). Some of these 
project to the striatum e.g. dorsal raphe nucleus (see Table 1.3) (Steinbusch et al., 
1981; Vertes, 1991).  
 
Midbrain raphe nuclei  Cell groups  Targets 
 
Dorsal raphe nucleus 
 
B6 and B7 
       ● Striatum 
       ● Amygdala 
       ● Locus coeruleus 
 
 
Median raphe nucleus 
 
B5 and B8 
       ● Hippocampus 
      ● Anterior hypothalamus 
 ● Mammillary bodies 
 
Table 1.3: Serotonergic cell groups in the midbrain raphe nuclei and 
their targets. (from Dahlstrom and Fuxe, 1964; Azmitia and Segal, 1978; Imai 
et al., 1986; Jacobs and Azmitia, 1992; McQuade and Sharp, 1997). 
1.5  Neuropathology of neurodegenerative diseases 
Neurodegenerative  diseases  are  characterized  by  the  slowly  progressive  loss  of 
neurological function without obvious causes such as infection, neoplasms, localized 
vascular  disease  or  toxicity  (Maimone  et  al.,  2001;  Bossy Wetzel  et  al.,  2004). 
Neurodegenerative diseases usually affect older age groups, although the young may 
be affected. Many neurodegenerative diseases are sporadic and a few are inherited. 
The specific clinical characteristics of any particular neurodegenerative disease can 
stem from the anatomical location of the affected region and the pathological changes 
occurring.  Two major classes of neurodegenerative disorder based on biochemical 
and structural abnormalities in certain molecules such as tau or α synuclein and are  
known  as  tauopathies  and  synucleinopathies.  Tau  is  a  microtubule associated 
protein  which  plays  an  important  role  in  microtubule  assembly  and  stabilization 
(Weingarten et al., 1975; Cleveland et al., 1977) and it has six different isoforms Chapter 1                                                                                      General Introduction 
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(Buee et al., 2000; Shahani and Brandt, 2002). Deposition of hyperphosphorylated 
tau is a characteristic feature of neurofibrillary tangles found in Alzheimer’s disease 
(Alonso et al., 2001; Geschwind, 2003; Klucken et al., 2003). 
Filamentous  tau  pathology  is  also  characteristic  of  other  disorders  such  as  Pick’s 
disease,  Progressive  Supranuclear  palsy,  Corticobasal  degeneration,  familial  front 
temporal  dementia  and  Parkinsonism  linked  to  chromosome  17  (FTDP 17) 
(Spilliantini  and  Goedert,  1998).  Synucleinopathies  are  a  group  of  disorders 
characterised  by  α synuclein  lesions  including  Parkinson’s  disease,  Alzheimer’s 
disease,  dementia  with  Lewy  bodies,  MSA,  Down  syndrome,  Hallervorden Spatz 
disease and Prion disease (Trojanowski and Lee, 1999).  
1.5.1 Abnormal protein aggregation and neurodegenerative diseases 
Normal cellular functions may lead to the production of significant levels of abnormal 
(e.g.  misfolded)  proteins  (Sherman  and  Goldberg,  2001;  Goldberg,  2003; 
McNaught  and  Olanow,  2006).  Furthermore,  within  neurons,  auto oxidation  of 
neurotransmitters  such  as  dopamine  can  produce  free  radicals  that  can  damage 
proteins (McNaught and Olanow, 2006). Abnormal protein aggregations interfere 
with  intracellular  processes  and  are  frequently  associated  with  neurodegenerative 
diseases such as Alzheimer’s and Parkinson’s diseases (Agorogiannis et al., 2004; 
McNaught and Olanow, 2006). A wide variety proteins implicated in the pathology 
of neurodegenerative diseases and aggregated in inclusions are shown in table 1.4. 
The aggregations known as Lewy bodies contain may proteins, including α synuclein 
(Zhou et al., 2004) (See table 1.4).    
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Protein  Function  Disease genes  Protein deposits  Disease 
14 3 3  Chaperone like function  Associate with α–Syn 
(10) 
 α–Synuclein  inclusion  α   Synucleinopathies 
Aβ β β β (2)  Unknown  APP, Presenilin1.2 
(8) 
Associate with AS 
and LB (10) 
Extracellular plaques  AD 
Ataxin1  Unknown  CAG repeat 
expansion (8) 
Inclusion  Spinocerebellar ataxia 
type1 
Androgen 
receptor 
Allow body respond to 
androgens 
CAG repeat 
expansion (8) 
Inclusion  Spinal and bulbar 
muscular atrophy 
Atrophin 1  Unknown  CAG repeat 
expansion (8) 
Inclusion  Dentatorubral 
pallidoluysian 
Bc12 antagonist 
of cell death 
(BAD) 
Regulate cell death  Associate with  α–
Syn (10) 
α–Synuclein  inclusion  α  Synucleinopathies 
Calmodulin 
(CaM) 
Calcium binding protein  Associate with α–Syn  
(10) 
α–Synuclein  inclusion  α  Synucleinopathies 
Calcium/Calmod
ulin dependent 
protein kinase 
Modulated the cellular 
response to calcium 
Associate with LB 
(10) 
LB  PD 
Clusterin/apolipo
 protein J (6) 
Cell aggregating factor  Associate with LB 
(10) 
LB  AD 
Copper/ zinc 
SOD 
Scavenging free radicals  Associate with LB 
(10) 
LB  PD 
Cytochrome 
oxidase 
Respiratory chains 
enzyme 
Associate with α–Syn 
(10) 
α–Synuclein  inclusion  α  Synucleinopathies 
Cdk5 (4)  Phosphorylation a 
molecular component of 
LB 
Associate with LB 
(10) 
LB  AD 
DJ 1 (3)  Involved in oxidative 
stress response 
PARK7  LB  FPD (autosomal 
recessive) 
Plasma 
membrane 
dopamine 
transporter 
(DAT) 
Terminating dopamine 
by reuptake it into 
presynaptic neurons 
Associate with α–Syn 
(10) 
 α–Synuclein  inclusion  α  Synucleinopathies 
Extracellular 
signal regulated 
protein kinases 
(ERKs) 
Involve in many cellular 
function 
Associate with α–Syn 
(10) 
α–Synuclein  inclusion  α  Synucleinopathies 
Non selenium 
glutathione 
peroxidase 
Antioxidant  enzyme  Associate with LB 
(10) 
LB  PD 
Heme oxygenise  Cellular stress protein  Associate with LB 
(10) 
LB  PD 
Heat shock 
proteins 
Chaperone like function  Both (α–Syn +LB) 
(10) 
LB+ α–Syn  inclusion  α  Synucleinopathies 
Huntingtin   Unknown  CAG repeat 
expansion (8) 
Huntington inclusion  Huntington disease 
LRRK2  Unknown  PARK8  LB  FPD (autosomal 
dominant) 
Lysosomes 
associate proteins 
Markers of lysosomes  Associate with LB 
(10) 
LB  PD 
Microtubule 
associated 
protein 1 
(MAP1A, B) 
α α α α SN binding proteins  Associate with  α–
Syn (10) 
α–Synuclein  inclusion  α  Synucleinopathies 
Microtubule 
associated 
protein 2(MAP2) 
Stabilize microtubule 
assembly 
Associate with LB 
(10) 
LB  PD 
Mitogen 
activated protein 
kinases (MARKs) 
Stress response, 
Receptor signalling 
activity 
Both (α–Syn +LB) 
(10) 
LB+ α–Syn  inclusion  α  Synucleinopathies 
Myotonin kinase  Unknown  CAG repeat 
expansion (8) 
Inclusion  Myotonic Dystrophy 
Neurofilaments  Cytoskeleton of neuron   Associate with LB 
(10) 
LB  PD 
P62  Ubiquitin binding 
protein 
Both (α–Syn +LB) 
(10) 
LB+ α–Syn  inclusion  α  Synucleinopathies 
 
 
Parkin 
 
 
Enzyme E3 ligase in UPS 
  
 
PARK2 
 
 
LB+ α–Syn  inclusion 
No LB 
 
PD 
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Protein kinase C 
isoforms 
Receptor signalling 
activity 
Associate with  α–
Syn (10) 
α–Synuclein  inclusion  α  Synucleinopathies 
Prion protein 
(PrP) 
Unknown  Mutation in PrP (8)  Prion plaque  Prion disease 
Phospholipase D2  Enzyme involve in 
phosphatidic acid 
Associate with  α–
Syn (10) 
α–Synuclein  inclusion  α  Synucleinopathies 
Proteasome 
subunits 
Proteasome possess the 
proteolytic site and 
stabilized the 
proteasome complex  
Associate with LB 
(10) 
LB  PD 
Rab5A  Neuronal endocytosis  Associate with α–Syn 
(10) 
 α–Synuclein  inclusion  α  Synucleinopathies 
Septin  Involve in cytokinesis 
and exocytosis 
Associate with LB 
(10) 
LB  PD 
Superoxide 
dismutase 
1(SOD1) 
Enzyme calayzes the 
conversion of toxic 
superoxide radicals to 
hydrogen peroxide and 
O2 
Mutation in SOD1 
(8) 
Bunina bodies  Familial amyotrophic 
lateral sclerosis 
Synphilin 1 (9)  α α α α SN binding proteins  Both(α–Syn +LB) 
(10) 
LB+ α–Syn  inclusion  α  Synucleinopathies 
TAT binding 
protein1 (5) 
Proteosome activator  Associate with  α–
Syn (10) 
 α–Synuclein  inclusion  α  Synucleinopathies 
Tau  Microtubule associated 
protein that stabilize 
neuronal microtubules 
Tau gene mutation  
Associate with α–Syn 
(10)  
Cytoplasmic tangles  AD+Tauopathies 
Torsin A (7)  Chaperone like function  Associate with LB 
(10) 
LB  PD 
Tyrosine 
hydroxylase 
Catalyse the first step in 
biosynthesis of 
catecholamine 
Associate with α–Syn  
(10) 
 α–Synuclein  inclusion  α  Synucleinopathies 
Tubulin (1)  Accelerate AS 
aggregation 
Both (α–Syn +LB) 
(10) 
LB+ α–Syn  inclusion  α  Synucleinopathies 
Ubiquitin 
carboxyl 
terminal 
hydrolase LI 
(UCH L1) 
De ubiquitinating 
Enzyme 
 PARK5  LB  FPD (autosomal 
dominant) 
 
Table 1.4: Proteins that aggregates in inclusions in neurodegenerative 
diseases, in Lewy bodies in Parkinson disease and proteins that associated with 
α synuclein  (AD:  Alzheimer’s  disease;  α Syn:  alpha synuclein;  FPD;  familial 
Parkinson ‘disease; LB: Lewy body; PD: Parkinson’s disease; UPS: Ubiquitin 
proteasome  system).  (1)  Abdul  Alim  et  al.  (2002);  (2)  Arai    et  al.  (1992);  (3) 
Bonifati et al. (2003); (4) Brion et al. (1995); (5) Ghee et al. (2000); (6) Sasaki  et 
al.  (2002);  (7)  Shashidharan  et  al.  (2000);  (8)  Taylor  et  al.  (2002);  (9) 
Wakabayashi et al. (2000); (10) Zhou et al. (2004). 
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1.6 Movement disorders and their neuropathology 
In  this  introduction  I  am  chiefly  concerned  with  neurodegenerative  conditions  of 
aminergic neurons and the basal ganglia which lead to movement disorders. These 
include:    
 
1.6.1 Multiple System Atrophy 
The  term  multiple  system  atrophy  (MSA)  was  introduced  by  Graham  and 
Oppenheimer (1969) to describe a neurodegenerative disorder occurring sporadically 
and  characterized  by  Parkinsonism,  cerebellar  dysfunction,  and  autonomic 
insufficiency (Wenning et al., 1995; Kaufmann, 1998). 
Neuronal  loss  and  gliosis  affect  the  substantia  nigra,  putamen,  locus  coeruleus, 
pontine nuclei, cerebellar Purkinje cells, inferior olive, intermediolateral columns of 
spinal cord and the dorsal motor nucleus of the vagus. There is evidence of loss of 
dopaminergic neurons in SNC (confirmed by the loss of pigment, but without Lewy 
bodies) as well as loss of dopamine and it’s synthetic enzyme TH; in addition, there is 
loss of  noradrenergic neurons in the locus ceruleus and adrenergic neurons in the 
rostral  ventrolateral  medulla  (Burn  and  Jaros,  2001;  Rehman,  2001).  The 
characteristic neuropathology of MSA is the presence of many cytoplasmic inclusions 
in glia (glial cytoplasmic inclusion) and, later, in neurons in the absence of Lewy 
bodies (Lantos and Papp, 1994). Immunocytochemistry shows that glial cytoplasmic 
inclusions are ubiquitin, tau and alpha synuclein positive (Gai et al., 1998; Lantos, 
1998; Terni et al., 2007). 
Data from PD brain banks showed that up to 10% of  patients diagnosed with PD turn 
out to have MSA (Colosimo et al., 1995; Kaufmann., 1998). Chapter 1                                                                                      General Introduction 
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1.6.2  Progressive Supranuclear Palsy 
Progressive  Supranucelear  palsy  (PSP)  is  commonly  known  as  Steele Richardson 
syndrome and was described by Steele et al (1964). 
Postural  instability,  gaze  palsy,  Parkinsonism  and  subcortical  dementia  clinically 
characterize  PSP.  The  degeneration  is principally  in  the brain  stem,  midbrain  and 
basal  ganglia.  The  main  lesions  are  in  the  substantia  nigra,  globus  pallidus, 
subthalamic nucleus and pons (Litvan, 1996). The major neurons affected are the 
dopaminergic nigrostriatal neurons in the SNC (particularly the ventromedial portion) 
and  decreases  in  dopamine  and  homovanillic  acid  levels  in  the  striatum;  the 
mesolimbic  and  mesocortical  systems  are  not  affected.  There  is  loss  of  the 
postsynaptic  dopamine  D2  receptors  in  basal  ganglia,  GABAergic  neurons  in  the 
striatum  and  the  cholinergic  neurons  in  brainstem  and  other  areas  of  the  brain 
(Ruberg et al., 1985; Lowe et al., 1997; Rehman, 2000). Pathological ultrastructural 
changes  centre  around  neurofibrillary  degeneration,  particularly  the  deposition  of 
hyperphosphorylated tau protein as neurofibrillary tangles (Schmidt et al., 1996). The 
treatment  of  PSP  with  L dopa  has  little  effect  due  to  loss  of  the  postsynaptic 
dopamine D2 receptors in basal ganglia  (Collins et al., 1995; Lowe et al., 1997). 
 
1.6.3 Corticobasal degeneration 
Corticobasal  degeneration  (CBD)  is  a  rare  and  slowly  progressive  neurological 
disease,  first  described  by  Rebeiz  (1968).  CBD  is  characterized  clinically  by  an 
asymmetrical akinetic rigid syndrome  associated with cognitive problems (apraxia 
and aphasia), extrapyramidal motor dysfunction (rigidity and dystonia) and moderate 
dementia late in the course of the disease (Rinne et al., 1994). The neuropathological Chapter 1                                                                                      General Introduction 
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changes in CBD include gliosis, nerve cell loss and atrophy of the posterior frontal or 
parietal  lobes  of  the  cerebral  cortex  with  the presence  of  swollen,  achromatic  tau 
positive Pick like cells (Dickson et al., 2000) and loss of pigmented nigral neurons in 
the lateral portion of the SN; Lewy bodies are absent (Rebeiz et al., 1968; Gibb et al., 
1989; Riley et al., 1990; Lowe et al., 1997).   
 
1.6.4 Huntington’s disease 
Huntington’s disease (HD) is a hyperkinetic, autosomal dominant inherited disorder 
characterized by progressive chorea, rigidity, dystonia, dementia, cognitive deficits 
and  psychological  disturbance.  Huntington’s  disease  takes  its  name  from  the 
American physician George Huntington who described it in 1872. The age of onset is 
normally  30  to  45,  but  the  extreme  range  is  2 80  years.  The  mutation  which  is 
responsible for HD is an expanded polyglutamine repeat (CAG) within exon 1 of the 
gene in chromosome 4 that codes for the Huntingtin protein (Hedreen and Folstein, 
1995; Reddy et al., 1999; Myers, 2004). 
Neuropathological changes in HD include degeneration of the caudate and putamen 
(Vonsattel et al., 1985) and selective loss of GABA and enkephalin positive medium 
spiny neurons that project from the striatum to the external segment of the globus 
pallidus (Perry et al., 1973; Sapp et al., 1995; Mitchell et al., 1999) (Figure 1.3).  
Some studies also report a loss in both nigrostriatal and in nonpigmented cells in the 
substantia nigra (Oyanagi et al., 1989; Bohnen et al., 2000). Dopamine levels have 
been found to be normal or increased, whereas homovanillic acid was found to be low 
(Bird and Iversen, 1974; Spokes, 1980; Kish et al., 1987).  Chapter 1                                                                                      General Introduction 
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Figure 1.3: Basal ganglia circuitry in Huntington’s disease, showing the 
direct and indirect pathways of the basal ganglia. Excitatory projections are shown in 
green; inhibitory projections are shown in blue; dopaminergic nigrostriatal projections 
are in shown red. Differences in the thickness of arrows indicates the relative degree of 
activation.    (CM/PF:  centromedian/farafasicular nucleus  of  thalamus;  D1:  dopamine 
receptor 1; D2: dopamine receptor 2; DA: dopamine; Enk: enkephalin; GABA: gamma 
aminobutyric acid; GLU: glutamate; Gpe: external segment of globus pallidus; Gpi: 
internal  segment  of  globus  pallidus;  SNC:  substantia  nigra  pars  compacta;  SNR: 
substantia  nigra  pars  reticulata;  STN:  subthalamic  nucleus;  SP:  substance  P;  VL: 
ventrolateral thalamus) (Partially adapted from DeLong, 1990). 
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A major ultrastructural pathological change is the aggregation of inclusions in neurons 
of  the  striatum  and  cortex  (Roizin  et  al.,  1974;  DiFiglia  et  al.,  1997).  These 
inclusions contain aggregations of Huntingtin protein and ubiquitin (Davies et al., 
1997; DiFiglia et al., 1997). The mechanisms of neuronal degeneration resulting from 
the mutation in Huntingtin protein are poorly understand and many hypotheses have 
been advanced including glutamatergic excitotoxicity (Young et al., 1988; Beal et al., 
1991; Ferrante, 1993), mitochondrial dysfunction (Horton et al., 1995; Gu et al., 
1996; Koroshetz et al., 1997), endoplasmic reticulum stress (Nishitoh et al., 2002) 
apoptosis (Saudou et al., 1998; Ona et al., 1999) and dysfunction of the ubiquitin 
proteasome system (Seo et al., 2004, 2007).      
 
1.6.5  Parkinson’s disease 
Parkinson’s’ disease (PD) is a progressive neurodegenerative movement disorder, first 
described  by  James  Parkinson  in  1817;  it  is  the  second  most  common 
neurodegenerative disease affecting 1 2% of people over 65 years of age (de Rijk et 
al., 1997). There are two major classes of PD (i) the late onset sporadic form which 
occurs over the age of 55 and (ii) the early onset familial form (Gwinn Hardy, 2002). 
The majority of cases of PD (90%) are sporadic (McNaught et al., 2006; Olanow 
and McNaught, 2006). 
 PD  is  characterized  clinically  by  tremor  that  occurs  at  rest  but  decreases  with 
voluntary movement (“resting tremor”), rigidity (increased limb resistance to passive 
movement),  bradykinesia  (slowness  of  movement),  gait  dysfunction,  postural 
instability (Dauer and Przedborski, 2003), depression and dementia.  
The  clinical  symptoms  appear  after  massive  reduction  of  striatal  dopamine  levels 
(80%) (Bernheimer et al., 1973; Hornykiewicz, 1998) associated with severe loss of Chapter 1                                                                                      General Introduction 
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dopaminergic  neurons  in  the  substantia  nigra  pars  compacta  (A9  dopaminergic 
neurons) (Hirsch et al., 1988; German et al., 1989; Pakkenberg et al., 1991). The 
ventrolateral tier of the SNC which projects to the putamen is more affected (Gibb 
and  Lees,  1991).  The  dopaminergic  neurons  (A10)  in  the  VTA  (that  project  to 
cortical  and  limbic  areas)  show  less  severe  cell  loss  (Jellinger,  2005).  Levels  of 
dopamine  are decreased in the substantia nigra, and ventral tegmental area and there 
is decreased TH activity in the SN and in the striatum (Fahn et al., 1971; Rinne et al., 
1974; McGeer and McGeer, 1976; Ploska et al., 1982; Javoy Agid et al., 1990). 
The level of dopamine metabolites (such as DOPAC and HVA) are also decreased in 
SN and the striatum (Sian et al., 1999). 
Loss  of  nigrostriatal  dopaminergic  neurons  promotes  an  activation  of  the  indirect 
pathway through the basal ganglia circuit (Filion et al., 1988). The initial part of this 
pathway  is  inhibitory  with  GABA/Enkephalin  striatal  neurons  that  project  to  the 
external segment of the globus pallidus. Inhibition of GABAergic neurons of GPe will 
release  the  subthalamic  nucleus  from  it’s  inhibition  (=  disinhibition)  by  GPe. 
Increased activity in the subthalamic nucleus will, in turn, cause excitation of the 
basal ganglia output nuclei (internal segment of globus pallidus and the substantia 
nigra pars reticulata) via the excitatory glutamatergic pathway that connects both of 
them. Reduced activity of GABA/substance P neurons of the direct pathway will also 
result  in  disinhibition  of  the  output  nuclei  projections  leading  to  inhibition  of 
thalamocortical neurons via the GABAergic projection which reduces activity of the 
glutamatergic neurons projecting to the motor areas of the cerebral cortex. This will 
result in many of the hypokinetic symptoms of Parkinson’s disease (Filion et al., 
1988)  (Figure  1.4).  Many  observations  support  this  mechanism,  such  as  reduced 
substance P in the output nuclei of the basal ganglia in Parkinson’s disease patients  Chapter 1                                                                                      General Introduction 
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Figure 1.4: Basal ganglia circuitry in Parkinson’s disease, showing the 
direct and indirect pathways of the basal ganglia. Excitatory projections are shown in 
green; inhibitory projections are shown in blue; dopaminergic nigrostriatal projections 
are shown in red. Differences in the thickness of arrows indicates the relative degree of 
activation.    (CM/PF:  centromedian/farafasicular nucleus  of  thalamus;  D1:  dopamine 
receptor 1; D2: dopamine receptor 2; DA: dopamine; Enk: enkephalin; GABA: gamma 
aminobutyric acid; GLU: glutamate; Gpe: external segment of globus pallidus; Gpi: 
internal  segment  of  globus  pallidus;  SNC:  substantia  nigra  pars  compacta;  SNR: 
substantia  nigra  pars  reticulata;  STN:  subthalamic  nucleus;  SP:  substance  P;  VL: 
ventrolateral thalamus) (Partially adapted from DeLong, 1990; Blandini et al., 2000). 
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(Agid  et  al.,  1987;  Waters  et  al.,  1988)  and  unchanged  enkephalin  levels  in  the 
external  segment  of  the  globus  pallidus  (Agid  et  al.,  1987).  Moreover,  ablation 
surgery performed on the subthalamic nucleus reduces the symptoms of Parkinson’s 
disease suggesting that excessive subthalamic nucleus activity is a key feature of the 
disorder (Bergman et al., 1990; Aziz et al., 1991; Limousin et al., 1995). Chesselet 
and Delfts (1996) suggest that the model may need correcting following evidence that 
activity  in  the  external  segment  of  globus  pallidus  is  increased  after  nigrostriatal 
dopamine depletion by MPTP, probably due to the increased neuronal discharge rate 
of  excitatory  glutamatergic  projections  from  the  subthalamic  nucleus  (Pan  and 
Walters,  1988;  Tremblay  and  Filion,  1989).  A  similar  finding  was  noted  in  6 
hydroxydopamine lesioned animals (Porter et al., 1994). 
1.6.5.1  Etiology of Parkinson’s disease 
The etiology of PD is not fully understood, but many cases may involve an interaction 
between genetic and environmental factors (Duvoisin, 1999; Mizuno et al., 1999; Le 
Couteur et al., 2002; Sherer et al., 2002; Schapira, 2006). Epidemiological studies 
suggest that exposure to environmental agents, such as pesticides, may increase the 
risk of PD (Gorell et al., 1998; Menegon et al., 1998). In addition to the involvement 
of environmental factors in PD, genetic factors are also involved, since about 5 10 % 
cases  are  believed  to  have  a  familial  Parkinsonism  (Olanow  and  Tatton,  1999; 
McNaught et al., 2006). Familial cases of PD have been  associated with mutations in 
proteins such as α synuclein on chromosome 4 (Polymeropoulos et al.,1997) and 
parkin on chromosome 6 (Kitada et al., 1998).   Mutation also in UCH L1 (Leroy et 
al., 1998), PINK1 (Valente et al., 2004), DJ 1 (Bonifati et al., 2003; Abou Sleiman 
et  al.,  2004)  and  LRRK2  (Funayama  et  al.,  2002).  For  reviews  see,  Cookson, 
(2005); Jain et al., (2005); Schapira, (2006). Many different genes involved in PD Chapter 1                                                                                      General Introduction 
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may relate to protein mis folding (McNaught et al., 2002; Ryu et al., 2002). For 
reviews, see Soto, (2003); Agorogiannis et al., (2004); McNaught and Olanow, 
(2006). This topic will be discussed later. 
 
Many factors lead to neurodegeneration in PD (Olanow and Tatton, 1999). These 
include: 
1)  Oxidative  stress,  where  damaging  levels  of  hydrogen  peroxide  and  then 
reactive oxygen species are increased as a result of: 
                    a  Increased dopamine turnover, 
                    b  A deficiency in glutathione, 
                    c  A build up of reactive iron which can lead to formation of hydroxyl   
                    radicals. 
2)  Mitochondrial dysfunction. 
3)  Excitotoxicity, which results from increased glutamate formation. 
4)   Apoptosis. 
Alongside these factors,  protein aggregation or mis folding is implicated in the cell 
death  mechanisms  in  PD  and  other  degenerative  conditions  (Moore  et  al.,  2005; 
McNaught et al., 2006). 
1.6.5.2  Neuropathology of Parkinson’s disease 
There are no changes in the gross morphology of the brains of PD patients. However, 
gross slices or histological sections reveal loss of neuromelanin pigmention in the 
substantia nigra (DA) and locus ceruleus (NE). Other regions such as the striatum and 
the globus pallidus appear normal. 
On  histopatholgical  examination  there  is  loss  of  the  dopaminergic  neurons  of  the 
substantia  nigra  pars  compacta.  In  typical  PD  (as  well  as  other  diseases  where 
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parkinsonism  is  a  component)  the  neuronal  loss  is  usually  most  marked  in  the 
ventrolateral  tier  of  neurons  which  mainly  project  to  the  striatum  (putamen) 
(Bernheimur  et  al.,  1973).    The  substantia  nigra  contains    about  550,000 
dopaminergic  neurons  (and  approximately  450,000  dopaminergic  one  are  in  pars 
compacta) and are reduced by at least two thirds in PD patients and nondopaminergic 
neurons are 260,000 and reduced by about a quarter in PD patients (Pakkenberg et 
al., 1991; Lang and Lozano, 1998a). The neuronal loss in the substantia nigra is 
accompanied by astrocytosis and microglial activation (Teismann et al., 2003). 
Other systems are affected in PD, and there is loss of (a) noradrenergic neurons and 
depletion of noradrenaline concentration in the locus ceruleus (Mann et al., 1983; 
Cash et al., 1987; Jellinger, 2005), (b) cholinergic neurons in the nucleus basalis of 
Meynert, pedunculopontine nucleus, Edinger Westphal nucleus and the dorsal motor 
nucleus of the vagus (Nakano and Hirano, 1983; Zweig et al., 1989; Gai et al., 
1992)  together  with  depletion  of  the  cholinergic  enzymes  (such  as  Choline 
Acetyltransferase)  in  the  putamen,  globus  pallidus  and  the  SNC  (Nishino  et  al., 
1988), (c) serotonergic neurons of the dorsal raphe nucleus (Jellinger, 2005) and a 
reduction in serotonin concentration in areas such as the striatum, substantia nigra, 
and  hippocampus  (Rinne  et  al.,  1974;  Scatton  et  al.,  1983;  Agid  et  al.,  1987; 
Mizuno,  2005).  There  is  also  a  reduction  in  tryptophan  hydroxylase  activity  in 
Parkinson’s disease patients (Sawada et al., 1985), as well as depleted 5 HT and its 
metabolites in the cerebrospinal fluid (CSF) (Tohgi et al., 1993). 
Other histopatholgical characteristics are the presence of neuronal intracytoplasmic 
inclusions  called  Lewy  bodies,  Lewy  neurites  (ubiquitin positive  degenerating 
neuronal processes), pale bodies which are considered as precursors of Lewy bodies 
(Dale et al., 1992) and a variable amount of extracellular neuromelanin and gliosis Chapter 1                                                                                      General Introduction 
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(McGeer  et  al.,  1988;  Fearnley  and  Lee,  1991;  Cornford  et  al.,  1995;  Forno, 
1996).   
1.6.5.3  Lewy body 
The  Lewy  body  is  a  neuronal  intracytoplasmic  inclusion  body  and  it  is  widely 
considered as the histopatholgical hallmark of PD (Pollanen et al., 1993; Cornford et 
al., 1995; Forno, 1996; Galvin et al., 1997; Shults, 2006). Lewy bodies were first 
described in the neurons of the substantia inominata and the dorsal vagal nucleus in 
PD by Friederich Lewy in 1912 and bear his name (Gibb and Poewe, 1986).  
Lewy bodies can be seen in the surviving dopaminergic neurons of the substantia 
nigra pars compacta in all most every case of PD (Jellinger, 1987; Hughes et al., 
1993; Pollanen et al., 1993; Cornford et al., 1995; Forno, 1996), dead and they are 
also seen in other groups of neurons including dopaminergic mesolimbic neurons, the 
cholinergic neurons of the nucleus basalis of Meynert, the noradrenergic neurons of 
the locus coeruleus, the serotonergic neurons of the raphe nuclei, the motor vagal 
nuclei,  pedunculopontine  nucleus,  the  Edinger Westphal  nucleus,  the 
intermediolateral cell column of the spinal cord,  the hypothalamus and autonomic 
ganglia (Jellinger, 1991).  Neurons with Lewy bodies which do not stain for TH  may 
be either non dopaminergic cells or dopaminergic cells that may be defective or non 
functional (Iravani et al., 2006).      
Morphologically,  Lewy  bodies  can  be  divided  into  two  types  which  are  found  in 
different locations in the brain:   
1)  classical brainstem LB is a spherical intraneuronal eosinphilic inclusion that 
has a diameter of 8 30  m with a central dense core and a pale peripheral halo 
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2)  Cortical Lewy bodies are a round intraneuronal eosinphilic inclusions without  
a halo but they have also angular and reniform shapes (Gibb et al., 1987; 
Lowe  et  al.,  1997;  Jellinger,  2005)  and  were  first  described  by  Okazaki  
(1961).  
Most affected neurons have a single LB, though multiples do occur LB (Dickson, 
2005).   Ultrastructurally, both classical and cortical Lewy bodies are composed of 
radially arranged intermediate filaments (7 20 nm) associated with granular electron 
dense material (Rajput and Rozdilsky, 1976; Pirozzolo et al., 1982; Crystal et al., 
1990; Xuereb et al., 1990;  Forno, 1996; McKeith et al., 1999; Jellinger et al., 
2001) (Figure 1.5). Both classical and cortical Lewy bodies are immunopositive for 
ubiquitin, α synuclein (Lennox et al.,1989; Love and Nicoll, 1992; Irizarry et al., 
1998; Spillantini et al., 1997;1998a) (Figure 1.5) and neurofilaments (Goldman et 
al., 1983; Hill et al., 1991; Schmidt et al., 1991) in addition to other components (see 
table 1.4).  Lewy neurites are ubiquitin positive degenerating neuronal processes first 
described in the hippocampus (Dickson et al., 1991) and also found in other brain 
regions such as amygdala, cingulate gyrus and temporal cortex (Dickson, 2005). Pale 
bodies are rounded granular pale eosinophilic areas seen in neurons of the substantia 
nigra and the locus coeruleus (Lowe et al., 1997). Lewy bodies are widely accepted 
pathological hallmark of both sporadic and familial PD, as well as dementia with 
Lewy bodies (Gibb et al., 1987; Gomez Tortosa et al., 2000). Lewy bodies can be 
also  seen  in  a  number  of  other  disorders,  such  as  Alzheimer’s  disease,  Down 
syndrome and Hallervorden Spatz disease (Arawaka et al., 1998; Lippa et al., 1999; 
Wakabayashi  et  al.,  1999;  Yokota  et  al.,  2007).The  mechanism by  which  Lewy 
bodies are formed and their relationship to neurodegenerative disease or age process  
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Figure 1.5: Lewy bodies are a characteristic feature of Parkinson’s 
disease.  Lewy  bodies  are  small  spherical  inclusions  that  (a)  can  be  stained  with 
haematoxylin/eosin, and (b) contain the protein α synuclein, which in this specimen was 
detected with a specific antibody. (c) Lewy bodies consist of radiating filaments that can 
be seen in this electron micrograph. (Panels a and b © Macmillan Magazines Ltd; panel 
c  is  adapted  with  permission  from  (Forno,  1996)  American  Association  of 
Neuropathologists). The set of three photos is from Beal, (2001).  
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remained unknown. One  possibility is that Lewy bodies reflect damage since proteins 
such as α synuclein or ubiquitin will accumulate and aggregate if  the ability of cells 
to degradate these proteins are exceeded or proteasomal function impaired (Sherman 
and  Goldberg,  2001);  those  aggregated  proteins  will    subsequently  provide  a 
nucleation center for the formation of inclusion bodies such as Lewy bodies (Chung 
et al., 2001a) and the accumulation of these inclusion bodies might induce further 
neuronal  dysfunction  and/or  cell  death  leading  to  neurodegeneration  (Alves 
Rodrigues et al., 1998; Bence et al., 2001; Chung et al., 2001a). Anther possibility 
is that Lewy bodies are a protective device as they form and function in a way similar 
to an aggresome (McNaught et al., 2002; Olanow et al., 2004). Aggresomes are 
cytoplasmic  inclusion  bodies  that  form  at  the  centrosome  (a  perinuclear  structure 
linked  to  the  microtubular  system)  as  a  cytoprotective  response  to  high  levels  of 
misfolded  proteins  (Johnston  et  al.,  1998;  Kopito,  2000).  There  is  evidence  that 
Lewy bodies in PD resemble aggresomes (cytoprotective) since they stain positively 
for specific markers of aggresome such as  γ tubulin and pericentrin as well as UPS 
components  (McNaught  et  al.,  2002).    In  PD,  the  aggresome  might  be  an 
intermediate stage in the formation of Lewy bodies which form if there is continued 
failure to clear abnormal proteins (McNaught et al., 2002; Olanow et al., 2004). 
Mutations in parkin (ubiquitin ligase) cause dysfunction in UPS components required 
for  protein  ubiquitination  leading  to  accumulation  of  poorly  degraded  cytotoxic 
proteins as well as impaired transport of ubiquitinated proteins to the aggresome; this 
may explain the lack of Lewy bodies in autosomal recessive juvenile parkinsonism 
and the lack of a cytoprotective response may further explain the early age of onset, 
and the rapidity and severity of neurodegeneration in such patients (McNaught and 
Olanow,  2003).    Inclusion  bodies  are  not  always  found  in  neurodegenerative Chapter 1                                                                                      General Introduction 
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conditions. For example, they do not occur in most laboratory models of Parkinson’s 
disease such as those produced through 6 OH dopamine or MPTP toxicity (Forno et 
al., 1993; Dauer and Przedborski, 2003), although they are present in rotenone 
induced  degeneration  in  rat  (Betarbet  et  al.,  2000).  Moreover,  some  human 
Parkinsonian conditions occur without Lewy body formation. As mentioned above, 
this is especially true of patients with mutations in  parkin (E3 ligase of UPS) and 
suggests that the E3 ligase may be critical for Lewy body formation. 
1.6.5.4  Treatments of Parkinson’s disease 
(A) Drugs treatments used in PD include:  
i.  Levo dopa has been commonest drug in the treatment of Parkinson’s disease 
since  1967  (Cotzias  et  al.,  1967).  Levodopa  or  L dopa  (3,4 
dihydroxyphenyalanine)  is  the  precursor  of  the  neurotransmitter  dopamine 
and  can  easily  cross  the  blood brain  barrier  where  it  is  converted  into 
dopamine by aromatic L amino acid decarboxylase. Unfortunately, efficacy 
reduces  with  prolonged  treatment  and  motor  complications  such  as 
dyskinesias and fluctuations (Lang and Lozano, 1998b). 
ii.  Bromocriptine, Pramipexole and Apomorphine are dopamine agonists which 
directly bind to and activate dopamine receptors in the brain and therefore 
have  the  same  effect  as  dopamine,  for  review,  see  Lang  and  Lozano, 
(1998b); Kuniyoshi and Jankovic, (2005). 
iii.  Monoamine oxidase B (MAO B) inhibitors such as Selegiline, prevent the 
metabolism of dopamine, and so will increase the availability of dopamine in 
the brain, for review, see Lang and Lozano, (1998b); Bertoni and Elmer, 
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iv.  Catechol O methyl  transferase  (COMT)  inhibitors  such  as  Entacapone, 
prevent the peripheral metabolism of dopamine thus allowing additional L 
DOPA to gain access to the brain, for review, see Wahba et al., (2005). 
v.  Anticholinergic drugs such as Benztropine and Trihexyphenidyl have been 
found effective in the treatment of Parkinson’s disease and may reduce the 
tremor and rigidity due to the imbalance in  cholinergic and dopaminergic 
systems interaction, for review, see Jabbari and Pazdan, (2005).   
(B) Surgical treatment has also been used to alleviate Parkinson’s disease and four 
procedures have been used :  
a.  lesions  of  the  basal  ganglia  such  as  pallidotomy  which  leads  to 
improved  parkinsonism  symptoms  and  suppresses  L dopa  induced 
dyskinesias (Laitinen et al., 1992; Dogali et al., 1995), 
b.  thalamotomy  to  relieve  tremor  and  L dopa  induced  dyskinesias 
(Ohye et al., 1982; Narabayashi et al., 1984). 
c.  Subthalamotomy  to  relieve  contra lateral  tremor,  rigidity,  and 
bradykinesia (Alvarez et al., 2001; Patel et al., 2003; Su et al., 2003) 
and  
d.   Deep  Brain  Stimulation  (DBS)   a  surgical  technique  used  to 
improve motor symptoms and L dopa induced dyskinesias by placing 
a  small  electrode  tip  in  target  areas  such  as  subthalamic  nucleus, 
thalamus  and  globus  pallidus  to  block  abnormal  nerve  signals  that 
cause motor symptoms in PD. The electrode is connected to a battery 
operated neurostimulator placed in near the clavicle (for review see 
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1.7 Lewy body proteins 
Lewy bodies contain a wide variety of proteins, but those that have received most 
attention  (and  which  have  been  linked  to  human  disorders  such  as  PD)  include 
ubiquitin, parkin and α synuclein.  I shall review each. 
1.7.1 Ubiquitin and the ubiquitin–proteasome system 
1.7.1.1 Ubiquitin: 
Ubiquitin (Ub) is a small protein (8.5 KDa) made up of 76 amino acids; due to its 
ubiquitous nature, it was named ubiquitin. It is expressed in human by three genes 
(Mayer et al., 1991). It was originally extracted from bovine thymus in the early 1970 
S  where it was thought to have properties relating to the differentiation of T and B 
lymphocytes (Goldstein et al., 1975) but it has now been found in all eukaryotic cells.   
It has a central role in the degradation of cytosolic, nuclear and endoplasmic reticulum 
proteins (Hochstrasser, 1996), so it acts as a covalent tag to mark damaged or short 
lived proteins for degradation by the ubiquitin–proteasome system.  Studies indicate 
that  It  is  implicated  in  cell  functions  such  as  the  mediation  of  stress  responses, 
regulation of differential gene expression, repair of damaged DNA (Goldstein et al., 
1975) and control of the cell cycle. 
 
1.7.1.2  The  degradation  of  proteins  by  the  ubiquitin–proteasome 
system: 
 
The ubiquitin–proteasome system (UPS) is an ubiquitous, multienzymatic proteolytic 
pathway that removes misfolded, ubiquitinated proteins (Ciechanover et al., 2000; 
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role in rapid degradation of 30 % or more of newly made proteins within the cell 
(Schubert et al., 2000) and it also plays a crucial role in a number of cellular events 
such  as  signal  transduction,  cell  cycling,  metabolism  and  the  immune  response 
(Pagano, 1997; Ben Neriah, 2002; Mukhopadhyay and Riezman, 2007). 
 Ubiquitin is first activated by the ubiquitin–activating enzyme (E1) in its C  terminal 
glycine residue to the thiol group of a cysteine residue on the activating enzyme (E1) 
via an ester bond. After that it is transferred to a cysteine thiol group on a ubiquitin 
carrier protein or ubiquitin–conjugating enzyme (E2) and, finally, it is ligated to a 
protein substrate by a ubiquitin–protein ligase (E3). At this step, two options exist; 
either ubiquitin is transferred to a protein substrate via the ubiquitin   protein ligase or  
the ubiquitin – protein ligase  accepts both protein substrate and ubiquitin–conjugating 
enzyme  for direct transfer of ubiquitin from the ubiquitin conjugating enzyme to the 
protein substrate (Hershko and Ciechanover, 1998). 
The  degradation  of  proteins  is  enhanced  when  more  than  one  ubiquitin  binds 
covalently to the target protein to form polyubiquitin chains (Cook et al., 1994). The 
proteins attached by polyubiquitin chains are usually degraded by ubiquitin / ATP – 
dependent  proteinase  known  as  26S  proteasome.  The  26S  proteasome  is  a  large 
multiprotein complex (2.5 MDa) (Voges et al., 1999), which is mainly cytosolic but 
can  also  be  found  in  nuclei  (Palmer  et  al.,  1996).  Ultrastructurally,  the  26S 
proteasome  is  composed  of  a  central  catalytic  20S  core  complex,  comprising  28 
subunits in a cylindrical arrangement and containing the protease active sites, with 
19S regulator complexes at each end (Coux et al., 1996). The 19S particle contains at 
least 17 subunits, including ATPases, de ubiquitinating enzyme and polyubiquitin 
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ubiquitin protein by de ubiquitinating enzymes (Wilkinson, 1997; Betarbet et al., 
2005; Olanow and McNaught, 2006) (Figure 1.6).       
 
1.7.1.3  The  role  of  the  ubiquitin–proteasome  system  in 
neurodegenerative disorders: 
 
Many neurodegenerative disorders are characterized by the presence of intraneural 
cytoplasmic inclusions containing ubiquitinated filamentous protein aggregates. 
These  inclusions  are  found  in  the  cytoplasm  (e.g.  endosomes,  lysosomes)  in 
Alzheimer’s disease and Prion encephalophathies (Mayer et al., 1996) and in nuclei 
in Huntington’s disease and spinocerebellar ataxias (Davies et al., 1997). 
Aggregations  of  ubiquitin  protein  were  first  detected  in  the  neurofibrillary  tangle 
(NFT) of Alzheimer’s disease (Mori et al., 1987) and have since been shown to be       
a feature of Lewy bodies (LB) in Parkinson’s disease and dementia with Lewy bodies 
(DLB), as well as inclusions in Pick’s disease and amyotrophic lateral sclerosis (Lowe 
et  al.,  1988)  and  polyglutamine  expansion  diseases  such  as  Huntington’s  disease 
(DiFiglia et al., 1997).  
 The ubiquitinated filamentous protein aggregates within these inclusions result from 
a dysfunction or overload of the ubiquitin–proteasome system, structural changes in 
the  protein  substrates  (Alves Rodrigues  et  al.,  1998),  mutations  that  impair  the 
normal  ubiquitin  pathway  e.g.  in  ubiquitin ligase  enzymes  (parkin),  or  de 
ubiquitinating enzymes (UCHL1) or protein substrates of UPS (α synuclein) or in 
transcripts for ubiquitin itself (Layfield et al., 2001), mitochondrial dysfunction and 
oxidative stress (Reinheckel et al., 2000; Shamoto Nagai et al., 2003). 
For example, mutant genes encoding for proteins of the ubiquitin–proteasome system 
were found to be responsible for inherited forms of familial Parkinson’s disease (PD) Chapter 1                                                                                      General Introduction 
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Figure 1.6: Degradation of abnormal proteins by the ubiquitin 
proteasome system. Proteins are ubiquitinated by a series of enzymatic 
reactions:  E1  enzymes  activate  ubiquitin  monomers,  E2  enzymes 
conjugate ubiquitin to proteins or to E3, which are in turn a series of 
ubiquitin  ligases  and  attach  chains  of  ubiquitin  to  specific  protein 
substrate.  Labelling  of  proteins  with  multiple  ubiquitin  molecules  are 
recognized by proteasome and degraded in an ATP manner. In the final 
step, ubiquitin monomers are removed from ubiquitin protein adducts by 
deubiquitinating  enzymes  (such  as  UCHL1)  so  they  can  recycle  to 
degradate  additional  abnormal  proteins.  Partially  adapted  from 
McNaught et al. (2001).       
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(Polymeropoulos et al., 1997; Kitada et al., 1998; Leroy et al., 1998; Shimura et 
al., 2000). These genes include PARK1 of α synuclein, PARK 2 of parkin and PARK 
5  of  ubiquitin C hydrolase 1  (UCHL1),  all  of  which  decrease  the  activity  of  the 
ubiquitin proteasome system (Kitada et al., 1998; Leroy et al., 1998; Chung et al., 
2001a; Steece Collier et al., 2002; Betarbet et al., 2005; Olanow and McNaught, 
2006). 
A  mutant  form  of  ubiquitin  called  ubiquitin
+1  has  been  detected  in  the  brain  of 
Alzheimer’s patients (Van Leeuwen et al., 1998). In this case, polyubiquitin chains 
made  by  ubiquitin
+1  are  completely  resistant  to  disassembly  by  deubiquinitinating 
enzymes.  This  causes  an  accumulation  and  aggregation  of  ubiquitinated  proteins, 
leading  to  neurodegeneration  (Lam  et  al.,  2000).  In  sporadic  Parkinson’s  disease 
there is a reduction in mitochondrial complex 1 activity in the substantia nigra pars 
compacta (Schapira et al., 1990b); inhibition of complex 1   activity might lead to 
impairment  of  the  UPS  which  is  an  ATP  dependent,  leading  to  accumulation  of 
ubiquitin proteins (DeMartino and Slaughter, 1999). 
 Impairment  of  the  ubiquitin proteasome  system  leading  to  accumulation  and 
aggregation  of  ubiquitinylated  proteins  does  not  appear  to  be  a  primary  event  in 
inclusion formation, but rather a secondary protective cellular response, so oxidative 
damage (Giasson et al., 2000) or glycosylation (Shimura et al., 2001) may be the 
initiating events in aggregation and inclusion formation, with ubiquitination forming a 
later stage in inclusion biogenesis as part of the normal cellular response to disease 
states. Immunohistochemical studies give insights in the relationship between UPS 
and  inclusion  formation.  These  shows  that,  while  ubiquitin  is  often  found  in 
inclusions, it is not obligatory. For example, the tau protein is the main component of 
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(Bancher et al., 1989) although it should be noted that tau protein can form fibrils in 
the absence of ubiquitin (Goedert et al., 1996).   In Parkinson’s disease, not all Lewy 
bodies are ubiquitin positive (Spillantini et al., 1998b) and α synuclein can also form 
fibrils in the absence of ubiquitin (Hashimoto et al., 1998). The degradation of non 
ubiquitinylated forms of α synuclein and tau proteins by proteasome in the absence of 
ubiquitin (Tofaris et al., 2001; David et al., 2002) is probably possible because both 
belong to natively unfolded proteins (Schweers et al., 1994).  
1.7.1.4  The  ubiquitinylated  inclusions  and  neurodegenerative 
disorders: 
 
One study (Kakizuka, 1998) has suggested that the formation of these inclusions 
might  induce  neural  dysfunction  and/or  cell  death  because  ubiquitin  protein 
aggregations cause neural toxicity and apoptosis. If so, the aggregation of proteins 
directly impairs the function of the ubiquitin proteasome system (UPS) which is likely 
to  be  involved  in  the  positive  feedback  mechanism  induced  by  the  protein 
accumulation  that  altered  its  function,  which  in  turn  increases  the  production  of 
aggregated proteins and ultimately results in neuronal cell death (Bence et al., 2001).     
Conversely, other concept have suggested that the formation of these inclusions is one 
of the protective strategies of the cell to process damaged, misfolded, mutant proteins.  
For  example,  the  Lewy  bodies  in  Parkinson’s  disease  may  represent  a  protective 
cellular response to protein aggregates as they behave structurally and functionally as 
aggrosome (Forno, 1996; Goldberg and Lansbury, 2000; McNaught et al., 2002; 
Olanow et al., 2004).  Similarly, in a mouse model of Huntington’s disease, nuclear 
inclusions are present in surviving neurons, suggesting that (at worse) the inclusion 
bodies are sub lethal or (at best) they might be protective (Reddy et al., 1998). Chapter 1                                                                                      General Introduction 
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Inclusion bodies are not always found in neurodegenerative conditions. For example, 
they do not occurs in most laboratory models of Parkinson’s disease such as those 
produced through 6 OH dopamine or MPTP toxicity (Forno et al., 1993; Dauer and 
Przedborski, 2003), through they are present in rotenone induced degeneration in rat 
(Betarbet  et  al.,  2000).  Moreover,  some  human  Parkinsonian  conditions  occur 
without  Lewy  body  formation.  This  is  especially  true  of  patients  with  parkin  (E3 
ligase of UPS) mutation, who lack Lewy bodies: it also suggest that the E3 ligase may 
be critical for Lewy body formation. 
The AS/AGU rat does not appear to produce Lewy bodies yet has dopamine release 
deficits and cell loss.  
 
1.7.2  Parkin 
 
Parkin is a 465 amino acid protein that has a molecular weight of 52 KDa (Kitada et 
al., 1998; Shimura et al., 1999), contains a ubiquitin like homology domain at its N 
terminus and may be involved in the recognition of the substrates (such as Pael R, 
synphilin 1, Cdc Rel 1 and O glycosylated from of α synuclein, see below) (Shimura 
et al., 2000), it has a central domain with unknown function and two ring fingers at 
the C terminus involved in E2 and substrate recognition and binding. Parkin has E3 
ubiquitin ligase activity (Imai et al., 2000; Shimura et al., 2000; Zhang et al., 2000), 
and  is  a  component  of  ubiquitin proteasome  system  that  identifies  and  degradates 
misfolded proteins (reviewed by Sherman and Goldberg, 2001; Cookson, 2005). 
Mutation  in  the  gene  encoding  parkin  has  been  implicated  in  autosomal recessive 
parkinsonism  (Kitada  et  al.,  1998)  and  the  gene  responsible  was  mapped  on 
chromosome 6 (Matsumine et al., 1997). Parkin mutations are found in patients with 
early onset Parkinson’s disease which has the similar clinical signs to Parkinsonism Chapter 1                                                                                      General Introduction 
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but where disordered sleep and abnormal dystonic movement can be alleviated by 
Levodopa (Dauer and Przedborski, 2003). Pathologically it is characterized by loss 
of SNC dopaminergic neurons but without Lewy bodies (Mizuno et al., 2001). 
Parkin  has  been  implicated  in  the  ubiquitination  of  four  proteins,  the  putative  G 
protein coupled transmembrane receptors Pael R (Imai et al., 2001), the interacting 
protein synphilin 1 (a protein with unknown function present in Lewy body) which 
interacted to α synuclein (Chung et al., 2001b), the synaptic vesicle protein Cdc Rel 
1(it  have  roles  in  synaptic  vesicle  transport,  fusion  and  recycling)    (Field  and 
Kellogg,  1999;  Zhang  et  al.,  2000;  Kartmann  and  Roth,  2001)  and  an  O 
glycosylated from of α synuclein (Shimura et al., 2001).   
The loss of parkin function leads to the toxic accumulation of substrate protein (Dev 
et al., 2003a); overexpression of mutated forms of parkin causes oxidative stress and 
lead to cell death via proteosomal inhibition (Hyun et al., 2002).  
1.7.3 Alpha synucleins 
 
Synucleins  are  a  family  of  15 20  KDa  proteins  that  have  been  described  in 
vertebrates,  are  present  in  neurons,  and  are  especially  abundant  at  presynaptic 
terminals. Originally, synuclein proteins were identified in the electric organ of the 
electric ray (Torpedo california) and the name synuclein is a contraction of “synapse 
and nucleus” (Maroteaux et al., 1988; Jakes et al., 1994). 
Three genes produce synucleins whose client forms include α synuclein, β synuclein 
and γ synuclein (Lavedan, 1998). 
Alpha synuclein is a presynaptic protein made up of 140 amino acids and is encoded 
by a gene on chromosome 4 (Ueda et al., 1993; Chen et al., 1995).  Normally, α 
synuclein  is  abundant  in  presynaptic  terminals  (Lee  and  Trojanowski,  2006). 
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(Ueda et al., 1993) and it has been identified as the major component of inclusions in 
many  neurodegenerative  disorders.  Such  as  the  Lewy  body  and  Lewy  neurites  of 
Parkinson’s disease (Spillantini et al., 1997), the Lewy body variant of Alzheimer’s 
disease, dementia with  Lewy body (Spillantini et al., 1997; Wakabayashi et al., 
1997; Arawaka et al., 1998; Baba et al., 1998; Irizarry et al., 1998; Takeda et al., 
1998) and glial neuronal cytoplasmic inclusions as in multiple system atrophy (Gai et 
al., 1998; Tu et al., 1998). 
The normal cellular functions of α synuclein are unknown, but several observations 
suggest synaptic functions and neural plasticity (Clayton and George, 1998). It is 
associated with synaptic vesicles in cultured rat hippocampal neurons (Withers et al., 
1997;  Murphy  et  al.,  2000)  and  it  linked  to  dopaminergic  transmission  (e.g. 
inhibition  of  tyrosine  hydroxylase  activity,  binding  to  the  presynaptic  dopamine 
transporter  (DAT)  and  being  translocated  to  the  cell  surface  where  it  accelerates 
dopamine uptake) (Lee et al., 2001; Perez et al., 2002).  
1.7.3.1 Alpha synuclein aggregation 
 
Alpha synuclein  is  naturally  unfolded  (Weinreb  et  al.,  1996)  and  assumes  an  α 
helical structure in association with membranes (Davidson et al., 1998).  By contrast, 
α synuclein aggregations exist in β sheet structure (El Agnaf  et al., 1998; Narhi et 
al., 1999; Conway et al., 2000a). 
Alpha synuclein tends to form fibrils and unfolded α synuclein can adopt a partially 
folded  intermediate  and  protofibril  during  fibril  formation.  Changes  in  cellular 
conditions  such  as  elevated  temperature  and  decreased  pH  accelerate  α synuclein 
fibril formation and tend to result in a partially folded intermediate structure (Uversky 
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Abnormal  aggregation  of  α synuclein  is  a  feature  of  many  neurodegeneration 
disorders. Several mechanisms lead to aggregation: impairment of breakdown due to 
failure  in  the  ubiquitin proteasome  system  (McNaught  et  al.,  2003)  such  as 
proteosomal inhibition leads to  α synuclein accumulation (Bennett et al., 1999) and 
aggregation  (Rideout  et  al.,  2001)  and  also  an  accumulation  and  aggregation  α 
synuclein  interact  with  ubiquitin proteasome  system  lead  to  impair  it  is  function 
(Bence et al., 2001; Tanaka et al., 2001; Snyder et al., 2003; Lee et al., 2004).  
1.7.3.2  Alpha synuclein and dopamine 
 
Aggregation  of  α synuclein  also  mediated  by  the  oxidation  environment  in 
dopaminergic  neurons  such  as  oxidative  stress  and  mitochondrial  impairment. 
Overexpression  of    α synuclein  may  increase  generation  of  intracellular  ROS  that 
induced dopaminergic cell death (Junn and Mouradian, 2002). 
Alpha synuclein plays a role in the regulation of dopamine biosynthesis by interacting 
directly  with  tyrosine  hydroxylase  (Perez  et  al.,  2002)  or  deceasing  it  is  gene 
expression and a wild type α synuclein inhibit enzyme that producing BH4 which is a 
cofactor required for tyrosine hydroxylase activity (Baptista et al., 2003). 
Anther hand, a loss of  α synuclein due to decreasing on the expression (Neystat et 
al.,  1999)  or  aggregation  (El  Agnaf  and  Irvine,  2000)  lead  to  more  dopamine 
production.    
1.7.3.3  Alpha synuclein aggregation and Parkinson’s disease 
 
Two  α synuclein  mutants  the  A53T  (Polymeropoulos  et  al.,  1997)  and  A30P 
(Kruger et al., 1998) cause rare inherited forms of familial Parkinson’s disease and 
stimulate α synuclein fibril formation (Conway et al., 1998; Narhi et al., 1999) as 
does another mutation E46K discovered by Zarranz et al (2004) in a Spanish family. Chapter 1                                                                                      General Introduction 
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1.8 Animal models in Parkinson’s disease 
To understand the pathophysiology of Parkinson’s disease (PD), as well as to test 
potential therapeutics, a number of animal models of PD have been developed. Many 
of these are based on the simple premise that the disease state is due to the death of 
dopaminergic neurons, so the most widespread models have employed neurotoxins 
such as 6 OHDA, MPTP and Rotenone.  
1.8.1 Neurotoxin based models 
1.8.1.1  6 hydroxydopamine (6 OHDA) 
6 hydroxydopamine was the first chemical agent used to produce an animal model of 
PD that had specific neurotoxic effects on catecholaminergic neurons (Ungerstedt, 
1968). Usually the 6 OHDA is injected unilaterally or bilaterally into the substantia 
nigra  or  striatum,  so  that  it  accumulates  in  dopaminergic  neurons  and  induces 
degeneration  probably  through  the  generation  of  hydrogen  peroxide  and  hydroxyl 
radicals in the presence of iron (Sachs and Jonsson, 1975; Glinka et al., 1997; Bove 
et al., 2005). The greatest loss was in the dopaminergic neurons of the SNC (A9), 
followed by the retrorubral field (A8) and the VTA (A10) (Rodriguez et al., 2001). 
There  was  a  reduction  in  striatal  dopamine  and  animals  showed  characteristic 
symptoms  such  as  rotation  (provided  the  6 OHDA  injection  was  unilateral)  and 
akinesia (with a bilateral 6 OHDA injection) (Betarbet et al., 2002; Schober, 2004).  
6 OHDA  lesions  do  not  result  in  Lewy  body  formation  in  the  substantia  nigra 
(Betarbet et al., 2002; Shimohama et al., 2003; Melrose et al., 2006). Chapter 1                                                                                      General Introduction 
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1.8.1.2  1 methyl 4 phenyl 1, 2,3,6 tetrahydro pyridine (MPTP) 
1 methyl 4 phenyl 1, 2,3,6 tetrahydro pyridine (MPTP) was discovered accidentally 
in  1982  when  a  group  of  drug  addicts  developed  sub  acute  severe  parkinsonism 
(Langston et al., 1983). MPTP crosses the blood brain barrier and is metabolized to 
1 methyl 4 phenylpyridin (MPP
+) by monoamine oxidase B.  MPP
+ is taken up via 
the  dopamine  transporter  and  accumulates  in  dopamine  neurons,  where  it  inhibits 
complex I of the electron transport chain leading to oxidative stress (Nicklas et al., 
1985; Tipton and Singer, 1993; Betarbet et al., 2002) (Figure 1.7). In primates, 
MPTP causes severe Parkinsonism symptoms including degeneration of dopaminergic  
neurons; there is also the appearance of micro inclusions which are unlike the Lewy 
bodies characteristic of idiopathic Parkinson’s disease pathology (Forno et al., 1993; 
Betarbet et al., 2002; Shimohama et al., 2003) but which nevertheless contain α 
synuclein  aggregations  (Kowall  et  al.,  2000).    MPTP  administration  to  mice  and 
nonhuman primates causes a greater loss in dopaminergic neurons in SNC (A9) and 
mainly in the ventrolateral segment (Sirinathsinghji et al., 1992; Varastet et al., 
1994; Jackson Lewis et al., 1995). As in PD, the neurons of the VTA (A10) and 
locus  coeruleus  are  less  affected  (Mitchell  et  al.,  1985;  Forno  et  al.,  1986; 
1993;1996)  but  there  is  massive  loss  of  the  dopamine  (90 99%)  in  the  striatum 
(Hantraye et al., 1993; Jackson Lewis et al., 1995); degeneration of dopaminergic 
neurons terminals was greater in the putamen than in the caudate (Moratalla et al., 
1992; Snow et al., 2000).  Mice have some locomotor defect comparable to PD such 
as hypokinesia, bradykinesia and akinesia (Sedelis et al., 2001) and primates develop 
motor dysfunctions such as tremor, bradykinesia, rigidity and postural impairment 
(Langston et al., 1984; Schultz et al., 1985; Stern, 1990; Jenner, 2003). Rodents 
such as mice and rats are less sensitive to MPTP neurotoxicity (Betarbet et al., 2002;  Chapter 1                                                                                      General Introduction 
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Figure  1.7:  Pathogenesis  of  neuronal  dysfunction  produced  by 
neurotoxins  that  affect  dopamine  neurons.  The  mechanisms  by  which 
neurotoxins kill dopamine neurons involve mitochondrial dysfunction and oxidative damage. 6 
hydroxydopamine (6 OHDA) is taken up by the dopamine transporter and it then generates free 
radicals.  1 methyl 4 phenyl 1,  2,3,6 tetrahydropyridine  (MPTP)  is  converted  by  monoamine 
oxidase B (MAOB) to 1 methyl 4 phenylpyridinium (MPP
+). MPP
+ is taken up by the dopamine 
transporter and can then be accumulated by mitochondria, leading to complex 1 inhibition and 
the  generation  of  free  radicals,  or  by  the  vesicular  monoamine  transporter,  thus  reducing 
toxicity. Rotenone is a direct inhibitor of complex 1, which also leads to free radical generation. 
MPTP and rotenone treatment increase the expression of α synuclein and, in later case, this leads 
to the formation of Lewy bodies.  From Beal, (2001).  
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Shimohama et al., 2003; Bove et al., 2005) and it’s use has generally been in primate 
studies. The main difficulty with MPTP as a model of PD is that it is an acute process, 
whereas PD is a slowly progressive disease (Shimohama et al., 2003). 
1.8.1.3  Rotenone 
Another model of PD is based on systemic exposure of rats to the pesticide rotenone 
which  is  an  inhibitor  of  mitochondrial  complex  1.  In  rodents,  rotenone  caused 
selective death of nigrostriatal dopaminergic neurons and the formation of ubiquitin 
and α synuclein positive inclusions and treated animals showed rigidity, bradykinesia, 
postural instability, unsteady gait and tremor (Betarbet et al., 2000; Sherer et al., 
2003).   The major disadvantages of this model are its variability, with some animals 
developing  lesions  and  other  not.  For  this  reason  bilateral  lesions  are  not  as 
predictably effective as bilateral treatment with 6 OHDA or MPTP (Betarbet et al., 
2002). 
 
1.8.2 Genetic based models  
A  second  groups  of  animal  models  has  been  developed  from  the  knowledge  that 
genetic defects can cause some forms of PD. 
 
1.8.2.1  Parkin genetic model 
Mutations  in  the  gene  encoding  parkin  are  linked  to  the  familial  PD  known  as 
autosomal recessive juvenile parkinsonism (AR JP) (Kitada et al., 1998). 
Drosophila  which has parkin mutation has been developed to investigate the role of 
parkin  loss  in  degeneration  of  dopaminergic  neurons.  The  results  suggest  that  the Chapter 1                                                                                      General Introduction 
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mutation does not cause degeneration of dopaminergic neurons and the locomotor 
problems (climbing and flying defects) are caused by mitochondrial defect in muscles. 
The flies exhibit reduced life span, muscle degeneration and males have spermatid 
defects (Greene et al., 2003). Several studies have described mutations and knockout 
of  the  parkin  gene  in  mice  and,  again,  there  was  no  evidence  for  a  reduction  of 
nigrostriatal  dopaminergic  neurons.  Brain  morphology  appeared  normal  and 
extracellular  dopamine  levels  were  increased  in  the  striatum  while  synaptic 
excitability  was  reduced  in  medium sized  striatal  spiny  neurons  (Goldberg et  al., 
2003; Itier et al., 2003; Von Coelln et al., 2004; Perez and Palmiter, 2005). These 
models give some insight into parkin function but do not explain the role of parkin in 
PD pathogenesis since Parkinsonian symptoms are largely lacking (Betarbet et al., 
2005).  
 
1.8.2.2  Alpha synuclein genetic model 
Mice which lack the α synuclein gene show normal brain structure and only modest 
alterations  in  dopaminergic  pathways    such  as  (a)  increased  dopamine  release 
following strong electrical stimuli, (b) a small reduction in striatal dopamine content 
and (c) attenuation of the dopamine dependent locomotor response to amphetamine 
(Abeliovich et al., 2000).  However, the over expression of both mutant and wild 
type  α synuclein  in  mice  led  to  the  formation  of  cytoplasmic  and  nuclear  micro 
inclusions containing α synuclein and ubiquitin in the neocortex, hippocampus and 
substantia nigra (albeit lacking fibrillar aggregates that are a characteristic of Lewy 
bodies). It led also to loss of nigrostriatal dopaminergic terminals in the striatum (but 
no loss of the nigrostriatal dopaminergic cells in the SNC) and reduced motor activity 
as examined by the rotorod test  (Beal, 2001; Masliah et al., 2000; van der Putten et Chapter 1                                                                                      General Introduction 
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al., 2000; Giasson et al., 2002; Lee et al., 2002; Fleming et al., 2004).  The over 
expression of wild type or mutant α synuclein in Drosophila led to the formation of 
Lewy body like inclusions containing synuclein, loss of dopaminergic neurons and 
locomotor dysfunction in the form of a progressive decline in climbing ability (Feany 
and Bender, 2000). There was retinal degeneration (which is not a feature of PD) 
(Feany  and  Bender,  2000).  It  remains  unclear  whether  the  motor  defect  can  be 
attributed  to  the  dysfunction  of  dopaminergic  neurons  (Beal,  2001).  Lentiviral 
mediated  overexpression  of  wild  type  α synuclein  in  rats  led  to  intraneuronal 
cytoplasmic aggregates but no cell loss (Lo Bianco  et al., 2002). 
1.8.3  Spontaneous rodent mutant models 
In addition to neurotoxic and genetically modified models, there have been a number 
of spontaneous rodent mutant models including the weaver, lurcher, reeler, Tshrhyt, 
tottering,  and  coloboma  mice  and  circling  (ci)  rat.  These  models  display  altered 
dopaminergic function or neurodegeneration that occur in PD and have deficits in 
motor behavior (Heintz and Zoghbi, 2000). The AS/AGU rat belong to this category 
of model.   
 
1.9 The AS/AGU rat 
The AS/AGU rat arose as a spontaneous mutation within a closed inbred colony of 
Albino Swiss (AS) rats in the Laboratory of Human Anatomy at Glasgow University. 
The  mutation  is  recessive  (Campbell  et  al.,  1996),  and  AS/AGU  rats  have  been 
isolated as a true breeding substrain. The phenotypic differences result from a single 
point mutation in the gene coding for the gamma isoform of protein kinase C (PKC γ) 
(Craig et al., 2001). The AS/AGU mutant exhibits serious movement impairments Chapter 1                                                                                      General Introduction 
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including hindlimb rigidity, a staggering gait, a tendency to fall over every few steps, 
a slight whole body tremor and difficulty in initiating movement (Clark and Payne, 
1994; Payne et al., 1998).  Previous studies including histological, neurochemical, 
immunocytochemical, and pharmacological and locomotor analysis revealed that in 
the mutant AS/AGU rats there are: 
A.  No obvious gross morphological differences between the brain of the normal 
AS and the mutant AS/AGU rats. The neocortical and cerebellar histology 
looks normal. 
B.  Neurochemical and immunocytochemical studies showed a loss in tyrosine 
hydroxylase immunoreactive cell bodies in the SNC of the mutant strain at 
aged beyond one year (Clark and Payne, 1994). 
C.  There  is  20 30%  reduction  in  whole  tissue  dopamine  levels  of  6  months 
AS/AGU mutants compared to the normal AS rats at same age measured in 
striatal micropunches using High Performance Liquid Chromatography with 
electrochemical detection (HPLC ECD) (Campbell et al., 1996). 
D.  Microdialytic  studies  found  a  great  reduction  (80 90%)  in  extracellular 
dopamine in the dorsal caudate putamen of 3 months AS/AGU mutants and 
older compared to the normal AS strain when measured with HPLC ECD 
(Campbell et al., 1998). 
E.   Behavioural  studies  found  that  AS/AGU  rats  have  a  marked  difficulty  in 
initiating movement, and generally the mutant rats perform badly in simple 
locomotor tests such as rotating in mid air and walking down a variety of 
inclined ramps of various widths compared to AS controls. The deficits are 
significant at 6 and 12 months. Locomotor deficiencies in AS/AGU rats can 
be ameliorated by L dopa administration (Campbell et al., 1998). Chapter 1                                                                                      General Introduction 
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F.  There is a marked depletion in utilization of 2 deoxy glucose in the substantia 
nigra pars compacta, subthalamic nucleus and ventrolateral thalamus (Lam et 
al., 1998). 
G.  These characteristics have been reviewed by Payne et al. (2000). They have 
been work out primarly on male AS/AGU rat because movement deficent are 
more obvious. 
H.  The  serotonergic  (5 HT)  raphe striatal  system  has  a  reduction  in  the 
extracellular  levels  of  5 HT  (70%)  in  the  dorsal  caudate putamen  of  the 
mutant compared to the controls and an increase in the levels of the 5 HT 
metabolite (5 HIAA) at 3 months and older. At later ages, there are reductions 
in whole tissue 5 HT and increases in 5  HIAA in the striatum and the dorsal 
raphe  nucleus  region,  companied  by  a  decrease  in  the  number  of  5 HT 
immunoreactive cells in the dorsal raphe nucleus. The median raphe nucleus 
was not affected (Al Fayez et al., 2005).    
 
1.9.1  The AS/AGU mutation 
Genetic  analysis  involving  multiple  backcrossing,  has  shown  a  very  tight  linkage 
between the agu mutation and a marker in the 3’ untranslated region of protein kinase 
C  γ isoform encoding gene. The protein kinase C γ gene is a single point mutation 
resulting from a stop codon between the regulatory and catalytic domains (Craig et 
al., 2001). 
Protein kinase C is a family of calcium activated, phospholipid dependent enzymes 
that are found in a wide variety of tissues (Saito and Shirai, 2002). In the nervous 
system, PKC is involved in widely diverse functions including activation of PKC in 
nerve  cells which it linked to modulation of ion channels  (Baraban et al., 1985; Chapter 1                                                                                      General Introduction 
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Madison  et  al.,  1986;  Shearman  et  al.,  1989),  the  desensitization  of  receptors 
(Huganir and Greengard, 1990), modification of neuronal plasticity (Routtenberg, 
1985; Akers et al., 1986), the enhancement of neurotransmitter release (Malenka et 
al.,  1986;  1987;  Tanaka  and  Nishizuka,  1994;  Stevens  and  Sullivan,  1998), 
implicated in general cellular processes such as apoptosis (Zirpel et al., 1998; Lee, 
2001; Ghoumari et al., 2002) and cell surface signal transduction (for review see 
Nishizuka, 1984 a,b; 1986). PKC has at least 10 isoforms that have been identified in 
mammalian tissue one of them is PKCγ (Ohno and Nishizuka, 2002; Popp et al., 
2006). 
  
PKCγ is a member of the PKC family which was originally thought to be restricted to 
brain and spinal cord (Huang et al., 1988; Nishizuka, 1988; Tanaka and Saito, 
1992; Saito and Shirai, 2002). It is highly expressed in purkinje cells and in the 
medium sized  neurons  of  the  striatum  and  globus  pallidus  that  project  to  the 
substantia nigra (Chen et al., 1995), in perikarya and neuropil in the striatum, and 
neuropil in substantia nigra (Yoshihara et al., 1991). Within the nervous system, it 
has  been  associated  with  a  variety  of  functions  including  neuron glial  plasticity 
(Narita et al., 2004), memory (Abeliovich et al., 1993), alcohol intake (Bowers and 
Wehner, 2001), sensory processing (Martin et al., 2001; Narita et al., 2001), anxiety 
(Bowers et al., 2000) and cerebellar afferent regulation (Chen et al., 1995).  Now 
known to be found in the heart (Rouet Benzineb et al., 1996), pulmonary epithelial 
cells (Lin et al., 2000), pulmonary fibroblast (Ludwicka Bradley et al., 2000) and 
immortalized mammary epithelial cells (Mazzoni  et al., 2003) so it is clearly not 
restricted to the nervous system.   Chapter 1                                                                                      General Introduction 
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There is a PKCγ ko mutant mouse which was developed to give insight into the effect 
of the mutation on cerebellum and this mouse is characterized by motor impairment 
and defects of Long term potentation (LTP), due to the persistence in adulthood of 
multiple  climbing  fibres  from  the  inferior  olivary  nucleus  to  Purkinje  cells 
(Abeliovich  et  al.,  1993;  Chen  et  al.,  1995).  There  is  no  evidence  of  a  similar 
problem  in  the  AS/AGU  rat:  equally,  there  is  no  evidence  of  basal  ganglia 
involvement in the PKCγ ko mouse.  
However,  it  is  of  interest  that  the  protein  kinase  C gamma  gene  is  mutated  in 
spinocerebellar  ataxia  type  14  which  is  an  autosomal  dominant  neurodegenerative 
disorder  characterized  by  slowly  progressive  cerebellar  dysfunction  including  gait 
ataxia, dysarthria and abnormal eye movements (Verbeek et al., 2005). 
 
1.10 Aims of the study 
In  this  study,  three  complimentary  experiments  were  carried  out  to  examine  the 
possible pathological responses of midbrain cell groups to the agu mutation in the 
gene coding for protein kinase C gamma (PKC γ). 
 The three experiments were: 
1)  Experiment 1 to examine levels of certain molecules in the midbrain cell 
groups using quantitative immunofluorescence microscopy of cell bodies or 
their surrounding neuropil. These molecules consisted of two groups:                                             
a)  Those giving information about the capacity of midbrain aminergic 
cell  bodies  to  synthesise  transmitters:  tyrosine  hydroxylase  for 
dopaminergic neurons and serotonin for serotonergic ones.  Chapter 1                                                                                      General Introduction 
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b)  Those which have been found to increase in human neurodegenerative 
conditions  such  as  Parkinson’s  disease:  ubiquitin,  parkin  and  α 
synuclein. 
2)  Experiment  2  to  look at  cell  bodies  in  the  SNC  of  the  AS  (control)  and 
AS/AGU  (mutant)  rats  using  light  and  transmission  electron  microscopy 
(TEM) to determine whether there are any strain differences in cell size or 
ultrastructure  or any signs of cell morbidity.                                                                                                                                                               
3)  Experiment 3 to look at TH+ve nigrostriatal dopaminergic terminals in the 
dorsal caudate putamen of the AS (control) and AS/AGU (mutant) rats using 
TEM to determine whether there are: 
a)  Differences in the percentages and numbers of such terminals. 
b)  Differences in synaptic vesicles numbers. 
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CHAPTER 2 
 
EXPERIMENT 1: 
Quantification of transmitter synthesis and degeneration 
associated molecules in midbrain and striatum: a 
comparison of AS and AS/AGU rats 
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2.1  Introduction 
 
 
The AS/AGU rat has been characterised as a mutation in the gene coding for protein 
kinase C γ (Craig et al., 2001) which results in an inability to release biogenic amines 
such as dopamine and serotonin in the striatum (Campbell et al., 1997; Al Fayez et 
al., 2005). 
The physiological failure, measured by in vivo microdialysis and HPLC ECD, occurs 
from an early age. Only in later life is there a measurable decrease in whole tissue 
dopamine or serotonin levels (Campbell et al., 1998, 2000; Payne et al., 2000; Al 
Fayez et al., 2005) or a decrease in aminergic cell numbers (Clarke and Payne, 
1994; Scott et al., 1994; Stewart et al., 1994; Al Fayez et al., 2005). This suggests 
that synthesis of amines is not compromised in early stages of the disorder, even 
though release is. However, overall levels of amines (as analysed by micropunch and 
HPLC ECD)  could  mask  considerable  variation  between  non functional  senescent 
neurons and hyperactive compensatory ones. The first aim, therefore, was to examine 
the synthetic capabilities of cells in the substantia nigra (dopamine) and midbrain 
raphe nuclei (serotonin) at different ages. A second aim was to examine levels of  
molecules associated with neurodegeneration in Parkinson’s disease, especially those 
associated with Lewy bodies such as ubiquitin, parkin and α synuclein (Love and 
Nicoll,  1992;  Irizary  et  al.,  1998).  This  is  because  most  laboratory  models  of 
nigrostriatal dysfunction do not exhibit the cellular inclusions which are traditionally 
thought of as a defining characteristic of the human condition (Forno et al., 1993; 
Dauer and Przedborski, 2003). Even if no such pathological features occur, it is 
important to know if there are elevations in intracellular levels of these molecules Chapter 2                                                                                                     Introduction                                                                                  
 
61 
since this would imply kinship between the laboratory model and the human disorder 
and, perhaps, similar mechanisms of dysfunction.    
 
2.1.1  Tyrosine hydroxylase (TH)      
Tyrosine hydroxylase (TH) has frequently been used as a marker of dopaminergic 
neurons  (Pearson  et  al.,  1983).  TH  catalyses  the  first  and  rate limiting  step  in 
biosynthesis of catecholamines (Nagatsu et al., 1964; Kuhar et al., 1999; Lehmann 
et al., 2006) responsible for the conversion of L tyrosine to L DOPA.  In the rat it is a 
homotetrameteric  protein  composed  of  498  identical  amino  acid  residue  subunits 
(Grima et al, 1985). It appears to be encoded by a single gene in all species (Kumer 
and Vrana, 1996; Fitzpatrick, 1999). The conversion of L tyrosine to noradrenaline 
and adrenaline was first shown in the adrenal medulla (Blaschko, 1939) and later 
confirmed in  the CNS and PNS (Flatmark, 2000). TH is present in a soluble and a 
membrane bound form (Nagatsu et al., 1964; Kuczenski and Mandell, 1972; Kuhn 
et al., 1990). TH activity is regulated by various mechanisms including induction of 
TH  gene  transcriptional  regulation,  phosphorylation  by  different  kinase  systems 
(PKA, PKC and PKG) and feedback inhibition by the end product; it also requires 
tetrahydrobiopterin or pteridine (BH4) as a co factor, molecular oxygen and ferrous 
iron (Fe
+2) for it is reaction (for review see, Kumer  and Vrana, 1996). 
TH  levels and  distribution have been studied enzymatically (McGeer et al., 1971; 
McGeer and McGeer, 1976; Sawada et al., 1987), by using immunohistochemical 
techniques (Gaspar et al., 1985; Martin et al., 1991 ; Holt et al., 1997; Hedreen, 
1999) and by fluorescence microphotometry in rat (Sutoo et al., 1991) and  human 
brain (Sutoo et al., 2001).   Chapter 2                                                                                                     Introduction                                                                                  
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TH  immunofluorescence  levels  have  been  determined  in  normal  and  pathological 
brains  by  TH  messenger  RNA  (detected  by  in  situ  hybridization)  and  TH  protein 
content in the cells (Kastner et al., 1993; Sutoo et al., 1994). 
Many  points  must  be  considered  in  analysing  TH  immunostaining  in  normal 
dopaminergic neurons of the mesencephalon as described by Kastner et al. (1993). 
TH immunostaining was variable from one neuron to another in the same region and 
from region to region (e.g. dopaminergic neurons of A8 have higher TH content).  TH 
immunolabelling of the midbrain are related to their projection organization within the 
striatum as in the striosome that has lower TH immunoreactivity.  TH concentrations 
are  not  related  to  the  neuromelanin  content  and  are  not  age  dependent.  TH 
immunostaining  levels  are  reduced  in  PD  patients  as  is  TH  mRNA  in  surviving 
dopaminergic nigral neurons and in TH ve dopaminergic neurons.  
 
2.1.2  Serotonin (5 HT) 
Serotonin  (5 HT)  is  an  aminergic  neurotransmitter  synthesized  in  several  cell 
groupings located in the midbrain and brain stem (Morgan et al., 1987; Jacobs and 
Azmitia,  1992;  Chojnacka Wojcik,  1995).  Like  dopamine,  midbrain  serotonergic 
neurons project mainly to the striatum and other forebrain regions (Azmiti and Segal, 
1978; Imai et al., 1986; Jacobs and Azmitia, 1992) and are depleted in human PD 
(Halliday et al., 1990; Paulus and Jellinger, 1991).  
Serotonin is formed from the amino acid tryptophan which is converted to 5 hydroxy 
tryptophan by the rate limiting enzyme tryptophan hydroxylase (Fitzpatrick, 1999), 
then converted to 5 HT by aromatic L amino acid decarboxylase. Serotonin can be 
metabolised  initially  into  5 hydroxy indole acetaldehyde  by  monoamine  oxidase Chapter 2                                                                                                     Introduction                                                                                  
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(MAO) and is further oxidised by aldehyde dehydrogenase to 5 hydroxy indole acetic 
acid (see Osborne, 1982). 
A reduction in serotonin concentration has been detected in the striatum, substantia 
nigra, hippocampus, and other regions of the Parkinsonian brain (Rinne et al., 1974; 
Scatton  et  al.,  1983;  Agid  et  al.,  1987;  Mizuno,  2005).  Also,  a  reduction  in 
tryptophan hydroxylase activity occurs in Parkinson’s disease patients (Sawada et al., 
1985),  together with depleted 5 HT and its metabolites in the cerebrospinal fluid 
(CSF) (Tohgi et al., 1993). The situation in laboratory models of PD can only be said 
to be highly variable and confusing.  In animals treated with MPTP, the serotonin 
concentration in the striatum and the  raphe nuclei has been reported as decreased 
(Pifl et al., 1991; Frechilla et al., 2001), unchanged (Rose et al., 1989) or increased 
(Gaspar et al., 1993). Rats treated neonatally with 6 OHDA exhibit serotonergic fibre 
hyperinnervation in the striatum accompanied by increased 5 HT and its metabolite 
(5 HIAA) in the striatum (Kostrzewa et al., 2006). Conversely, others have found 
that the tissue content of 5 HT and 5 HT innervation were significantly decreased in 
the striatum of 6 OHDA treated rat (Takeuchi et al., 1991). 
 
2.1.3  Lewy body proteins 
Many  age related  neurodegenerative  disorders  including  PD  involve  abnormal 
aggregation and deposition of mis folded proteins within affected neurons. 
In  PD,  the  aggregation  and  deposition  of  mis folded  proteins  in  the  nigrostriatal 
dopaminergic  neurons  of  the  substantia  nigra  is  a  noted  characteristic.  Mis folded 
proteins  such  as  ubiquitin,  parkin  and  α synuclein  are    accumulated  in  the  Lewy 
bodies  that  are  a  pathological  hallmark  feature  of  PD  (Pollanen  et  al.,  1993; 
Cornford et al., 1995; Forno, 1996; Galvin et al., 1997; Shults, 2006). Chapter 2                                                                                                     Introduction                                                                                  
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(i) Ubiquitin is a 76 amino acid protein that has a major role in regulated protein 
degradation  by  the  ubiquitin proteasome  pathway  (Hershko  and  Ciechanover, 
1998). This pathway plays a major role in the degradation of abnormal proteins that 
result  from  oxidative  stress,  neurotoxicity  and  mutations  (Alves Rodrigues  et  al., 
1998). 
Ubiquitin appears to be incorporated into inclusion bodies which occur in the major 
neurodegenerative  diseases  including  Alzheimer’s  disease  and  Parkinson’s  disease 
(Lowe  et al., 2001).  
(ii) Parkin is a protein that has ubiquitin ligase a activity (Imai et al., 2000; Shimura 
et al., 2000; Zhang et al., 2000) and therefore also plays an important role in the 
ubiquitin proteasome  pathways.  A  mutation  in  the  parkin  gene  is  implicated  in  a 
familial type of PD called autosomal recessive juvenile parkinsonism (Kitada et al., 
1998). 
(iii)  Alpha synuclein    is  a  presynaptic  protein  (Clayton  and  George,  1998; 
Spillantini et al., 1998a). Like parkin, a mutation of α synuclein has been identified 
in  one  form  of  autosomal  dominant  familial  PD  (Polymeropoulos  et  al.,  1997; 
Kruger et al., 1998). 
Lewy  body  proteins  have  been  discussed  in  depth  in  chapter  1  (the  general 
introduction).   
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2.2  Rationale for measurement technique  
Levels of compounds can be measured in brain regions by traditional techniques such 
as competitive protein binding or high pressure liquid chromatography (Thorpe and 
Thorpe, 2000; Wilson, 2000). Similarly, enzymes can be measured by incubation of 
tissue slices with radiolabelled precusors (Thorpe and Thorpe, 2000). 
However,  in  each  case,  measurements  are  being  made  on  a  heterogeneous  tissue 
sample, whether it be a core or a slice. This has the disadvantage of including neurons 
and  glial cells of many types  as well as the inability to distinguish between  cell 
bodies  and  neuropil.  To  get  round  these  obvious  disadvantages,  the  decision  was 
made to sample large numbers of individual cells from known regions of CNS. One 
way to do this is to employ immunocytochemistry  where the primary antibody is 
directed toward a molecule of interest (e.g. ubiquitin) and the secondary antibody is a 
fluorescent  one.  The  amount  of  fluorescence  coming  from  each  cell  gives  a 
quantitative measure of the abundance of the molecule. Provided measurements are 
made  on  tissues  which  have  been  prepared,  processed,  treated  and  measured  in 
exactly the same way, this allows good comparisons to be made between individuals 
or  groups  (Kastner  et  al.,  1993).  This  is  especially  true  where  a  pair  of  animals 
(control and mutant) are analysed together at every stage. This was the case here. All 
inter group comparisons are then made by dependent (i.e. paired) statistics.    
The  aim  of  Experiment  1  is  therefore  to  examine  levels  of  molecules  that  give 
information about  
i.  synthesis of the aminergic neurotransmitters TH and 5 HT and  
ii.  levels  of  molecules  which  have  been  found  in  intracellular  inclusions  in 
Parkinson’s disease using quantitative immunofluorescence microscopy.    Chapter 2                                                                                   Materials and Methods 
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2.3  Materials and Methods  
  
2.3.1 Animals 
18 AS control and 18 AS/AGU mutant male rats were used in this experiment. 
The numbers in each age group were: 
(1)  6 AS and 6 AS/AGU aged 6 months old. 
(2)  6 AS and 6 AS/AGU aged 12 months old. 
(3)  6 AS and 6 AS/AGU aged 18  months old. 
2.3.2 Tissue preparation 
All rats were deeply anaesthetized with an overdose of sodium pentobarbitone B.P 
(Vet.),  (2  ml  of  60  mg/ml,  Rhone Merieux,  Spire  Greencentre,  Harlow,  Essex)  
injected intraperitoneally, and then the thoracic cavity was opened. One hundred ml of 
mammalian Ringer solution containing the vasodilator Lignocaine was injected into 
the  left  ventricle    followed  by  500ml  4%  paraformaldehyde  (Sigma   Aldrich  Inc, 
P6148) in 0.1M phosphate buffer, excess fluid being drained via an incision through 
the right atrium (Appendix 1). The brains were dissected out and immersion fixed in 
4%  paraformaldehyde  in  0.1M  of  phosphate  buffer  overnight.  Pieces  of  brain 
containing areas of interest were dehydrated through an ascending ethanol series using 
a  Histokinette  2000  automatic  tissue  processor  (Reichert Jung,  Germany)  then 
embedded in paraffin wax at 57ºC and serially sectioned at 7 m using a Microtome 
(Spencer, 820, USA) (Appendix 2). The ribbons of sections were laid out in parallel 
rows on a tray. Chapter 2                                                                                   Materials and Methods 
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2.3.3 Toluidine blue Staining 
Three sections from the middle and ends of each row were collected and stained with 
1%  aqueous  toluidine  blue  (R.ALAMB,  UK)  (Appendix  3A).  They  were  then 
examined under a light microscope to locate the rostral, central and caudal ends of the 
substantia nigra, dorsal and median raphe nuclei and the striatum in order to provide 
reference  sections  for  matching  sections  of  the  AS and  the  AS/AGU  rats  using  a 
standard atlas of the rat brain (Paxinos and Watson, 1982).(Figure 2.1). 
2.3.4 Immunocytochemistry (ICC) on paraffin sections 
 It  is  an  essential  feature  of  this  experiment  that  AS  and  AS/AGU  sections  were 
processed and assessed together as pairs. Adjacent sections were chosen, collected 
and stretched in a paraffin section mounting bath for 1 3 mins at 40ºC. They were 
then mounted on APES (3 aminopropltriethoxysilane) coated slides and dried in a 
37ºC oven overnight and then at 56ºC for 2 hours. The sections were deparaffinized 
and rehydrated before undergoing a heat mediated antigen retrieval technique (Shi et 
al., 1991). Slides were immersed in boiling 0.01M sodium citrate buffer (pH 6.0) in a 
Prestige stainless steel pressure cooker (Norton et al., 1994).  The temperature was 
then raised to 120ºC for 1 minute. Sections were rinsed in distilled water followed by 
0.01M  phosphate  buffered  saline  (PBS,  1x5  mins),  and  then  incubated  in  1.5% 
hydrogen peroxide (H2O2) for 10 minutes to inactivate endogenous peroxidase. After 
rinsing in distilled water (2x5 mins) and in PBS (2x5 mins), sections were treated 
with 1% normal  goat serum (NGS, Sigma Aldrich, G9023, UK) in PBS with 3% 
Triton  X 100  (Sigma  Chemical.  CO)  for  60  min  at  room  temperature  to  reduce 
nonspecific background staining (Appendix 3B). 
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Figure 2.1:  Coronal sections of midbrain to show substantia nigra: 
Sections (a, d, and g) were stained with toluidine blue. Sections (b, e and h) were 
stained with immunoperoxidase DAB for TH. 
The sections show the rostral (a and b) central (d and e) and caudal (g and h) 
regions of the substantia nigra (x2.5). (c, f and i from Paxinos and Watson, 1982). 
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2.3.5 Immunoperoxidase staining 
 
This method of ICC staining was carried out according to a protocol that has been in 
use  for  25  years  (Hsu  et  al.,  1981)  and  was  used  to  confirm  the  identify  of  the 
substantia nigra, midbrain raphe nucleus and the striatum in matching sections of the 
AS  and  the  AS/AGU  rats  by  staining  for  the  rate limiting  enzyme  tyrosine 
hydroxylase  (TH)  (within  the  SN  and  striatum)  and  serotonin  (5 HT)  (within  the 
midbrain raphe nucleus),(Figure 2.1 and 2.2). 
Sections were incubated for 24 h in a humidity chamber at 4ºC with the primary 
antibody to TH or 5 HT diluted in blocking serum (1% NGS in PBS with 0.3% Triton 
X  100). The rest of the procedure was carried out at room temperature. After rinsing 
in PBS (3x5 mins), sections were incubated for 60 min in a biotinylated  secondary 
antibody. Following incubation for 60 min in Avidin Biotin Complex (ABC) reagent 
(1:50; 20 l of solution A and 20 l of solution B in 1ml of PBS; Vectastain ABC kit, 
Vector Laboratories, INC, PK 6100, Peterborough UK), sections were then rinsed in 
PBS (3x5 mins) and 0.1 M phosphate buffer (PB, 1x5 mins). The location of the 
antigen antibody  complex  was  visualized  by  incubating  sections  in  a  medium 
containing 0.05% 3,3 diaminobenzidine (DAB substrate KIT for peroxidase, Vector 
Laboratories, INC, SK 4100, Peterborough UK) for 2 5 min. This step was carried out 
with care in fume cupboard and all equipment which came in contact with DAB was 
soaked  with  bleach  in  order  to  denature  it,  as  DAB  is  potentially  carcinogenic 
(International  Agency  for  Research  on  Cancer,  1972).  Finally,  the  sections  were 
rinsed  in  distilled  water,  dehydrated  and  mounted  with  glass  coverslips  using 
histomount  (RALAMB,  HS 103,  UK).  Slides  were  then  examined  under  a  light 
microscope using a standard atlas of the rat brain (Paxinos and Watson, 1982).  
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Figure  2.2  :  Coronal  sections  of  (a)  substantia  nigra  (x40),  (c)  dorsal  and 
median  raphe  nuclei  (DRN  and  MRN),(x20)  and  (e)  striatum,(x20)  from  a 
control (AS) male rat aged 12 months. Sections have been immunostained for 
TH. VTA, ventral tegmental area; SNC, substantia nigra pars  compacta; SNR, 
pars  reticularis;  SNL,  pars  lateralis;  DCPU,  dorsal  caudate putamen;  LCPU, 
lateral caudate putamen; VCPU, ventral caudate putamen; GP, globus pallidus. 
(b, d and f from Paxinos and Watson, 1982). 
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Control sections were obtained by removing the primary antibody to test for any non–
specific background staining. 
Areas of interest were recorded using a digital camera, NIKON; Coolpix 995 (3.34 
Mega pixel). 
2.3.6 Immunofluorescence staining 
Whilst  toluidine  blue  and  immunoperoxidase  DAB  staining  for  TH  were  used  to 
confirm  the  position  of  sections,  strain  differences  were  assessed  by  quantitative 
immunofluorescence.  The  same  procedures  used  in  ICC  were  followed  to  prepare 
sections for the primary antibody. Sections were incubated in a humidity chamber for 
24 h at 4ºC with primary antibody  diluted  in the blocking serum. After rinsing in 
PBS (3x5 mins), the sections were incubated in a humidity chamber for 24 h at 4ºC 
with  a  fluorescent  secondary  antibody  at  a  dilution  of  1:100  in  PBS. Slides  were 
covered with a caterwrap foil to give protection from bleaching in this step and during 
the rest of the procedure. The sections were then mounted with glass coverslips using 
Vectashield (H 1400, UK) after rinsing in distilled water (3x5 mins) and were ready 
for fluorescence quantification that was  carried  out on the same day. The area of 
interest was recorded using a Leica Wild MP52 photo automat camera fitted to the 
microscope.   
2.3.7 Double labeling Immunofluorescence staining 
This method was used to confirm the present of Lewy body proteins such as ubiquitin, 
parkin and α synuclein in the (TH) +ve cells or neuropil in the substantia nigra in the 
adjacent sections of the AS and the AS/AGU rats. 
Sections were incubated in a humidity chamber for 24 h at 4ºC with a mixture of two 
primary antibodies (e.g. anti tyrosine hydroxylase and anti ubiquitin) diluted at 1:500 Chapter 2                                                                                   Materials and Methods 
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in the blocking serum. After rinsing in PBS (3x5 mins), the sections were incubated in 
a  humidity  chamber  for  24  h  at  4ºC  with  a  fluorescent  secondary  antibody 
(Fluorescein  and Rhodamine ), at dilution of 1:100 in PBS for both. Slides were 
covered to give protection from bleaching in this step and the rest of the procedure. 
The sections were then mounted with glass coverslips using Vectashield (H 1400, 
UK) after rinsing in distilled water (3x5 mins). 
Areas  of  interest  were  recorded  using  a  Leica  Wild  MP52  photo automat  camera 
fitted to the microscope. 
2.3.8  Fluorescence  and  the  quantitative  fluorescence 
microscope: 
 
The  physiological  or  pathological  changes  that  occur  in  cells  can  be  studied  by 
sensitive  techniques  involving  the  use  of  fluorescent  compounds  coupled  with  a 
photometric fluorescence microscope. 
Fluorescence is a type of luminescence where the absorption of light energy raises a 
molecule to a higher energy state, with subsequent releasing of energy in the form of 
light. In practical terms the wavelength of the emitted light is always longer than the 
excitatory light, so excitation in the ultraviolet leads to fluorescence in the visible 
range (usually in the blue or green) and excitation in the blue or green will usually 
lead to emission in the red. The advantage of using fluorescence is that it is possible to 
quantify  the  uptake  of  probe  into  a  cell  surface  membrane  or  into  cell  organelles 
without damaging the cell. 
The sensitivity and selectivity of fluorescence detection has excited the interest of 
microscopists since the1950s (for review see Taylor and Salmon, 1989; Wampler 
and Kutz, 1989). Chapter 2                                                                                   Materials and Methods 
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Immunofluorescence  has  been  the  most  common  application  of  fluorescence 
microscopy in cell biology. It combines the specificity and sensitivity of fluorescence 
microscopy with the selective binding of antibodies to restricted regions of antigen 
molecules.  
Immunofluorescence quantification in these studies was achieved by using a Leitz 
Laborlux S microscope and photometric system (Figure 2.3), which consisted of a 
photometer  attachment  with  photomultiplier  (ERNST  LETZ  WETZLAR  GMBH, 
301 289,133, Germany), which converts the light flux into electric signals. A control 
panel (Figure 2.4) allows the starting of the automatic measuring process, and coarse 
and fine amplification of the measuring signal, digital display unit and the power units 
for  stabilizing  the  light  sources.  I  followed  immunofluorescence  quantification 
techniques used over several years by researchers in the Division of Biochemistry and 
Molecular Biology in Glasgow University  (Modha et al., 1997; Ribeiro et al., 1998 
; Al Adhami et al. , 2001 ; Akhkha  et al, 2002 ; Al Adhami et al. , 2003). 
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Figure 2.3: Leitz Laborlux S microscope photometer showing the major 
components (photometer, control panel and the power units). 
 
 
 
Figure 2.4: Leitz Laborlux S microscope photometer control panel showing the 
Display, A button for the starting the measuring process and I button to take the 
measurement and JO knob (adjust display reading to zero). 
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2.3.9 Fluorescence quantification 
 
Fluorescence immunoreactivity of certain molecules in the midbrain cell groups or the 
striatum was quantified using a Leitz Laborlux S microscope photometer equipped 
with the filter set for Rhodamine Red X (excitation, 570 nm and emission, 590 nm) an 
objective lens x50 (Fluoreszenz) and with a measurement field set at 150  m
2 (The 
measurement was confirmed using a graduated slide from Graticules LTD Tonbridge 
Kent, England).
 Immunofluorescence was quantified in cells of the rostral substantia 
nigra pars compacta (SNC; Approximately -4.8mm relative to bregma), central SNC 
(Approximately  -5.3mm  relative  to  bregma),  caudal  SNC  (Approximately  -6.3mm 
relative to bregma), pars lateralis (SNL), pars reticularis (SNR),  the ventral tegmental 
area  (VTA),  the  dorsal  raphe  nucleus  (DR;  Approximately  -7.8  mm  relative  to 
bregma) and the median raphe nucleus and dorsal, lateral and the ventral parts of the 
caudate putamen (Approximately -0.3 mm relative to bregma) (Paxinos and Watson, 
1982) of both AS (control) and AS/AGU (mutant) rats. The central SNC (the largest 
part) was also subdivided into medial and lateral halves and measurement started from 
the medial half and progressed toward the lateral half. 
After  the  sections  were  put  on  the  Leitz  Laborlux  S  microscope  stage,  a  bright 
sampling frame, viewed down the microscope eyepiece, was adjusted to a constant 
size of 15x10  m throughout the experiment as this size was found to enclose the cell 
body satisfactorily. The only exception was α synuclein since this is a pre synaptic 
protein and therefore not found in cell bodies; here, the sampling frame  was adjusted 
to  enclose  an  area  of  neuropil  of  constant  size  (120x120   m)  throughout  the 
experiment (Figure 2.5 and 2.6).  
As  well  as  immunofluorescence positive  cells  or  neuropil  areas  the  background 
fluorescence was also measured and subtracted from the recorded measurements.  Chapter 2                                                                                   Materials and Methods 
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Figure  2.5:  A  coronal  section  of  substantia  nigra  shows  a  bright  sampling 
frame and its size (10x15  m) that is adjusted to enclose a TH immunostained 
cell (x1000). 
 
 
Figure  2.6:  A  coronal  section  of  substantia  nigra  shows  a  bright  sampling 
frame  and  its  size  (120x120   m)  that  is  adjusted  to  enclose  α Synuclein 
immunostained neuropil (x500). 
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(Appendix 5). 
The number of measured cells per animal was at least 50 in each area. This being the 
approximate numbers on a single section which showed a nucleus and nucleolus. 
The  fluorescence  measurements  are  shown  in  arbitrary  units,  the  range  of  values 
obtained being from 0.01 30. Tyrosine hydroxylase immunofluorescence per volume 
of cell was measured (the volume of SNC cells measured in chapter 3 page 154). 
2.3.10  Statistical analysis 
The  results  were  analysed  by  paired  t test  using  the  Minitab  statistics  package 
(MINITAB Release 13.30). 
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2.3.11  Calibration of fluorescent measurements 
It was not possible to calibrate the arbitrary units against objects of known fluorescent 
emission.  However,  it  was  possible  to  test  the  relationship  between  fluorescence 
observed and primary antibody for TH on adjacent midbrain sections. Concentrations 
ranged between 1:50 and 1:2000 and show a strong liner relationship (Table 2.1 and 
Figure 2.7).  
 
 
Primary antibody concentrations 
(TH) 
Fluorescence (arbitrary units) 
1:50  20.48 
1:100  19.44 
1: 250  16.86 
1: 500  13.83 
1: 1000  11.85 
1: 2000  8.16 
Table  2.1:  Calibration  of  fluorescent  measurements:  first  column  a  series  of  
primary  antibody  concentrations  against  TH  and  their  fluorescent 
measurements (arbitrary units) in a second column. 
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Figure  2.7:  Calibration  of  fluorescent  measurements:  a  series  of  primary 
antibody  concentrations  (TH)  and  their  fluorescent  measurements  (arbitrary 
units). 
 
 
 
 
 
 
Correlations: Primary antibody concentrations, Fluorescence (arbitrary 
units)  
 
Pearson correlation of Primary antibody concentrations 
and Fluorescence 
(arbitrary units) = -0.944 
 
P-Value = 0.005 
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2.4  Results for tyrosine hydroxylase 
 
2.4.1  Quantified  tyrosine  hydroxylase  immunofluorescence  in  the 
midbrain of AS and AS/AGU rats aged six months. 
 
The results for tyrosine hydroxylase (TH) immunofluorescence show a statistically 
significant difference between the two groups in the rostral and caudal ends of the 
SNC,  and  the  lateral  half  of  the  central  SNC.  (P<0.05  or  higher).  There  are  no 
statistical differences between the two groups in the levels of TH in the medial half of 
the central SNC, SNL, VTA or the SNR. In each case where there is a significant 
difference,  the  mutant  rats  have  higher  levels  than  the  control  strain.  Tyrosine 
hydroxylase immunofluorescence per volume of cell show a statistically significant 
difference between the two groups in the rostral, cental and caudal ends of the SNC. 
The results are summarized in table 2.2. 
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AS 
 
AS/AGU 
 
P 
Rostral SNC 
                        
      
     Flu/cell volume 
 
  8.53 ± 1.40 
 
0.015 ± .002 
 
12.44 ± 2.21 
 
0.061 ± .009 
 
< 0.05 
 
< 0.01 
 
13.98 ± 2.19 
 
  0.021 ± 0.003 
 
18.45 ± 3.37 
 
  0.077 ± 0.014 
 
< 0.05 
 
< 0.05 
 
16.81 ± 2.50 
 
  0.017 ± 0.003 
 
18.88 ± 3.40 
 
  0.075 ± 0.014 
 
NS 
 
< 0.01 
Central SNC 
 (a) overall       
 
     Flu/cell volume          
 (b) medial 
 
           
     Flu/cell volume         
 (c)  lateral 
 
 
     Flu/cell volume 
 
11.17 ± 2.02 
 
  0.026 ± 0.004 
 
18.02 ± 3.43 
 
  0.079 ± 0.014 
 
< 0.05 
 
< 0.05 
 
Caudal SNC 
 
     Flu/cell volume 
 
10.20± 1.38 
 
 0.013 ± 0.002 
 
14.54 ± 2.05 
 
  0.052 ± 0.009 
 
< 0.01 
 
< 0.01 
 
SNL 
 
 
16.73 ± 2.46 
 
17.18 ± 1.94 
 
NS 
 
SNR 
 
 
17.83 ± 2.20 
 
18.06 ± 1.79 
 
NS 
 
VTA 
 
 
14.10 ± 1.67 
 
17.81 ± 3.57 
 
NS 
Table  2.2:  Tyrosine  hydroxylase  (TH)  quantification  (arbitrary  units  of 
fluorescence) in the midbrain of AS control and AS/AGU mutant rats aged six 
months  (n=6  per  group),(Flu/cell  volume:  fluorescence  per  cell  volume).  All 
values are mean arbitrary units ± SEM. All comparisons are paired t tests (NS,  
not significant). 
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2.4.2  Quantified  tyrosine  hydroxylase  immunofluorescence  in  the         
midbrain of AS and AS/AGU rats aged 12 months. 
 
The results for tyrosine hydroxylase (TH) immunofluorescence show a statistically 
significant difference between the two groups in all TH +ve cells in the SNC. (P<0.05 
or greater). In the SNL, SNR and the VTA there are no statistical differences between 
the two groups. Tyrosine hydroxylase immunofluorescence per volume of cell show a 
statistically significant difference between the two groups in the rostral, cental and 
caudal ends of the SNC. The results are summarized in table 2.3. In each case where 
there is a significant difference, the mutant rats have higher levels than the control 
strain. 
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AS 
 
AS/AGU 
 
P 
 
Rostral SNC 
 
     Flu/cell volume 
 
11.09 ± 0.47 
 
  0.017 ± 0.001 
 
16.36 ± 0.57 
 
  0.068 ± 0.003 
 
< 0.001 
 
< 0.001 
 
11.93 ± 0.47 
 
  0.018 ± 0.001 
 
15.02 ± 0.67 
 
  0.062 ± 0.003 
 
< 0.01 
 
< 0.001 
 
11.32 ± 0.53 
 
  0.019 ± 0.001 
 
       14.89 ± 1 
 
    0.062 ± 0.002 
 
< 0.05 
 
< 0.001 
Central SNC 
 (a) overall 
 
     Flu/cell volume 
           
 (b) medial 
 
     Flu/cell volume 
           
 (c)  lateral 
 
     Flu/cell volume 
 
12.53 ± 0.43 
 
  0.017 ± 0.001 
 
15.14 ± 0.42 
 
  0.061 ± 0.004 
 
< 0.01 
 
< 0.001 
 
Caudal SNC 
 
     Flu/cell volume 
 
10.59 ± 0.55 
 
  0.016 ± 0.001 
 
15.39 ± 0.64 
 
  0.064 ± 0.003 
 
< 0.001 
 
< 0.001 
 
SNL 
 
 
10.13 ± 0.26 
 
10.18 ± 0.26 
 
NS 
 
SNR 
 
 
12.09 ± 0.65 
 
12.82 ± 0.84 
 
NS 
 
VTA 
 
 
11.92 ± 0.30 
 
12.11 ± 0.31 
 
NS 
Table  2.3:  Tyrosine  hydroxylase  (TH)  quantification  (arbitrary  units  of 
fluorescence) in the midbrain of AS control and AS/AGU mutant rats aged 12 
months  (n=6  per  group),(Flu/cell  volume:  fluorescence  per  cell  volume).  All 
values are mean arbitrary units ± SEM. All comparisons are paired t tests (NS,  
not significant). 
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2.4.3  Quantified  tyrosine  hydroxylase  immunofluorescence  in  the 
midbrain of AS and AS/AGU rats aged 18 months. 
 
The results for tyrosine hydroxylase (TH) immunofluorescence show a statistically 
significant difference between the two groups in all regions except the SNL (P<0.05 
or  greater).  Tyrosine  hydroxylase  immunofluorescence  per  volume  of  cell  show  a 
statistically significant difference between the two groups in the rostral, cental and 
caudal ends of the SNC. The results are summarized in table 2.4. In all regions, the 
mutant rats have higher levels than the control strain.  
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AS 
 
AS/AGU 
 
P 
 
Rostral SNC 
 
     Flu/cell volume 
 
9.29 ± 0.54 
 
0.014 ± 0.001 
 
18.56 ± 1.63 
 
0.063 ± 0.012 
 
< 0.01 
 
< 0.01 
 
10.28 ± 1.33 
 
0.016 ± 0.002 
 
19.26 ± 2.75 
 
0.08 ± 0.011 
 
< 0.01 
 
< 0.01 
 
10.34 ± 1.56 
 
0.016 ± 0.002 
 
18.64 ± 3.15 
 
0.075 ± 0.014 
 
< 0.01 
 
< 0.01 
Central SNC 
 (a) overall 
 
     Flu/cell volume 
            
 (b) medial 
 
     Flu/cell volume    
 (c) lateral 
 
 
     Flu/cell volume 
 
10.25 ± 1.25 
 
0.015 ± 0.001 
 
19.93 ± 2.38 
 
0.083 ± 0.01 
 
< 0.001 
 
< 0.001 
 
Caudal SNC 
 
     Flu/cell volume 
 
11.30 ± 2.18 
 
0.017 ± 0.003 
 
19.14 ± 2.58 
 
0.08 ± 0.012 
 
< 0.01 
 
< 0.01 
 
SNL 
 
 
9.85 ± 1.17 
 
15.46 ± 3.03 
 
NS 
 
SNR 
 
 
9.68 ± 0.84 
 
15.58 ± 2.11 
 
< 0.05 
 
VTA 
 
 
9.88 ± 0.93 
 
16.01 ± 2.38 
 
< 0.05 
Table  2.4.  Tyrosine  hydroxylase  (TH)  quantification  (arbitrary  units  of 
fluorescence) in the midbrain of AS control and AS/AGU mutant rats aged 18 
months  (n=6  per  group),(Flu/cell  volume:  fluorescence  per  cell  volume).  All 
values are mean arbitrary units ± SEM. All comparisons are paired t tests (NS,  
not significant). 
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2.4.4  A  comparison  of  tyrosine  hydroxylase(TH)  levels  in  the 
midbrain of AS and AS/AGU rats at different ages. 
 
Tyrosine hydroxylase levels decrease with age in AS (control) rats in the central SNC, 
SNL, SNR and VTA. In general, the decreases are progressive but modest. In other 
regions such as the rostral and caudal SNC, there are no effects of age and TH levels 
are constant over the range examined in this experiment. 
By contrast, TH levels in AS/AGU (mutant) rats may rise with age (rostral SNC, 
caudal  SNC)  or  fall  initially  but  then  rise  again,  so  that  TH  levels  at  18  months 
resemble those at 6 months (all other regions).    
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2.5  Results for serotonin 
2.5.1  Quantified  serotonin  (5 HT)  immunofluorescence  in  the 
midbrain of  AS and AS/AGU rats aged six months 
The results for serotonin (5 HT) immunofluorescence show a statistically significant 
difference between the two groups for the dorsal raphe nucleus (P<0.05). AS/AGU 
(mutant) rats had higher levels than AS (control). There was no statistical difference 
between the two groups for the median raphe nucleus. The results are summarized in 
table 2.5. 
   
AS 
 
 
AS/AGU 
 
P 
 
Dorsal raphe 
nucleus 
 
4.81 ± 0.23 
 
 
6.07 ± 0.23 
 
< 0.05 
 
Median raphe 
nucleus 
 
4.36 ± 0.13 
 
 
4.74 ± 0.19 
 
NS 
Table  2.5.  Serotonin  quantification  (arbitrary  units  of  fluorescence)  in  the 
midbrain  of  AS  control  and  AS/AGU  mutant  rats  aged  six  months  (n=6  per 
group). All values are mean arbitrary units ± SEM. All comparisons are paired t 
tests (NS,  not significant) . 
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2.5.2  Quantified  serotonin  (5 HT)  immunofluorescence  in  the 
midbrain of AS and AS/AGU rats aged 12 months 
 
The results for serotonin (5 HT) immunofluorescence show a statistically significant 
difference between the two groups in the dorsal raphe nucleus (P<0.01) with mutants 
having higher levels than controls. There is no statistical difference between the two 
groups  in  the  levels  of  serotonin  in  the  median  raphe  nucleus.  The  results  are 
summarized in table 2.6. 
   
AS 
 
 
AS/AGU 
 
P 
 
Dorsal raphe 
nucleus 
 
3.93 ± 0.33 
 
 
5.45 ± 0.47 
 
< 0.01 
 
Median raphe 
nucleus 
 
3.51 ± 0.58 
 
 
5.58 ± 1.07 
 
NS 
 
Table  2.6:  Serotonin  quantification  (arbitrary  units  of  fluorescence)  in  the 
midbrain  of  AS  control  and  AS/AGU  mutant  rats  aged  12  months  (n=6  per 
group).  All  values  are  mean  arbitrary  units  ±  SEM.  All  comparisons  are  by 
paired t tests (NS,  not significant). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 2                                                                                                              Results 
 
93 
2.5.3  Quantified  serotonin  (5 HT)  immunofluorescence  in  the 
midbrain of AS and AS/AGU rats aged 18 months 
 
The results for serotonin (5 HT) immunofluorescence show a statistically significant 
difference between the two groups in the dorsal raphe nucleus (P<0.001) with mutants 
having higher levels than controls. There is no statistical difference between the two 
groups  in  the  levels  of  serotonin  in  the  median  raphe  nucleus.  The  results  are 
summarized in table 2.7. 
   
AS 
 
 
AS/AGU 
 
P 
 
Dorsal raphe 
nucleus 
 
3.23 ± 0.4 
 
 
7.98 ± 0.24 
 
< 0.001 
 
Median raphe 
nucleus 
 
3.46 ± 0.36 
 
 
4.46 ± 0.59 
 
NS 
Table  2.7:  Serotonin  quantification  (arbitrary  units  of  fluorescence)  in  the 
midbrain  of  AS  control  and  AS/AGU  mutant  rats  aged  18  months  (n=6  per 
group).  All  values  are  mean  arbitrary  units  ±  SEM.  All  comparisons  are  by 
paired t tests (NS,  not significant). 
 
 
 
 
2.5.4  A comparison of serotonin (5 TH) levels in the midbrain of 6, 
12 and 18 months AS and AS/AGU rats 
5 HT levels progressively decrease with age in the AS (control) rats in the dorsal 
raphe nucleus, whereas they increase at the oldest age in AS/AGU rats. 5HT levels do 
not change with age in the median raphe nucleus in either group. 
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2.6  Results for ubiquitin 
 
2.6.1  TH and ubiquitin (Ub) labelling of adjacent sections 
In  the  case  of  senescence associated  molecules,  it  was  essential  to  confirm  that 
measurements were being made on aminergic cells. This was achieved by a labelling 
carried  out  in  adjacent  sections.  For  both  strains,  adjacent  sections  were  stained 
respectively for TH and ubiquitin using fluorescent secondary antibodies. 
A double labelling with TH and ubiquitin showed that about 90% of the cells in the 
SNC  stained with both TH and ubiquitin and only 10% stained with only one of them 
(table  2.8  and  figure  2.8).    Only  those  cells  positively  confirmed  for  TH  were 
measured for ubiquitin fluorescence.  
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Percentage %   
Cell stained 
  AS 
                              SEM 
AS/AGU 
                           SEM 
               91.5 %    (±1.4)                 90.9 %  (± 0.43) 
                88.9 %   (± 0.05)                 88.3 %  (± 0.04) 
TH and Ub                   6 M 
                                      
                                   12 M 
 
                                
                                   18 M 
                89.7 %   (± 0.08)                 88.1%   (± 0.12) 
                7.5 %     (± 0.06)                 8.1%     (± 0.04) 
                9.6 %     (± 0.01)                10.2 %   (± 0.03) 
Ub not TH                    6 M  
 
                                   12 M                     
                                            
                                    
                                   18 M         
                9.1 %     (± 0.01)                 9.9 %    (± 0.01) 
                 1 %       (± 0.13)                  1 %      (± 0.05) 
                1.5 %   (± 0.005)                  1.5 %   (± 0.007) 
TH not Ub                    6 M 
 
                                   12 M 
 
                                           
                                   18 M                                                    
                 1 %      (±0.025)                   2 %     (± 0.026) 
Table 2.8: Percentage of cells in the SNC that immunofluorescence stained with 
tyrosine hydroxylase (TH) or ubiquitin (Ub) or both of them.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 2                                                                                                              Results 
 
96 
 
 
       
 
 
       
 
 
Figure 2.8: TH and ubiquitin (Ub) labelling of adjacent sections. (a) AS TH 
immunostained cells of substantia nigra (green color). (b) AS Ub immunostained 
cells  of  substantia  nigra  (red  color).  (c)  AS/AGU  TH immunostained  cells  of 
substantia  nigra  (green  color).  (d)  AS/AGU  Ub immunostained  cells  of 
substantia nigra (red color). (x500).  
     
Examples 
 
            Cell bodies immunostained with both TH (a and c) and ubiquitin (b and  
            d). 
            
          Cell bodies immunostained with TH only (c) which appear black in (d). 
 
          Cell bodies immunostained with ubiquitin only (b and d) which appear     
            black in (a and c). 
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2.6.2  Quantified  ubiquitin  immunofluorescence  in  the  midbrain  of 
AS and AS/AGU rats aged 6 months 
 
The  results  for  ubiquitin  (Ub)  immunofluorescence  show  a  statistically  significant 
difference between the two groups in the rostral SNC, central SNC (overall, medial 
and lateral regions), caudal SNC, and the dorsal raphe nucleus (DRN) (P<0.05 or 
greater). Ubiquitin levels are significantly higher in the AS/AGU mutant. There are no 
statistical differences between the two groups in the levels of Ub (P>0.05) in the SNL, 
SNR, VTA, median raphe nucleus (MRN), oculomotor nucleus or pontine nucleus. 
The results are summarized in table 2.9. 
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AS 
 
AS/AGU 
 
P 
 
Rostral SNC 
 
4.16 ± 0.25 
 
 
5.74 ± 0.15 
 
 
< 0.01 
 
5.79 ± 0.35 
 
 
7.79 ± 0.35 
 
< 0.001 
 
5.75 ± 0.46 
 
 
7.21 ± 0.39 
 
< 0.05 
Central SNC 
         (a) overall 
 
          
         (b) medial 
 
 
         (c)  lateral   
 
 
5.82 ± 0.28 
 
 
8.35 ± 0.50 
 
< 0.001 
 
Caudal SNC 
 
 
4.55 ± 0.25 
 
 
6.14 ± 0.19 
 
< 0.001 
 
SNL 
 
 
5.54 ± 0.66 
 
5.90 ± 0.29 
 
NS 
 
SNR 
 
 
5.23 ± 0.45 
 
5.56 ± 0.44 
 
NS 
 
VTA 
 
 
5.79 ± 0.44 
 
6.57 ± 0.59 
 
NS 
 
Oculomotor 
nucleus 
 
4.56 ± 0.60 
 
4.88 ± 0.24 
 
NS 
 
DRN 
 
 
4.26 ± 0.32 
 
6.05 ± 0.24 
 
< 0.01 
 
MRN 
 
 
4.32 ± 0.23 
 
4.45 ± 0.29 
 
NS 
 
Pontine nucleus 
 
3.77 ± 0.25 
 
4.11 ± 0.41 
 
NS 
 
Table  2.9:  Ubiquitin  quantification  (arbitrary  units  of  fluorescence)  in  the 
midbrain  of  AS  control  and  AS/AGU  mutant  rats  aged  6  months  (n=6  per 
group). All values are mean arbitrary units ± SEM. All comparisons are paired t 
tests (NS,  not significant). 
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2.6.3  Quantified  ubiquitin  immunofluorescence  in  the  midbrain  of 
AS and AS/AGU rats aged 12 month 
 
The  results  for  ubiquitin  (Ub)  immunofluorescence  show  a  statistically  significant 
difference between the two groups in the rostral SNC, central SNC (overall and lateral 
region), caudal SNC and the dorsal raphe nucleus (DRN) (P<0.05 or greater).  In each 
case,  AS/AGU  mutants  had  higher  levels  than  controls.  There  are  no  statistical 
differences between the two groups in the levels of Ub in the central SNC (medial 
region), SNL, VTA, median raphe nucleus (MRN), oculomotor nucleus or pontine 
nucleus. The results are summarized in table 2.10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 2                                                                                                              Results 
 
100 
 
 
 
 
AS 
 
AS/AGU 
 
P 
 
Rostral SNC 
 
 
4.21 ± 0.35 
 
 
6.97 ± 0.79 
 
 
< 0.05 
 
 
4.25 ± 0.50 
 
6.00 ± 0.58 
 
< 0.001 
 
5.06 ± 0.61 
 
5.85 ± 0.55 
 
NS 
Central SNC 
        (a) overall 
 
 
        (b) medial 
 
 
         (c) lateral 
 
 
3.69 ± 0.63 
 
6.34 ± 0.79 
 
< 0.01 
 
Caudal SNC 
 
 
4.77 ± 0.47 
 
6.97 ± 0.71 
 
< 0.01 
 
SNL 
 
 
4.94 ± 0.05  
 
4.96 ± 0.04 
 
NS 
 
SNR 
 
 
4.87 ± 0.13 
 
4.92 ± 0.12 
 
NS 
 
VTA 
 
 
4.79 ± 0.26 
 
5.19 ± 0.37  
 
NS 
 
Oculomotor 
nucleus 
 
4.99 ± 0.69 
 
5.01 ± 0.58 
 
NS 
 
DRN 
 
3.68 ± 0.46 
 
7.05 ± 0.95 
 
< 0.05 
 
 
MRN 
 
 
4.43 ± 0.27 
 
4.47 ± 0.26 
 
NS 
 
Pontine nucleus 
 
 
4.59 ± 0.31 
 
4.74 ± 0.17 
 
NS 
Table  2.10:  Ubiquitin  quantification  (arbitrary  units  of  fluorescence)  in  the 
midbrain  of  AS  control  and  AS/AGU  mutant  rats  aged  12  months  (n=6  per 
group). All values are mean arbitrary units ± SEM. All comparisons are paired t 
tests (NS,  not significant). 
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2.6.4  Quantified  ubiquitin  immunofluorescence  in  the  midbrain  of 
AS and AS/AGU rats aged 18 month 
 
The  results  for  ubiquitin  (Ub)  immunofluorescence  show  a  statistically  significant 
difference between the two groups in the rostral SNC, central SNC (overall, medial 
and lateral regions), caudal SNC, SNL, SNR, VTA, DRN and the MRN. (P<0.05 or 
higher). In each case, AS/AGU mutants had higher levels than AS controls. There are 
no statistical differences between the two groups in the levels of Ub (P>0.05) in the 
oculomotor nucleus or pontine nucleus.. The results are summarized in table 2.11. 
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AS 
 
AS/AGU 
 
P 
 
Rostral SNC 
 
 
7.94 ± 0.20 
 
 
16.26 ± 0.46  
 
 
< 0.001 
 
7.28 ± 1.02 
 
15.75 ± 0.93 
 
< 0.001 
 
7.85 ± 1.14 
 
17.18 ± 0.77  
 
< 0.001 
Central SNC 
         (a) overall 
 
 
         (b) medial 
 
 
         (c) lateral 
 
 
6.60 ± 0.89  
 
14.30 ± 1.18 
 
< 0.001 
 
Caudal SNC 
 
 
6.59 ± 0.47 
 
14.26 ± 0.84 
 
< 0.001 
 
SNL 
 
 
8.37 ± 0.59 
 
11.00 ± 0.66 
 
< 0.01 
 
SNR 
 
 
8.61 ± 0.57 
 
11.09 ± 0.52 
 
< 0.001 
 
VTA 
 
 
7.06 ± 0.40 
 
11.53 ± 0.49 
 
< 0.001 
 
Oculomotor 
nucleus 
 
4.59 ± 0.24 
 
4.83 ± 0.19 
 
NS 
 
DRN 
 
 
6.15 ± 0.38 
 
13.47 ± 1.03 
 
< 0.001 
 
MRN 
 
 
7.46 ± 0.42 
 
9.60 ± 0.57 
 
< 0.05 
 
Pontine nucleus 
 
 
6.41 ± 0.35 
 
7.08 ± 0.67 
 
NS 
Table  2.11:  Ubiquitin  quantification  (arbitrary  units  of  fluorescence)  in  the 
midbrain  of  AS  control  and  AS/AGU  mutant  rats  aged  18  months  (n=6  per 
group). All values are mean arbitrary units ± SEM. All comparisons are paired t 
tests (NS,  not significant). 
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2.6.5  A comparison of ubiquitin(Ub) levels in the midbrain of 6, 12 
and 18 months AS and AS/AGU rats 
 
In  every  region  except  the  oculomotor  nucleus,  cells  show  a  gradual  increase  in 
ubiquitin immunofluorescence with age in AS (control) rats. However, the increase 
with age is much greater in AS/AGU (mutant) rats, leading to significant differences 
between the two strains at 18 months in all regions except the pontine and oculomotor 
nuclei.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 2                                                                                                              Results 
 
104 
2.7  Results for parkin 
 
2.7.1  TH and parkin labelling of adjacent sections 
Both TH and parkin labelling were carried out in which adjacent sections from AS 
and  AS/AGU  brains  were  stained  for  TH  and  parkin  using  fluorescent  secondary 
antibodies. 
Labelling with TH and parkin showed that about 90% of the cells in the SNC  stained 
with both TH and parkin and the remainder with only one of them (Table 2.12). 
(Figure 2.9).  In dopaminergic areas, such as the SNC and VTA, only cells which  
were TH positive were counted for parkin. 
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Percentage %   
Cell stained 
  AS 
                         SEM 
AS/AGU 
                             SEM 
           89.6 %    (± 0.01)                89.1 %      (± 0.24) 
          88.9 %    (± 0.02)                88.2 %       (± 0.03) 
TH and parkin              6 M 
                                      
                                   12 M 
 
                                
                                   18 M 
          87.8 %    (± 0.04)                87.7 %      (± 0.05) 
           8.9 %     (± 0.05)                 9.9 %       (± 0.04) 
          9.6 %     (± 0.02)                 10.3 %     (± 0.03) 
Parkin not TH               6 M  
 
                                   12 M               
                                            
                                    
                                   18 M         
          10.7 %   (± 0.03)                 11.3 %     (± 0.05) 
            1.5 %    (± 0.02)                   1 %        (± 0.03) 
           1.5 %    (± 0.01)                  1.5 %      (± 0.03) 
TH not parkin               6 M 
 
                                   12 M 
 
                                           
                                   18 M                      
           1.5 %    (± 0.01)                   1 %        (± 0.05) 
Table 2.12.: Percentage of cells in the SNC that immunofluorescence stained with 
tyrosine hydroxylase (TH) or parkin or both of them.  
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Figure  2.9:  TH  and  parkin  labelling  of  adjacent  sections.  (a)  AS  TH  
immunostained  cells  of  substantia  nigra  (green  color).  (b)  AS  parkin 
immunostained  cells  of  substantia  nigra  (red  color).  (c)  AS/AGU  TH  
immunostained  cells  of  substantia  nigra  (green  color).  (d)  AS/AGU  parkin 
immunostained cells of substantia nigra (red color). (x500). 
 
Examples 
 
            Cell bodies immunostained with both TH (a and c) and parkin.(b and d). 
            
          Cell bodies immunostained with TH only (c) which appear black in (d). 
 
          Cell bodies immunostained with parkin only (b and d) which appear       
            black in (a) and (c). 
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2.7.2  Quantified parkin immunofluorescence in the midbrain of AS 
and AS/AGU rats aged 6 months 
 
The results for parkin immunofluorescence show a statistically significant difference 
between the two groups for the central SNC, caudal SNC and the DRN. (P<0.05 or 
greater). AS/AGU (mutant) rats have higher levels than AS (control).  There are no 
statistical differences between the two groups in the rostral SNC, SNL, SNR, VTA, 
median raphe nucleus (MRN), oculomotor nucleus or pontine nucleus. The results are 
summarized in table (2.13). 
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AS 
 
AS/AGU 
 
P 
 
Rostral SNC 
 
4.88 ± 0.27 
 
 
6.29 ± 0.70 
 
 
NS 
 
 
4.19 ± 0.17 
 
5.32 ± 0.26 
 
< 0.05 
 
4.19 ± 0.11 
 
5.44 ± 0.62 
 
NS 
Central SNC 
        (a) overall 
 
       
        (b) medial 
 
         
        (c) lateral 
 
 
4.21 ± 0.33 
 
5.96 ± 0.89 
 
NS 
 
Caudal SNC 
 
 
5.35 ± 0.74 
 
6.44 ± 0.67 
 
< 0.01 
 
SNL 
 
 
4.38 ± 0.39 
 
4.66 ± 0.25 
 
NS 
 
SNR 
 
 
3.85 ± 0.27 
 
4.64 ± 0.24 
 
NS 
 
VTA 
 
 
3.76 ± 0.25 
 
4.55 ± 0.40 
 
NS 
 
Oculomotor 
nucleus 
 
4.11 ± 0.17 
 
4.19 ± 0.10 
 
NS 
 
DRN 
 
 
3.18 ± 0.19 
 
4.31 ± 0.10 
 
< 0.01 
 
MRN 
 
 
3.15 ± 0.08 
 
3.33 ± 0.24 
 
NS 
 
Pontine nucleus 
 
 
3.41 ± 0.07 
 
3.43 ± 0.09 
 
NS 
Table  2.13:  Parkin  quantification  (arbitrary  units  of  fluorescence)  in  the 
midbrain  of  AS  control  and  AS/AGU  mutant  rats  aged  6  months  (n=6  per 
group). All values are mean arbitrary units ± SEM. All comparisons are paired t 
tests (NS,  not significant). 
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2.7.3  Quantified parkin immunofluorescence in the midbrain of AS 
and AS/AGU rats aged 12 months 
 
The results for parkin immunofluorescence show a statistically significant difference 
between the two groups for the rostral SNC, central SNC (overall, medial and lateral 
regions),  caudal  SNC  and  the  DRN  (P<0.05  or  greater).  In  each  case,  AS/AGU 
mutants  had  higher  levels  than  AS  controls.  There  are  no  statistical  differences 
between  the  two  groups  in  the  levels  of  parkin  in  the  SNL,  SNR,  VTA,  MRN, 
oculomotor nucleus or pontine nucleus. The results are summarized in table 2.14. 
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AS 
 
AS/AGU 
 
P 
 
Rostral SNC 
 
3.17 ±  0.13 
 
5.02 ± 0.15 
 
 
< 0.001 
 
 
3.55 ± 0.66 
 
5.18 ± 0.39 
 
< 0.01 
 
3.70 ± 0.75 
 
5.14 ± 0.40 
 
< 0.05 
Central SNC 
         (a) overall 
 
 
         (b) medial 
 
 
         (c)  lateral 
 
 
3.41 ± 0.59 
 
5.23 ± 0.41 
 
< 0.001 
 
Caudal SNC 
 
 
2.79 ± 0.18 
 
4.78 ± 0.14 
 
< 0.001 
 
SNL 
 
 
3.64 ± 0.58 
 
3.64 ± 0.57 
 
NS 
 
SNR 
 
 
3.67 ± 0.59 
 
3.74 ± 0.59 
 
NS 
 
VTA 
 
 
3.53 ± 0.58 
 
3.54 ± 0.43 
 
NS 
 
Oculomotor 
nucleus 
 
3.71 ± 0.30 
 
3.79 ± 0.26 
 
NS 
 
DR 
 
 
2.65 ± 0.09 
 
4.69 ± 0.45 
 
< 0.01 
 
MR 
 
 
2.99 ± 0.12 
 
3.16 ± 0.09 
 
NS 
 
Pontine nucleus 
 
 
3.01 ± 0.04 
 
3.07 ± 0.06 
 
NS 
Table 2.14: Parkin immunofluorescence (arbitrary units of fluorescence) in the 
midbrain  of  AS  control  and  AS/AGU  mutant  rats  aged  12  months  (n=6  per 
group). All values are mean arbitrary units ± SEM. All comparisons are paired t 
tests (NS,  not significant). 
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2.7.4  Quantified parkin immunofluorescence in the midbrain of AS 
and AS/AGU rats aged 18 months 
 
The results for parkin immunofluorescence show a statistically significant difference 
between the two groups in the rostral SNC, central SNC (overall, medial and lateral 
regions),  caudal  SNC  and  the  DRN  (P<0.05  or  greater).  In  each  case,  AS/AGU 
mutants  had  higher  levels  than  AS  controls.  There  are  no  statistical  differences 
between  the  two  groups  in  the  levels  of  parkin  in  the  SNL,  SNR,  VTA,  MRN, 
oculomotor nucleus or pontine nucleus. The results are summarized in table 2.15. 
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AS 
 
AS/AGU 
 
P 
 
Rostral SNC 
 
3.02 ± 0.16 
 
5.73 ± 0.63 
 
 
< 0.01 
 
3.48 ± 0.39 
 
6.40 ± 1.06 
 
< 0.01 
 
3.37 ± 0.32 
 
6.29 ± 1.11 
 
< 0.05 
Central SNC 
         (a) overall 
 
 
         (b) medial 
 
 
         (c)  lateral 
 
 
3.58 ± 0.46 
 
6.51 ± 1.02 
 
< 0.01 
 
Caudal SNC 
 
 
3.33 ± 0.19 
 
6.29 ± 0.17 
 
< 0.001 
 
SNL 
 
 
3.11 ± 0.26 
 
4.58 ± 0.63 
 
NS 
 
SNR 
 
 
3.53 ± 0.37 
 
4.74 ± 0.67 
 
NS 
 
VTA 
 
 
4.08 ± 0.37 
 
4.12 ± 0.56 
 
NS 
 
Oculomotor 
nucleus 
 
3.33 ± 0.22 
 
 
3.42 ± 0.34 
 
NS 
 
DRN 
 
 
2.56 ± 0.31 
 
5.64 ± 0.33 
 
< 0.001 
 
MRN 
 
 
2.86 ± 0.23 
 
3.43 ± 0.26 
 
NS 
 
Pontine nucleus 
 
 
3.26 ± 0.25 
 
3.37 ± 0.23 
 
NS 
Table  2.15:  Parkin  quantification  (arbitrary  units  of  fluorescence)  in  the 
midbrain  of  AS  control  and  AS/AGU  mutant  rats  aged  18  months  (n=6  per 
group). All values are mean arbitrary units ± SEM. All comparisons are paired t 
tests (NS,  not significant). 
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2.7.5  A comparison of parkin levels in the midbrain of 6, 12 and 18 
months AS and AS/AGU rats 
 
In  AS  (control)  rats,  there  was  a  gradual,  slight  decrease  in  parkin 
immunofluorescence with age in virtually all brain regions. By contrast, there was a 
gradual, slight rise in parkin immunofluorescence with age in the AS/AGU mutant 
rats for regions such as the central SNC and dorsal raphe nucleus. In some cases this 
led to a statistically significant difference between the two groups at older ages, but 
not at earlier ones. 
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2.8  Results for α synuclein 
 
2.8.1  Double labelling 
The staining with alpha synuclein was in the neuropil of the SNC. A double labelling 
was  carried  out  on  a  same  sections  from  AS  and  AS/AGU  rats  using  fluorescent 
secondary antibodies for TH and alpha synuclein. 
A double labelling with TH and alpha synuclein showed that most of the cells in the 
SNC of both AS(control) and AS/AGU(mutant) rats were stained with TH.  In the 
adjacent sections, stained for alpha synuclein, the SNC cells are non fluorescing and 
appear brown or black.  (Figure 2.10).   
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Figure  2.10:  TH  and  Alpha synuclein  double  labelling.  (a)  AS  TH  
immunostained cells of substantia nigra (green color).  (b) AS alpha synuclein 
immunostained  in  the  substantia  nigra  (red  color).  (c)  AS/AGU  TH  
immunostained  cells  of  substantia  nigra  (green  color).  (d)  AS/AGU  alpha 
synuclein immunostained in the substantia nigra (red color). (x500). 
 
Examples 
 
         Cell bodies  immunostained with TH (a and c) not stained  with alpha 
synuclein and appear black or brown (b and d). Alpha synuclein immunostained 
in the neuropil. 
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2.8.2  Quantified α Synuclein immunofluorescence in the midbrain of 
AS and AS/AGU rats aged 6 months 
 
Alpha Synuclein  immunofluorescence  of  the  neuropil  showed  a  statistically 
significant difference between the two groups in the rostral SNC, central SNC and the 
caudal SNC. (P<0.05) with levels being highest in AS/AGU mutants. There are no 
statistical differences between the two groups in the levels of α Synuclein in the SNR 
and the VTA. The results are summarized in table 2.16. 
 
 
 
 
 
 
AS 
 
AS/AGU 
 
P 
 
Rostral SNC 
 
1.33 ± 0.4 
 
1.67 ± 0.3 
 
 
< 0.05 
 
Central SNC 
 
 
1.15 ± 0.11 
 
1.98 ± 0.41 
 
< 0.05 
 
Caudal SNC 
 
 
0.64 ± 0.08 
 
0.97 ± 0.08 
 
< 0.05 
 
SNR 
 
 
1.43 ± 0.19 
 
1.98 ± 0.32 
 
NS 
 
VTA 
 
 
0.48 ± 0.06 
 
0.52 ± 0.08 
 
NS 
Table 2.16: Alpha Synuclein quantification (arbitrary units of fluorescence) in 
the midbrain of AS control and AS/AGU mutant rats aged 6 months (n=6 per 
group). All values are mean arbitrary units ± SEM. All comparisons are paired t 
tests (NS,  not significant). 
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2.8.3  Quantified α Synuclein immunofluorescence in the midbrain of 
AS and AS/AGU rats aged 12 months 
 
Alpha Synuclein  immunofluorescence  of  the  neuropil  showed  a  statistically 
significant difference between the two groups in the rostral SNC, central SNC and the 
caudal SNC (P<0.01 or greater) with levels being highest in AS/AGU mutant. There 
are no statistical differences between the two groups in the levels of α Synuclein in 
the SNR and the VTA. The results are summarized in table 2.17. 
 
 
 
 
 
AS 
 
AS/AGU 
 
P 
 
Rostral SNC 
 
1.07 ± 0.14 
 
2.46 ± 0.35 
 
 
< 0.01 
 
Central SNC 
 
 
1.88 ± 0.51 
 
4.56 ± 0.61 
 
< 0.01 
 
Caudal SNC 
 
 
1.51 ± 0.16 
 
3.26 ± 0.12 
 
< 0.001 
 
SNR 
 
 
4.25 ± 0.72 
 
5.42 ± 0.45 
 
NS 
 
VTA 
 
 
1.13 ± 0.11 
 
1.16 ± 0.10 
 
NS 
Table 2.17: Alpha Synuclein quantification (arbitrary units of fluorescence) in 
the midbrain of AS control and AS/AGU mutant rats aged 12 months (n=6 per 
group). All values are mean arbitrary units ± SEM. All comparisons are paired t 
tests (NS,  not significant). 
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2.8.4  Quantified α Synuclein immunofluorescence in the midbrain of 
AS and AS/AGU rats aged 18 months 
 
Alpha Synuclein  immunofluorescence  of  the  neuropil  showed  a  statistically 
significant difference between the two groups in the central part of the SNC. (P<0.05). 
There  are  no  statistical  differences  between  the  two  groups  in  the  levels  of  α 
Synuclein in the rostral SNC, the caudal SNC, SNR or the VTA. In some cases, this 
may be due to the large standard errors within the group.  The results are summarized 
in table 2.18. 
 
 
 
 
 
AS 
 
AS/AGU 
 
P 
 
Rostral SNC 
 
1.58 ± 0.28 
 
 
3.74 ± 0.69 
 
 
NS  
 
Central SNC 
 
 
2.78 ± 0.75 
 
       6.12 ± 0.8 
 
< 0.05 
 
Caudal SNC 
 
 
1.79 ± 0.45 
 
4.66 ± 1.06 
 
NS  
 
SNR 
 
 
3.91 ± 1.04 
 
6.43 ± 1.41 
 
NS  
 
VTA 
 
 
1.55 ± 0.36 
 
1.55 ± 0.39 
 
NS 
Table 2.18: Alpha Synuclein quantification (arbitrary units of fluorescence) in 
the midbrain of AS control and AS/AGU mutant rats aged 18 months (n=6 per 
group). All values are mean arbitrary units ± SEM. All comparisons are paired t 
tests (NS,  not significant). 
 
 
2.8.5  A comparison of α synuclein levels in the midbrain of AS and 
AS/AGU rats aged 6, 12 and 18 months  
 
Alpha synuclein levels progressively increase with age in the AS (control) and the 
AS/AGU (mutant)  in the central SNC, caudal SNC and the VTA. Chapter 2                                                                                                              Results 
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2.9  Results in the striatum 
 
2.9.1  Quantified Tyrosine hydroxylase (TH) immunofluorescence in 
the striatum of AS and AS/AGU rats aged 12 months 
 
The  results  for  TH  immunofluorescence  show  a  statistically  significant  difference 
between the two groups in the dorsal caudate putamen (DCPU) (P<0.01) with TH 
levels significantly reduced in the AS/AGU rats. There are no statistical differences 
between the two groups in the levels of TH in the lateral or ventral caudate putamen 
(LCPU,VCPU). The results are summarized in table 2.19. 
 
 
 
 
 
AS 
 
AS/AGU 
 
P 
 
DCPU 
 
24.75 ± 2.87 
 
13.5 ± 4.02 
 
 
< 0.01 
 
LCPU 
 
 
17.45  ± 3.55 
 
14.58 ± 4.55 
 
NS 
 
VCPU 
 
 
10.6 ± 3.33 
 
9.57 ± 3.88 
 
NS 
Table 2.19: Tyrosine hydroxylase quantification (arbitrary units of fluorescence) 
in the striatum of AS control and AS/AGU mutant rats aged 12 months (n=6 per 
group). All values are mean arbitrary units ± SEM. All comparisons are paired t 
tests (NS  not significant). 
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2.9.2  Quantified  serotonin  (5 HT)  immunofluorescence  in  the 
striatum of AS and AS/AGU rats aged 12 months 
The results for 5 HT immunofluorescence show a statistically significant difference 
between the two groups in the dorsal caudate putamen (P<0.05) with 5 HT levels 
significantly reduced in the AS/AGU rats. There are no statistical differences between 
the two groups in the levels of 5 HT in the lateral striatum or ventral striatum. The 
results are summarized in table 2.20. 
 
 
 
 
AS 
 
AS/AGU 
 
P 
 
DCPU 
 
6.7 ± 0.99 
 
4.72 ± 0.94 
 
 
< 0.05 
 
LCPU 
 
 
4.25 ± 1.50 
 
3.68 ± 0.98 
 
NS 
 
VCPU 
 
 
4.22 ± 1.00 
 
4.00 ± 1.00 
 
NS 
Table  2.20:  Serotonin  quantification  (arbitrary  units  of  fluorescence)  in  the 
striatum  of  AS  control  and  AS/AGU  mutant  rats  aged  12  months  (n=6  per 
group). All values are mean arbitrary units ± SEM. All comparisons are paired t 
tests (NS,  not significant). 
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2.9.3  Quantified ubiquitin (Ub) immunofluorescence in the striatum 
of  AS and AS/AGU rats aged 12 months 
There are no statistical differences between the two groups in the levels of Ub in the 
dorsal, lateral or the ventral caudate putamen or in the striatum cells. The results are 
summarized in table 2.21. 
 
 
 
 
 
AS 
 
AS/AGU 
 
P 
 
DCPU 
 
6.8 ± 0.76 
 
 
9.17 ± 2.29 
 
 
NS 
 
LCPU 
 
 
6.6 ± 0.69 
 
7.43 ± 2.24 
 
NS 
 
VCPU 
 
 
6.37 ± 0.73 
 
7.05 ± 2.27 
 
NS 
 
Striatum cells 
 
 
1.13 ± 0.12 
 
1.29 ± 0.25 
 
NS 
Table  2.21:  Ubiquitin  quantification  (arbitrary  units  of  fluorescence)  in  the 
striatum  of  AS  control  and  AS/AGU  mutant  rats  aged  12  months  (n=6  per 
group). All values are mean arbitrary units ± SEM. All comparisons are paired t 
tests (NS,  not significant). 
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2.9.4  Quantified parkin immunofluorescence in the striatum of AS 
and AS/AGU rats aged 12 months 
There are no statistical differences between the two groups in the levels of Parkin in 
the dorsal, lateral or the ventral caudate putamen or in the striatum cells. The results 
are summarized in table 2.22. 
   
             AS 
 
AS/AGU 
 
P 
 
DCPU 
 
 
5.98 ± 0.29 
 
9.80 ± 1.60 
 
 
NS 
 
 
LCPU 
 
       4.90 ± 0.41 
 
7.15 ± 1.34 
 
NS 
 
VCPU 
 
5.28 ± 0.61 
 
6.42 ± 1.02 
 
NS 
 
Striatum cells 
 
1.10 ± 0.04 
 
1.19 ± 0.05 
 
NS 
Table  2.22:  Parkin  quantification  (arbitrary  units  of  fluorescence)  in  the 
striatum  of  AS  control  and  AS/AGU  mutant  rats  aged  12  months  (n=6  per 
group). All values are mean arbitrary units ± SEM. All comparisons are paired t 
tests (NS,  not significant). 
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2.9.5  Quantified α Synuclein immunofluorescence in the striatum of 
AS and AS/AGU rats aged 12 months 
 
There  are  no  statistical  differences  between  the  two  groups  in  the  levels  of  α 
Synuclein  in  the  dorsal,  lateral  or  the  ventral  caudate putamen.  The  results  are 
summarized in table 2.23. 
 
 
 
 
AS 
 
AS/AGU 
 
P 
 
DCPU 
 
5.33 ± 0.99 
 
9.00 ± 1.02 
 
 
NS 
 
LCPU 
 
 
3.53 ± 1.45 
 
5.15 ± 1.55 
 
NS 
 
VCPU 
 
 
4.30 ± 1.42 
 
5.88 ± 1.65 
 
NS 
Table 2.23: Alpha Synuclein quantification (arbitrary units of fluorescence) in 
the striatum of AS control and AS/AGU mutant rats aged 12 months (n=6 per 
group). All values are mean arbitrary units ± SEM. All comparisons are paired t 
tests (NS,  not significant). 
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2.10  Discussion 
 
 
2.10.1 Tyrosine hydroxylase  
 
The  synthesis  and  the  release  of  dopamine  are  modulated  by  known  mechanisms 
including  presynaptic  and  dendritic  autoreceptors  (Nowycky  and  Roth,  1978; 
Santiago  and  Westerink,  1991),  changes  in  the  firing  rate  of  dopamine  neurons 
(Farnebo and Hamberger, 1971) and the  feedback inhibition of TH by the end 
product (Nagatsu et al., 1964 ; Lovenberg and Victor, 1974; Kumer and Vrana, 
1996). 
The above should be borne in mind when considering the results found in the present 
experiment for TH immunofluorescence in individual cells of the substantia nigra. 
These  neurons  are  known  to  release  very  little  dopamine  in  the  striatum  –  with 
extracellular levels only 10 20 % of normal (Campbell et al., 1996). However, there 
has never been any evidence that they lack the ability to synthesise dopamine   in fact 
whole tissue micropunches of the midbrain and striatum have shown that dopamine 
levels remain normal until six months or more (Campbell et al., 1997). Here, I can 
now demonstrate that TH levels in the cell bodies of the SNC are actually elevated. 
This  is  what  might  be  expected  of  a  relatively  normal  neuron  where  the  primary 
deficit was in synaptic release.  
In the central part of the SNC, TH levels were higher in the lateral region than in the 
medial. Although it is unclear why this is so, it is of interest that Goto et al (1989) and 
Suttoo et al (2001) found the greatest loss of dopaminergic neurons in the lateral SNC 
region of Parkinson’s patients that projects to the dorsal putamen (Gibb and Lees, 
1991; 1994). TH levels per volume of cell were higher in the rostral, central and Chapter 2                                                                                                        Discussion 
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caudal.   By contrast to the SNC, the SNL and VTA (see chapter1 page 8) show little 
change in TH levels with age in either groups.  In the first description of the AS/AGU 
rat the SNL and VTA were not as severely affected as the neighbouring SNC (Clarke 
and Payne, 1994) and the VTA is also less affected in human PD (Uhl et al., 1985).  
Unlike the SNC, TH levels are considerably reduced in the dorsal caudate putamen of 
the  AS/AGU  mutant  rats  compared  to  the  controls.  This  where  the  dopaminergic 
terminals (rather than the cell bodies) are located. Whole tissue dopamine levels in the 
dorsal and lateral caudate putamen are known to be  reduced in the AS/AGU mutant 
rat  compared  to  the  AS  control  between  6  and  12  months  of  age  using  high 
performance  liquid  chromatography  with  electrochemical  detection  of  micropunch 
samples (Campbell et al., 1996; 1998). Similar effects reductions of dopamine levels 
in  the  dorsal  striatum  have  been  seen  in  the  weaver  mouse  (Roffler Tarlov  and 
Graybiel, 1984), in post mortem Parkinson’s disease patients (Hornykiewicz, 1995) 
and in living patients with the disorder (Leenders et al., 1986,1990).  MPTP exposure  
(Moratalla et al., 1992; Snow et al., 2000) can also greatly reduce striatal dopamine 
(Campbell et al., 1998, 2000). 
One possible conclusion from these results is that, whilst the terminals are clearly 
dysfunctional, the cell bodies of DA neurons are not only normal at these ages, but 
capable of normal physiological responses to depleted DA release.  
2.10.2 Serotonin 
Serotonin appears to mimic dopamine. Thus, 5 HT levels in individual cells of the 
dorsal raphe nucleus are elevated in the AS/AGU mutant compared to the AS control 
  even though 5 HT release in the striatum is known to be greatly reduced  (Al Fayez 
et al., 2005). Again, this suggests that the neuron remains relatively normal in terms 
of its synthesising capacity and, perhaps, its feedback responses. Chapter 2                                                                                                        Discussion 
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It  is  interesting    that  the  dorsal  raphe  nucleus  (which  projects  to  the  striatum)  is 
affected in the AS/AGU mutant, but the median raphe nucleus (which does not) is not. 
The effects include not only the reduced ability to release 5 HT in the striatum under 
normal physiological conditions, but also the loss of serotonergic cell bodies in the 
dorsal raphe with age (Al Fayez et al., 2005). 
Many studies have described a reduction in the levels of serotonin in several brain 
regions of Parkinson’s disease patients (Rinne et al., 1974; Scatton et al., 1983; Agid 
et al., 1987) and lesions of the DRN lead to a decrease in serotonin levels in the 
striatum whereas lesions of MRN do not (Van der Kar and Lorens, 1979). The AS 
(control) rats  have reduced 5 HT levels with age in the dorsal raphe nucleus and, 
again,  it  is  known  that  old  rats  show  lower  levels  of  serotonin  and  dopamine 
(Goicoechea et al., 1997).   
2.10.3   Lewy body proteins 
Dysfunction  of  the  ubiquitin proteasome  system  (UPS)  has  been  implicated  in 
Parkinson’s disease  and other neurodegenerative disorders  and ubiquitin (Ub) is  a 
major  component  of  inclusions  such  as  Lewy  bodies  in  PD  (Gai  et  al.,  2000; 
McNaught et al., 2002). In the present study Ub, parkin and α synuclein levels were 
increased  in  SNC  cell  bodies  or  striatal  neuropil  with  age  in  both  controls  and 
mutants, but more in the mutant. In particular, the lateral half of the central SNC 
showed increasing levels of Ub and parkin with age compared to the medial half in 
the mutants. It is of interest that the lateral half of the SNC is also more affected in 
rats following treatment with proteasome inhibitors (McNaught et al., 2004). The 
levels of Ub, parkin and α synuclein do not change in the SNR, SNL and the VTA in 
the mutant rats.  Again, rats treated with proteasome inhibitors demonstrate a lack of 
neurodegeneration in the SNR (McNaught et al., 2004), and the VTA less is affected Chapter 2                                                                                                        Discussion 
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in human PD (Uhl et al., 1985).  The levels of Ub and parkin also increase with age in 
AS/AGU mutant rats compared to AS controls in the dorsal raphe nucleus; however, 
there  is  no  change  in  the  median  raphe  nucleus,  suggesting  that  the  raphe striatal 
serotonergic system is affected differentially. Despite this, levels of Ub, parkin and α 
synuclein in the striatum were not changed with age, nor did they differ between the 
two strains. However, it must be remembered that the technique samples  a mixture of 
cells and terminals so that a change in one population might be masked. The dorsal  
raphe nucleus and the caudal end of the SNC showed higher ubiquitin and parkin 
levels  compared  to  other  areas  in  the  midbrain  of  AS/AGU  mutant  rats,  perhaps 
indicating that these areas are especially affected. Neuronal death is more severe in  
lower regions of the midbrain and the rate increases with age (Braak et al., 2003).  
Elevations in molecules such as ubiquitin, parkin and alpha synuclein  in mutants (and 
with  age)  are  difficult  to  interpret  since  the  normal  function  of  some  of  these 
molecules  is  poorly  understood  (see  chapter  1  page  38,  44,  45)  (Clayton  and 
George, 1998). The comparison here must be with neurodegenerative states, such as 
Parkinson’s disease, where levels are elevated and the proteins incorporated into cell 
inclusions  (Lennox  et  al.,1989;  Love  and  Nicoll,  1992;  Spillantini  et  al., 
1997;1998a; Irizary et al., 1998). Such inclusions have not been found in rodents   
except under special treatments such as rotenone (Betarbet et al., 2000)   so it is 
uncertain whether the elevations found in present study suggest a pre inclusion state. 
This will be one of the features looked for in the second experiment. 
The first experiment shows that biogenic amine activity (DA and 5 HT) is lowered in 
the striatum, but that the midbrain cell bodies remain synthetically active. In addition, 
molecules associated with human Lewy bodies (ubiquitin, parkin and α synuclein) are 
elevated in the mutant   even though  inclusion bodies as such do not occur.                                                                                                                                    Chapter 3                                                                           
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CHAPTER 3 
 
EXPERIMENT 2: 
Stereology of dopaminergic neurons in the SNC of the 
AS and AS/AGU rats using light and transmission 
electron microscopy 
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3.1  Introduction 
 
The substantia nigra is implicated in Parkinson’s disease through degeneration of its  
dopaminergic neurons (Hornykiewicz and Kish, 1987; Lang and Lozano, 1998a; 
Hague et al., 2005; Jenner and Olanow, 2006). The cell bodies in the substantia 
nigra pars compacta can be classified chemically (dopaminergic or nondopaminergic) 
or  morphologically  (medium  or  small)  (Fallon  and  Loughlin,  1985).  The 
dopaminergic neurons project to the striatum (Chiodo, 1988; Parent and Hazrati, 
1994;  1995a;  Blandini  et  al.,  2000;  Crossman,  2000;  DeLong  and  Wichmann, 
2007). 
The first description of the substantia nigra was made by Vicqd’Azyr in 1786 and 
Soemmering  in  1791  (Hajdu  et  al.,  1973).  Many  studies  have  described  the 
population of cells in the substantia nigra according to their appearance using the light 
microscope (Cajal, 1904; Rioch, 1929; Taber, 1961; Hanaway et al., 1970; Fallon 
and  Loughlin,  1985;  1995).    The  first  description  of  the  ultrastructure  of  the 
substantia  nigra  using  electron  microscopy  was  carried  out  in  the  mouse  by  Bak 
(1967), who examined different forms of pharmacological treatment on the substantia 
nigra and caudate nucleus. He described a single type of neuron (15  m diameter) and 
characterized it as electron lucent.  Shortly afterward Hirosawa (1968) and Schwyn 
and Fox (1969)  also described a single cell type in the substantia nigra of monkeys 
with a diameter of 30 40  m and a granular reticulum distributed in the periphery of 
the cytoplasm; in the cat, a single neuron type was described in both the substantia 
nigra pars compacta and reticulata, 15 50  m in diameter and with a prominent rough 
endoplasmic  reticulum  (Rinvik  and  Grofova,  1970).  By  contrast,  three  distinct Chapter 3                                                                                                     Introduction                                                                          
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neurons were described in the rat substantia nigra, large neurons (25 40 m) with well 
developed RER in the substantia nigra pars reticularis, medium neurons (15 20 m) 
with an eccentric nucleus  in the pars compacta and small neurons (10 12 m) in both 
nigral regions (Gulley and Wood, 1971). In another rat study  Hajdu et al. (1973) 
described  two  different  types  of  neuron  in  the  substantia  nigra,  including  a  large 
neuron up to 40 m in a diameter with well developed RER and a small neuron with  
pale  cytoplasm.    D’Agostino  and  Luse,  (1964)  described  the  ultrastructure  of 
pigmented cells in human substantia nigra.  
The  death  of  dopaminergic  neurons  in  the  substantia  nigra  of  PD  patients  can 
potentially occur in three main ways:  
i.  Necrosis  is  characterized  by  excessive  ionic  flux  through  the  plasma 
membrane leading to swelling of cellular organelles and rupture of the outer 
membrane  (Jenner  and  Olanow.,  1998;  Murphy  et  al.,  1999;  Sapolsky, 
2001).  
ii.  Apoptosis,  or    programmed  cell  death,  is  characterised  by  chromatin 
condensation,  nuclear  fragments  and  cytoplasmic  shrinkage  (Kerr  et  al., 
1972; Mochizuki et al., 1996; Anglade et al., 1997; Tompkins et al., 1997; 
Burke  and  Kholodilov,  1998;  Tatton,  2000;  Andersen,  2001;  Jellinger, 
2001; Tatton et al., 2003).   
iii.  Autophagy  is  characterised  by  nuclear  chromatin  condensation,  numerous 
vacuoles in the cytoplasm, moderate vacuolation of endoplasmic reticulum; 
mitochondria remain intact (Anglade et al., 1997).  
 
Changes in ultrastructure in the substantia nigra have been studied in animal models 
of Parkinson’s disease such as MPTP. A study by Cochiolo et al. (2000) showed  Chapter 3                                                                                                     Introduction                                                                          
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marked  mitochondrial  swelling  in  SNC  neurons  with  deformation,  disruption  and 
disintegration of cristae, but no changes in other organelles in the SNC. By contrast, 
Mizukawa et al. (1990) found dilated RER and Golgi apparatus, and a decrease in the 
number of ribosomes in their RER as well as disarranged mitochondrial cristae. After 
6 OHDA  administration,  the  SNC  showed  round,  homogeneous,  electron dense 
chromatin  clumps  in  the  nucleus  and  nuclear  membrane  invagination,  but  other 
organelles remained intact (Marti et al., 2002).  
It is difficult to establish whether such changes in cell structure are due to necrosis or 
apoptosis. One possible is that some insults can induce both necrosis and apoptosis 
(and could be responsible for neuronal loss in either PD or animal models) such as 
exposure  to  high  glutamate  concentration  and  ATP  depletion  or  lipid  and  protein 
peroxidation  induced  by  reactive  oxygen  species  and  depletion  of  glutathione 
(Dawson and Dawson, 1996; Jenner, 2001; Sapolsky, 2001; Higuchi, 2004). A 
second possible is that improve methods of differentiating of apoptosis and necrosis 
suggest that both modes of cell death could be found in the same cell (Proskuryakov 
et al., 2003; Wei et al., 2004). 
Cell death involving apoptosis and necrosis can be detected by different techniques 
such  as  ISEL  (e.g.  TUNEL)  or  fluorescent  DNA  binding  dyes,  and  electron 
microscopy  (Olanow  and  Tatton,  1999)  as  well  as  by  conventional  gel 
electrophoresis (Smyth and Berman, 2002). A few studies using TUNEL techniques 
have failed to detect apoptosis in Parkinson’s disease patients (e.g. Dragunow et al., 
1995; Kosel et al., 1997; Wullner et al., 1999); nevertheless electron microscopy has 
demonstrated many features of this form of cell death (Baba et al., 1994; Oztas and 
Topal, 2003), and a combination of TUNEL method and morphological identification Chapter 3                                                                                                     Introduction                                                                          
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(e.g.  electron  microscopy)    has  been  considered  quite  an  effective  way  to  detect 
apoptosis (He et al., 2000). 
Death by apoptosis has also been reported in other neurodegenerative disorders such 
as Alzheimer’s disease (AD), Huntington’s disease (HD) and Multiple system atrophy 
(MSA) (Jellinger, 2000) by necrosis in AD (Akiyama et al., 2000) and Creutzfeldt 
Jakob disease (Ferrer, 1999) and by autophagy in AD (Cataldo et al., 1994) and 
Huntington’s disease (Roizin et al., 1974).  
The death of dopaminergic neurons in animal models of PD can occur by (i) necrosis 
(such as MPP
+ induced necrosis in a mesencephalon derived dopaminergic neuronal 
cell line) (Choi et al., 1999) (ii) apoptosis  from agents such as MPTP (Tatton and 
Kish, 1997; Spooren et al., 1998; Serra et al., 2002), 6 OHDA (He et al., 2000; 
Marti  et  al.,  2002)  and  Rotenone  and  MPP
+  (in  cultures  of  rat  mesencephalic 
neurons)
  (Lim et al., 2007) and (iii) autophagy from agents such as MPTP (Oztas 
and Topal, 2003).  
 
The aim of experiment 2 is therefore to look at cell bodies in the SNC to see if there 
are difference between the AS (control) and AS/AGU (mutant) rats and look for any 
signs of cell death using TEM. 
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3.2  Materials and Methods  
 
3.2.1  Animals 
Three AS control and 3 AS/AGU mutant male rats aged 12 months were used for 
TEM. 
Five AS control and 5 AS/AGU mutant male rats aged 12 months were used for light 
microscopy. 
3.2.2  Initial tissue preparation 
3.2.2.1   for TEM 
All rats were deeply anaesthetized with an overdose of sodium pentobarbitone B.P 
(Vet.),  (2  ml  of  60  mg/ml,  Rhone Merieux,  Spire  Greencentre,  Harlow,  Essex) 
injected intraperitoneally, and then the thoracic  cavity  was opened.  A  mammalian 
Ringer solution (200 ml) containing the vasodilator Lignocaine was injected into the 
left ventricle for one minute followed by 500 ml 3% glutaraldehyde (Agar  Aldrich 
Inc, P6148) in 0.1M phosphate buffer, blood and excess fluid being drained via an 
incision  through  the  right  atrium  (Appendix  1).  The  brain  was  dissected  out  and 
immersion fixed in 3% glutaraldehyde in 0.1M of phosphate buffer overnight. Pieces 
of  brain  containing  areas  of  interest  were  serially  sectioned  at  70 m  using  a 
Vibrotome (Agar Scientific, BNBA 010664, Agar Scientific LTD, UK). 
3.2.2.2   for light microscopy 
All rats were deeply anaesthetized with an overdose of sodium pentobarbitone B.P 
(Vet.),  (2  ml  of  60  mg/ml,  Rhone Merieux,  Spire  Greencentre,  Harlow,  Essex)  Chapter 3                                                                                   Materials and Methods 
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injected intraperitoneally, and then the thoracic cavity was opened. One hundred ml of 
mammalian Ringer solution containing the vasodilator Lignocaine was injected into 
the  left  ventricle    followed  by  500ml  4%  paraformaldehyde  (Sigma   Aldrich  Inc, 
P6148) in 0.1M phosphate buffer, excess fluid being drained via an incision through 
the right atrium (Appendix 1). The brains were dissected out and immersion fixed in 
4%  paraformaldehyde  in  0.1M  of  phosphate  buffer  overnight.  Pieces  of  brain 
containing areas of interest were dehydrated through an ascending ethanol series using 
a  Histokinette  2000  automatic  tissue  processor  (Reichert Jung,  Germany)  then 
embedded in paraffin wax at 57ºC and serially sectioned at 7 m using a Microtome 
(Spencer, 820, USA) (Appendix 2). The ribbons of sections were laid out in parallel 
rows on a tray. 
3.2.3  Tissue verification 
In  order  to  confirm  the  identity  of  the  area  from  which  semi thin  and  ultra thin 
sections  would  eventually  be  analysed,  toluidine  blue  and  anti TH 
immunocytochemistry with DAB staining were carried out. 
3.2.3.1 Toluidine blue staining 
Sections from the central SNC  (Approximately -5.3mm relative to bregma) (Paxinos 
and  Watson,  1982)  from  AS  and  AS/AGU  rats  were  stained  with  1%  aqueous 
toluidine blue (R.ALAMB, UK) (Appendix 3A). Slides were then examined under a 
light microscope. 
3.2.3.2  Immunoperoxidase staining 
The sections containing  the central SNC (Approximately -5.3mm relative to bregma) 
(Paxinos and Watson, 1982) from the AS (control) and the AS/AGU (mutant) rats Chapter 3                                                                                   Materials and Methods 
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were incubated for 24 h in a humidity chamber at 4ºC with the primary antibody 
(Monoclonal mouse anti tyrosine hydroxylase, MAB 5280, Chemicon Europe Ltd (1: 
1000) diluted in blocking serum (1% NGS in PBS with 0.3% Triton X  100). The rest 
of  the  procedure  was  carried  out  at  room  temperature.  After  rinsing  in  PBS  (3x5 
mins), sections were then incubated for 60 min in a biotinylated anti mouse secondary 
antibody (1:200 dilution), (Vector Laboratories, INC, BA 2001, Peterborough UK). 
Following 60 min incubation in Avidin Biotin Complex (ABC) reagent (1:50; 20 l of 
solution  A  and  20 l  of  solution  B  in  1ml  of  PBS;  Vectastain  ABC  kit,  Vector 
Laboratories, INC, PK 6100, Peterborough UK), sections were then rinsed in PBS 
(3x5 mins) and 0.1 M phosphate buffer (PB, 1x5 mins). The location of the antigen 
antibody  complex  was  visualized  by  incubating  sections  in  a  medium  containing 
0.05%  3,3 diaminobenzidine  (DAB  substrate  KIT  for  peroxidase,  Vector 
Laboratories, INC, SK 4100, Peterborough UK) for 2 5 min; this step was carried out 
with care in a fume cupboard, and all equipment which came in contact with DAB 
was soaked with bleach in order to denature it, as DAB is potentially carcinogenic 
(International  Agency  for  Research  on  Cancer,  1972).  Finally,  the  sections  were 
rinsed  in  distilled  water,  dehydrated  and  mounted  with  glass  coverslips  using 
histomount  (RALAMB,  HS 103,  UK).  Slides  were  then  examined  under  a  light 
microscope.  
3.2.4   Electron microscopy 
Once  the  area  of  the  SNC  had  been  confirmed  with  toluidine  blue  and  anti TH 
staining  (see  above).  Sections  containing    the  SNC  from  AS  (control)  and  the 
AS/AGU (mutant) rats were rinsed with PB and placed in a solution of 1% Osmium 
tetroxide in PB for 20 minutes in an agitator. The sections were rinsed with distilled 
water  (3x30  mins)  and  dehydrated  through  a  series  of  graded  concentrations  of Chapter 3                                                                                   Materials and Methods 
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acetone from 70 to 100%, followed by a descending ratio of acetone to durcupan resin 
(3:1, 1:1, 1:3) and two changes of durcupan resin. The sections were flat embedded in 
durcupan resin between two small sheets of acetate, sandwiched between two glass 
slides, weighted down with metal weights and heated at 60ºC overnight in an oven 
(Appendix  6).  The  top  acetate  sheet  were  peeled  off,  stock  embedded  sections 
attached onto the end of a blank embedding block using RS adhesive and left for at 
least 30 min in an oven. The block containing the area of interest was trimmed. 
3.2.4.1   Semi thin sections processing and staining 
 Semi thin sections (1 m) containing the SNC from the AS (control) and AS/AGU 
(mutant) rats were cut from the block using diamond knives (Drukker International, 
Netherlands) on a Reichert Jung Ultracut E ultramicrotome. The semi thin sections 
were stained with 1% Toluidine Blue buffered to pH 8.5 with sodium borate and 
examined under the light microscope to determine the area to be thin sectioned and to 
be used in stereology. 
3.2.4.2  Ultrathin sections processing and staining 
Ultrathin sections (80 90nm thickness) from the SNC of AS (control) and AS/AGU 
(mutant)  rats  were  cut  from  selected  blocks  using  diamond  knives  (Drukker 
International, Netherlands) on a Reichert Jung Ultracut E ultramicrotome. Ultrathin 
sections were collected on 300 mesh coated copper grids (300 Mesh Thin Bar Copper 
3.05mm, G2720C, Agar Scientific, UK) and double stained with uranyl acetate and 
lead  citrate  (Reynolds,  1963).  The  grids  containing  sections  were  stained  in  lead 
citrate for 5 mins, placed in sodium hydroxide 7 times, washed in distilled water 7 
times,  stained  in  12.5%  methanolic  uranyl  acetate  for  5  mins,  washed  in  distilled Chapter 3                                                                                   Materials and Methods 
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water 7 times, stained in lead citrate for 5 mins, placed in sodium hydroxide 7 times , 
washed in distilled water 7 times and left to dry for 20 mins. 
Ultrathin sections were examined at a magnification of 5900X using a transmission 
electron microscope (JEOL JEM 100S, No. IEM 100S 4, JEOL LTD, Tokyo, Japan). 
All the SNC cells containing a nucleolus were photographed. This organell was used 
to confirm that the section is centrally placed through the cell body (Oorschot, 1996). 
3.2.4.3  Pre embedding immunocytochemistry 
See chapter 4 page 163. 
Cells are often  considered positive (and immunogold labelling specific) when two or 
more particles are located within the cytoplasm (Mengual and Pickel, 2002). In the 
present study, I have used five  or more as a criterion.  
3.2.5  Image analysis 
 Images were captured on plate film. The films were put in a  working dilution of 
500ml D19 Kodak developer (Kodak path, Paris) in 500ml of water for 3 mins, and 
then were rinsed in water for one minute before placing in Amfix (Amfix, Champion, 
UK) for 5 mins, rinsed in water for 20 mins and dried. The negatives of electron 
micrographs were scanned using an Epson scanner (Epson perfection 4990), and the 
contrast and exposure were adjusted using Paint Shop before printing. 
3.2.6  Stereological techniques   
Stereological  methods  are  used  to  obtain  quantitative  information  about  three 
dimensional structures from simple counts made on two dimensional slice images to 
facilitate correlation between structure and function. Chapter 3                                                                                   Materials and Methods 
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3.2.6.1  Volume fraction (Vv) 
The stereological method was developed for use on geological specimens by Delesse 
in 1848, who indicated that the volume fraction of mineral in the whole rock was 
equal to the area fraction of mineral on the cut surface of a sample of the rock. This 
confirmed that the area of the phase of interest per unit of area is equivalent to the 
volume of that phase per unit of volume. 
                                        Aa (area fraction) = Vv (volume fraction) 
                                                  Aphase / Aref  = Vphase / Vref 
Thomson  in  1930  and  Glagolev  in  1933  showed  that  we  could  estimate  volume 
fraction through a random point counting method.   The volume fraction Vv and area 
fraction Aa can be estimated in an unbiased manner by using a randomly positioned 
point grid and counting the number of points hitting the phase of interest P (phase) 
and the number of points hitting the reference space P (ref), the volume fraction of 
the phase of interest being estimated from 
                                               Vv = Aa = P (phase) / P (ref)   
The volume of a particular phase V(phase) can be estimated from  
V(phase) = V(ref) x Vv (phase, ref) 
The volume reference V(ref) can be calcaulated by the Cavalieri principle. 
 
3.2.6.2  Surface density (SV) 
Surface density (SV) represents the amount of surface contained in a reference volume 
and it can be estimated by dividing the number of intersections (I) by the total length 
of test line (LT) 
SV  = 2 x I /LT Chapter 3                                                                                   Materials and Methods 
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3.2.6.3  Volume estimates 
The volume (V) of any arbitrary object can be estimated using the Cavalieri principle 
(Mayhew, 1991; 1992). The object has to be serially sectioned at known distance (d) 
where  the sectiones are  parallel and the first slice must be randomly placed. The 
areas of only one face of each section are estimated by randomly superimposing a 
systematic array of test points on each face. 
The volume can be estimated using:  
V = P x a x d 
Where (P) is the sum of points falling on all section faces, (a) the area associated with 
each test point and (d) the distance between the sections (Mayhew, 1991; 1992). 
Other stereological methods can estimate volume weight mean volume which 
provides an unbiased estimate of particle volume (Mayhew, 1992). 
The volume weight mean volume can be estimated from  
Volume weight mean volume = (I 0)
3
 x п/3 
Where I 0  is the point sampled intercept length average. 
 
3.2.6.4  Stereology using the light microscope 
This  method  was  used  to  estimate  the  diameter  (maximum  and  minimum)  of  the 
dopaminergic neurons in the SNC of 3 AS (control) and 3 AS/AGU (mutant) rats. 
One section (7  m thick) per animal  from the central SNC (Approximately -5.3mm 
relative to bregma) (Paxinos and Watson, 1982). 
 Sections were stained with: 
(a) 1% aqueous toluidine blue  to analyse at least 50 cells per section  
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(b) Immunoperoxidase for tyrosine hydroxylase to analyse at least 50 cells 
per section (Figure 3.2). 
The sections were analysed using a NIKON light microscope with a drawing tube 
(NIKON, OPTIPHOT 2, Japan). Average sizes of dopaminergic neurons containing a 
nucleolus were calculated. 
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Figure 3.1: Coronal sections of substantia nigra pars compacta (SNC) from (a) 
control (AS) and (b) mutant (AS/AGU) male rats aged 12 months. Sections have 
been  stained  with  toluidine  blue.  In  the  inset  box,  lines  show  a  maximum 
diameter (MAX DM) and a minimum diameter (MIN DM) (x400). 
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Figure 3.2: Coronal sections of substantia nigra pars compacta (SNC) from (a) 
control (AS) and (b) mutant (AS/AGU) male rats aged 12 months. Sections have 
been  DAB  immunostained  for  TH.  In  the  inset  box,  lines  show  a  maximum 
diameter (MAX DM) and a minimum diameter (MIN DM) (x400). 
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3.2.6.5  Stereology using the transmission electron microscope 
In this stereological method, a simple point counting technique was used to estimate 
the Vv of mitochondria, rough endoplasmic reticulum and lipofuscin granules. The 
measurement  was  made  on  30  SNC  dopaminergic  cells  per  animal  from  3  AS 
(control) and 3 AS/AGU (mutant) rats. 
The Vv was determined using a 1cm square grid. The square grid was superimposed 
on each micrograph randomly three times. The number of grid points that fell on the 
cell organelle (mitochondria, RER, lipofuscin granules) and the number of grid points 
that fell on the reference space (cell and cytoplasm) were counted (Weibel, 1979; 
Mayhew, 1991) and the Vv were calculated.    
 
3.2.7  Statistical analysis 
The results were analysed by two sample t test using the Minitab statistics package 
(MINITAB Release 13.30). 
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3.3  Results 
 
3.3.1  The diameter of SNC cells and nuclei in paraffin wax sections 
stained with toluidine blue in the midbrain of AS and AS/AGU 
rats aged 12 months 
 
The results show statistically significant differences between the two groups in the 
diameter (maximum and minimum) of the SNC cells and their nuclei with AS/AGU 
(mutant) rats having smaller neurons than the AS (control) animals. The results are 
summarized in table 3.1. 
 
 
 
SNC cells 
 
AS 
 
 
AS/AGU 
 
P 
Maximum dimension of cell 
body ( m) 
 
 
16.76 ± 0.64 
 
 
11.76 ± 1.1 
 
 
< 0.01 
 
Minimum dimension of cell 
body ( m) 
 
 
6.99 ± 0.24 
 
 
5.06 ± 0.44 
 
 
< 0.01 
Maximum dimension of 
nucleus ( m) 
 
 
5.74 ± 0.31 
 
4.30 ± 0.05 
 
< 0.05 
Minimum dimension of 
nucleus ( m) 
  
 
 
5.56 ± .0032 
 
4.15 ± 0.04 
 
< 0.001 
Table 3.1: The diameter (maximum and minimum) of the SNC cells and their 
nuclei stained with toluidine blue in the midbrain of AS control and AS/AGU 
mutant rats aged 12 months (n=5 per group). All values are mean  m ± SEM. All 
comparisons are two sample t tests. 
 
 
 
` 
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3.3.2  The diameter of SNC cells and nuclei in paraffin wax sections 
stained with  immunoperoxidase  DAB staining  for  TH  in the 
midbrain of AS and AS/AGU rats aged 12 months 
 
The  results  show  statistically  significant  differences  between  the  two  groups  in 
minimum cell body diameter and maximum nucleus diameter of the SNC cells with 
AS/AGU (mutant) rats being smaller than the AS (control).  Differences in maximum 
cell diameter and minimum nucleus diameter did not reach significant. The results are 
summarized in table 3.2. 
 
 
 
SNC cells 
 
AS 
 
 
AS/AGU 
 
P 
Maximum dimension of cell 
body ( m) 
 
 
16.88 ± 0.99 
 
 
14.27 ± 0.26 
 
 
NS 
 
Minimum dimension of cell 
body ( m) 
 
 
7.26 ± 0.42 
 
 
5.59 ± 0.13 
 
 
< 0.05 
Maximum dimension of 
nucleus ( m) 
 
 
6.77 ± 0.46 
 
5.32 ± 0.21 
 
< 0.05 
Minimum dimension of 
nucleus ( m) 
  
 
5.98 ± 0.27 
 
5.23 ± 0.19 
 
NS 
Table 3.2: The diameter (maximum and minimum) of the SNC cells and nuclei 
stained  with  immunoperoxidase  DAB  staining  for  TH  in  the  midbrain  of  AS 
control and AS/AGU mutant rats aged 12 months (n=5 per group). All values are 
mean  m ± SEM. All comparisons are two sample t tests (NS, not significant). 
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3.3.3  A  Comparison  of  ultrastructure  of  the  SNC  cells  of  AS 
(control) and AS/AGU (mutant) rats aged 12 months 
 
 
No obvious morphological differences were seen in the nigrostriatal neurons of AS 
(control) compared to AS/AGU (mutant) rats. Neurons were of medium size with 
rounded nuclei exhibiting one or more indented envelopes, many mitochondria and 
considerable rough endoplasmic reticulum, Golgi apparatus and lipofuscin granules 
(see figure 3.3 3.6).  
There were no obvious Lewy body inclusions. Many microglial cells were seen near 
SNC cells in AS/AGU  rats (see figure 3.6).  In figure 3.7 a cell in the SNC has 
cytoplasm  shrinkage,  cell  membrane  budding  and  chromatin  condensation  at  the 
nuclear membrane. 
 
Most SNC cells stained with immunogold have more than 5 gold particles (at least 
two  gold  particles  in  cytoplasm  are  considered  positive)    and  most  of  these  gold 
particles are near the RER. 
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Figure 3.3: Electron micrograph showing SNC cell (immunogold stained with 
TH) in an AS (control) rat aged 12 months (x6000). In inset boxes (a) lipofuscin 
granule (b) Golgi Apparatus, (c) rough endoplasmic reticulum (RER) and (d and 
e) mitochondria. (N, Nucleus; NE, Nucleolus; small arrows show gold particles). 
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Figure 3.4: Electron micrograph showing SNC cell in an AS (control) rat aged 12 
months  (x5900).  In  inset  boxes  (a)  Lipofuscin  granules  (b)  RER  and  (c) 
mitochondria.  (N,  Nucleus;  NE,  Nucleolus;  blue  arrows  show  indented 
envelopes). 
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Figure 3.5: Electron micrograph showing SNC cell (immunogold stained with 
TH)  in  an  AS/AGU  (mutant)  rat  aged  12  months  (x6000).  In  inset  boxes  (a) 
lipofuscin  granule  and  (b)  rough  endoplasmic  reticulum  (RER)  (c)  Golgi 
apparatus and (d and e) mitochondria (x50,000). (N, Nucleus; NE, Nucleolus; 
small arrows show gold particles). 
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Figure 3.6: Electron micrograph showing SNC cell in an AS/AGU (mutant) rat 
aged  12  months  (x5900).  In  inset  boxes  (a)  RER  (b)  mitochondria  and  (c) 
Lipofuscin  granules.  (N,  Nucleus;  NE,  Nucleolus;  blue  arrows  show  indented 
envelopes; M, microglial cell). 
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Figure 3.7: Electron micrograph (A) showing a shrunken SNC cell (immunogold 
stained with TH) in an AS/AGU (mutant) rat aged 12 months (x6000). (B) shows 
a detail of the same cell (x20,000). (N, Nucleus; small black arrows show gold 
particles). 
           Chromatin condensation at nuclear membrane. 
           Cell membrane budding. 
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3.3.4  The volume fraction (Vv), surface density (SV) and volume (v) 
of SNC neuron organelles in the midbrain of AS and AS/AGU 
rats aged 12 months 
 
The results show statistically significant differences between the two groups in the 
volume  fraction  of  the  mitochondria  (in  cell  and  cytoplasm)  and  the  rough 
endoplasmic reticulum (in cell and cytoplasm), cell volume and the nuclear volume of 
SNC cells. The AS/AGU (mutant) rats had higher volume fractions, cell volume and 
nuclear volume than the AS (control). There were no statistical differences in the 
volume fraction of  lipofuscin granules or the numbers of nuclear indentations and 
nuclear surface density. The results are summarized in table 3.3. 
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SNC cell organelles 
 
AS 
 
 
AS/AGU 
 
P 
 
Mitochondrial Vv:  Cell 
 
 
0.042 ± 0.002 
 
 
0.051 ± 0.002 
 
 
< 0.05 
Mitochondrial Vv: 
Cytoplasm 
 
0.0817 ± 0.001 
 
0.089 ± 0.006 
 
 
< 0.05 
 
RER Vv: Cell 
 
 
  0.0247 ± 0.0003 
 
0.0313 ± 0.0009 
 
 
< 0.05 
 
RER Vv: Cytoplasm 
 
 
0.0463 ± 0.0023 
 
 
0.0563 ± 0.011 
 
 
< 0.05 
Lipofuscin granules Vv: 
Cell 
 
 
0.0067 ± 0.0003 
 
 
0.017 ± 0.003 
 
 
NS 
Lipofuscin granules Vv: 
Cytoplasm 
 
 
0.012 ± 0.001  
 
0.031 ± 0.007 
 
NS 
 
Nuclear membrane SV 
 
 
0.09 ± 0.006 
 
0.11 ± 0.01 
 
NS 
 
SNC cell volume (V) 
 
 
664.1 ± 25 
 
240.3 ± 22 
 
< 0.001 
 
SNC nuclear volume (V) 
 
 
133 ± 7.3 
 
53.13 ± 0.60 
 
 
< 0.001 
Table 3.3: Volume fraction (Vv), surface density (SV) and volume (V) of the SNC 
cell and its organelles in the midbrain of AS control and AS/AGU mutant rats 
aged 12 months (n=3 per group). All values are mean ± SEM. All comparisons 
are two sample t tests (NS, not significant). 
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3.4  Discussion 
 
 
 
The  AS/AGU  rat  has  a  dysfunction  of  the  midbrain  monoaminergic  systems 
projecting to the caudate putamen, including the nigrostriatal dopaminergic system 
(Clarke and Payne, 1994) and the raphe striatal serotonergic system (Al Fayez et al., 
2005). That dysfunction takes the form of  a marked  reduction in dopamine and 
serotonin release in the striatum (Campbell et al., 1997; Al Fayez et al., 2005) as 
well  as  reduced  whole  tissue  levels  of  dopamine  and  serotonin  as  revealed  by 
micropunch (Campbell et al., 1998; 2000; Al Fayez et al., 2005). The dysfunction is 
known  to  occur  before  any  gross  morphological  difference  or  cell  loss  can  be 
identified (Payne et al., 1998). 
The animals  examined in Experiment 2 were aged 12 months. That is, they would be 
expected to display both physiological and morphological evidence of the disorder as 
this is in the beginning of the period of cell loss (Payne et al., 2000). The movement 
disorder is, of course, also well established (Payne et al., 2000).  
The  first  point  to  make  is  that  the  ultrastructure  of  SNC  neurons  in  AS  animals 
resembled existing reports in other rat strains (Gulley and Wood, 1971; Hajdu et al., 
1973) that have medium size neurons containing a round eccentric nucleus with slight 
nuclear indentations, and an abundance of cellular organelles including endoplasmic 
reticulum and Golgi apparatus.  
Regarding  possible  pathological  changes,  no  inclusion  bodies  can  be  seen  in  the 
AS/AGU  (mutant)  neurons,  though  these  are  a  hallmark  of  Parkinson’s  disease 
(Pollanen et al., 1993; Forno, 1996; Takahashi and Wakabayashi, 2001; Yokota 
et al., 2007). Inclusion bodies are not always found in neurodegenerative laboratory Chapter 3                                                                                                        Discussion 
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models. For example, they do not occur in most laboratory models of Parkinson’s 
disease such as those induced by 6 OH dopamine or MPTP toxicity (Forno et al., 
1993; Dauer and Przedborski, 2003), though they are present in rotenone induced 
degeneration in rat (Betarbet et al., 2000).    
Lewy bodies in human Parkinson’s disease contain a complex mixture of mis folded 
proteins including α synuclein, parkin and ubiquitin (Lennox et al., 1989; Love and 
Nicoll, 1992; Spillantini et al., 1997; 1998a; Irizary et al., 1998; McNaught et al., 
2006).  It  is  of  interest  that,  even  though  inclusion  bodies  were  not  seen  in  the 
AS/AGU rat, Experiment 1 showed that levels of these molecules were elevated in 
cell  bodies  within  the  midbrain  (or  in  the  surrounding  neuropil).  There  has  been 
controversy  over  the  role  of  some  of  these  molecules  in  the  pathological  process 
(McNaught and Olanow, 2006). Recently, Periquet et al. (2007) have shown that 
some truncated forms of α synuclein lead reliably to aggregate formation whereas 
other  do  not.  In  the  case  of  the  AS/AGU  rat,  fluorescence  readings  show  that  α 
synuclein is not present in the cell bodies in detectable amounts, so no inclusions 
would be expected. It is also possible that there could be changes in  α synuclein in 
the AS/AGU rat (and in other laboratory models) but they do not affect key regions of 
the molecule.  
A robust finding is that the size and volume of nigrostriatal dopaminergic neuron cell 
bodies are reduced in AS/AGU mutant rats suggesting that they are shrinking. Similar 
observations were found in dopaminergic neurons in the SNC treated with MPTP 
(Langston et al., 1984) or 6 OHDA (Chio et al., 1999) as well as in the SNC of PD 
patients (Anglade et al., 1997).  The nucleus is also reduced in size and volume, 
suggesting that the whole cell is affected. 
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Regarding  cell  organelles,  the  volume  fractions  of  mitochondria  and  rough 
endoplasmic  reticulum  of  the  SNC  cells  are  higher  in  the  AS/AGU  mutants  rats. 
There are many possible reasons for this observation:  
i.  The numbers of mitochondria and RER increase in AS/AGU (or decrease in 
AS) rats.  
ii.  The  numbers  of  mitochondria  and  RER  stay  the  same,  but  the  organelles 
change  their  size.  This  would  increase  the  chance  of  “hitting”  a 
mitochondrion  with  a  grid  point.  One  possibility  is  that  this  is  due  to  an 
increase in mitochondrial size as part of the swelling which occurs in the SNC 
neurons of other PD animal models as a characteristic feature of cell death 
(Langston et al., 1984; Tanaka et al., 1988; Arai et al., 1990; Mizukawa et 
al., 1990; Rapisardi et al., 1990; Cochiolo et al., 2000). 
iii.   The number (and size) of mitochondria and RER stay the same, but the cell 
or its cytoplasm shrinks in AS/AGU rats or swells in AS ones. Again, this 
would increase the chance of “hitting” a mitochondrion and/or RER as they 
become packed together.  
 
As mentioned above, the size of the SNC nuclei are greater in AS (control) than in 
AS/AGU (mutant) rats. However, nuclear indentation (a characteristic of pathological 
change) (Anglade et al., 1997; Marti et al., 2002) and the nuclear surface density 
(SV) were not increased in the mutants nor was chromatin clumping seen, although it 
occurs in MPTP treatment (Tanaka et al., 1988). 
 
The nucleolus of both AS and AS/AGU TH+ve cells in the SNC frequently showed  a 
few  gold  particles.  We  know  that  the  nucleolus  has  a  role  in  ribosomal  RNA 
synthesis, processing and ribosome maturation (Gerbi et al., 2003). It may also have Chapter 3                                                                                                        Discussion 
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a role in TH regulation of gene expression (Kumer and Vrana, 1996). In addition to 
that there is positive staining of the nucleolus in 6 OHDA treated rats used silver 
impregnation methods (Jeon et al., 1995).   
 
Many microglial cells were seen near SNC cells in AS/AGU rats and the microglial 
activation accompanies the neuronal loss in the substantia nigra in the brains of PD 
patients (Banati et al., 1998; Teismann et al., 2003), as well as MPTP treated mice 
(Czlonkowska  et  al.,  1996;  Kohutnicka  et  al.,  1998)  and  6 OHDA treated  rats 
(Akiyama and McGeer, 1989; Rodrigues et al., 2001). Ultrastructurally, microglial 
cells can be seen near the SNC cells in the brain of PD patients (Anglade et al., 
1997).  
Taken  collectively,  these  characteristic  features  may  indicate  that  SNC  cells  are 
starting to die by apoptosis which occurs in many other animal model of PD (Tatton 
and Kish, 1997; Spooren et al., 1998; He et al., 2000; Marti et al., 2002; Serra et 
al., 2002; Novikova et al., 2006) and in Parkinson’s disease patients (Mochizuki et 
al., 1996; Anglade et al., 1997; Tompkins et al., 1997; Burke and Kholodilov, 
1998; Tatton, 2000; Andersen, 2001; Tatton et al., 2003). It is possible that cells 
with more altered ultrastructure have died already and therefore can not be sampled. 
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EXPERIMENT 3: 
Nigrostriatal dopaminergic terminals in the AS and 
AS/AGU rat 
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4.1  Introduction 
 
Nigrostriatal  dopaminergic  neurons  mainly  project  to  the  striatum  (for  other 
connections, see table 1.1, chapter 1 page 8) (Chiodo, 1988; Pickel et al., 1992a; 
Parent and Hazrati, 1994; 1995a; Blandini et al., 2000; Crossman, 2000; DeLong 
and Wichmann, 2007) where they form synapses on medium spiny neurons (12 
20 m)  (Smith  and  Bolam,  1990),  which  are  the  main  neurons  in  the  caudate 
putamen (DiFiglia et al., 1976; Bishop et al., 1982; Gerfen and Wilson, 1996). They 
form about 95% of striatal neurons (Kemp and Powell, 1971) and they use GABA as 
a neurotransmitter (Parent and Hazrati, 1995a). The remainder of striatal neurons 
are interneurons (DiFiglia et al., 1976; Bishop et al., 1982) which are classified into 
large cholinergic neurons (25 40 m in diameter) (Bolam et al., 1984), medium size 
(5 15  m) neurons which use GABA as a neurotransmitter (DiFiglia et al., 1976; 
Bishop et al., 1982; Bolam et al., 1984; Oertel and Mugnaini, 1984; Smith et al., 
1987; Pasik et al., 1988; Kita, 1993) and medium neurons containing neropeptide Y, 
Somatostatin or nitric oxide synthase (Vincent et al., 1983 a,b; Smith and Parent, 
1986; Dawson et al., 1991). 
Another group of striatal cells are TH positive and have been described in non human 
primates by Dubach et al. (1987) and in the rat (Tashiro et al., 1989). They have also 
been described in MPTP  and 6 OHDA  treated animals (Betarbet et al., 1997), so 
they may be less susceptible to these toxins.   
The  degeneration  of    nigrostriatal  dopaminergic  neurons  occurs  in  animal  models 
treated with MPTP (e.g. monkey  and baboons) (Shimohama et al., 2003) and in rats 
treated  with  6 OHDA  (Ichitani  et  al.,  1991;  Betarbet  et  al.,  2002).  Regarding Chapter 4                                                                                                     Introduction     
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ultrastructural changes in axons and terminals,  the striatal degeneration that occur in 
animals treated with MPTP appears quite variable. For example, axonal swelling and 
myelin sheath disruption has been reported in the dog (Rapisardi et al., 1990) and  
terminals  lacking  synaptic  vesicles  occur  in  MPTP treated  mice  (Cochiolo  et  al., 
2000). In 6 OHDA treated rats  there are increases in the terminal size and the number 
of vesicles (Pickel et al., 1992b; Stanic et al., 2003). 
The  AS/AGU  rat  is  characterised  by  its  apparent  inability  to  release  DA  in  the 
striatum  (Campbell  et  al.,  1997).  This  evidence  comes  from  microdialysis 
experiments with indwelling cannulae. The fact that greatly reduced extracellular DA 
(10% of normal) is matched by greatly increased DA metabolites such as DOPAC and 
HVA, led Payne et al. (2000)  to propose a dysfunction of synaptic packaging of DA, 
leaving it free within the cytoplasm to be acted  upon by mitochondrial enzymes. 
However, there is no information on (a) the abundance of dopaminergic terminals in 
the  striatum  of  the  AS/AGU  mutant,  (b)  the  abundance  of  synaptic  vesicles  in 
dopaminergic  terminals  or  (c)  their  zonation  within  the  terminal  relative  to  the 
synaptic cleft and the “readily releasable pool”. 
 
The aim of experiment 3 is therefore to look to TH+ve dopaminergic terminals in the 
dorsal caudate putamen to see if there are difference between the AS (control) and 
AS/AGU (mutant) rats using TEM. 
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4.2  Materials and Methods  
 
 
4.2.1  Animals 
Three AS control and three AS/AGU mutant male rats aged 12 months. 
Three AS control and three AS/AGU mutant male rats aged 3 months. 
 
It is essential to be able to distinguish dopaminergic terminals within the striatum 
from other terminals. This involves immunocytochemical labelling of terminals with 
an  antibody  to  tyrosine  hydroxylase  followed  by  secondary  labelling  by  3,3 
diaminobenzidine  (DAB)  or  immuno gold  particles  for  visualization.  To  ensure 
labelling, fixation must be with the lowest possible percentage of glutaraldehyde that 
is consistent with the retention of ultrastructural detail.  After considerable trial and 
error a mixture of 1% glutaraldehyde: 4% paraformaldehyde was chosen as permitting 
visualization with both  
(a) DAB,  and  
(b) Immunogold particles (1 nm) with silver enhancement. 
4.2.2  Tissue preparation for transmission electron microscopy  
All rats were deeply anaesthetized with an overdose of sodium pentobarbitone B.P 
(Vet.),  (2  ml  of  60  mg/ml,  Rhone Merieux,  Spire  Greencentre,  Harlow,  Essex) 
injected intraperitoneally, after which the thoracic cavity was opened. A mammalian 
Ringer solution (200 ml) containing the vasodilator Lignocaine was perfused via the 
left ventricle for one minute followed by 500 ml mixture of 4% paraformaldehyde and 
1% glutaraldehyde (Agar  Aldrich Inc, P6148) in 0.1M phosphate buffer, blood and 
excess fluid being drained via an incision through the right atrium (Appendix 1). The Chapter 4                                                                                   Materials and Methods 
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brain was dissected out and immersion fixed in a mixture of 4% paraformaldehyde 
and  1%  glutaraldehyde    in  0.1M  of  phosphate  buffer  overnight.  Pieces  of  brain 
containing areas of interest were serially sectioned at 70 m using a Vibrotome (Agar 
Scientific, BNBA 010664, Agar Scientific LTD, UK). 
4.2.3  Tyrosine hydroxylase immunoperoxidase staining 
The sections containing the dorsal region of the caudate putamen (Approximately -0.3 
mm relative to bregma Paxinos and Watson, 1982), from the AS (control) and the 
AS/AGU (mutant) rats were incubated for 24 h in a humidity chamber at 4ºC with the 
primary  antibody  (Monoclonal  mouse  anti tyrosine  hydroxylase,  MAB  5280, 
Chemicon Europe Ltd (1: 1000) diluted in blocking serum (1% NGS in PBS with 
0.3% Triton X  100). The rest of the procedure was carried out at room temperature. 
After  rinsing  in  PBS  (3x5  mins),  sections  were  then  incubated  for  60  min  in  a 
biotinylated  anti mouse  secondary  antibody  (1:200  dilution),  (Vector  Laboratories, 
INC, BA 2001, Peterborough UK). Following 60 min incubation in Avidin Biotin 
Complex (ABC) reagent (1:50; 20 l of solution A and 20 l of solution B in 1ml of 
PBS; Vectastain ABC kit, Vector Laboratories, INC, PK 6100, Peterborough UK), 
sections were then rinsed in PBS (3x5 mins) and 0.1 M phosphate buffer (PB, 1x5 
mins). The location of the antigen antibody complex was visualized by incubating 
sections in a medium containing 0.05% 3,3 diaminobenzidine (DAB substrate KIT for 
peroxidase, Vector Laboratories, INC, SK 4100, Peterborough UK) for 2 5 min; this 
step was carried out with care in a fume cupboard, and all equipment which came in 
contact  with  DAB  was  soaked  with  bleach  in  order  to  denature  it,  as  DAB  is 
potentially  carcinogenic  (International  Agency  for  Research  on  Cancer,  1972). 
Finally, the sections were rinsed in distilled water, dehydrated and mounted with glass Chapter 4                                                                                   Materials and Methods 
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coverslips using histomount (RALAMB, HS 103, UK). Slides were then examined 
under a light microscope.  
4.2.4  Pre embedding immunocytochemistry 
The sections containing the dorsal region of the caudate putamen (Approximately -0.3 
mm relative to bregma Paxinos and Watson, 1982), from the AS (control) and the 
AS/AGU (mutant) rats were treated with 1% sodium borohydride for 30 min (Kosaka 
et al., 1986), rinsed in PBS many times (9x10 min), incubated in blocking solution 
(Appendix 7) for 30 minutes and incubated overnight in mouse antiserum to tyrosine 
hydroxylase  (Monoclonal  mouse  anti tyrosine  hydroxylase,  MAB  5280,  Chemicon 
Europe Ltd) diluted to 1:300 in incubation buffer (Appendix 7). Sections were then 
processed using a silver enhanced immunogold method (Chan et al., 1990). After the 
sections were rinsed in washing buffer (3x10 min), they were incubated for 4 hours in 
1nm goat anti mouse IgG immunogold (Amersham UK) diluted 1:50 in incubation 
buffer. Sections were then rinsed in washing buffer (3x15 min) and in PBS (3x5 min), 
postfixed in 2% glutaraldehyde in PBS for 10 minutes, rinsed in distilled water, and 
treated with a silver enhancement solution (IntenSE  M kit, Amersham UK) according 
to the manufacturer’s instructions. The optimal time for the silver enhancement step 
was found to be between 12 and 15 minutes at approximately 20
oC. The sections were 
then  rinsed  in  distilled  water  (3x5  min),  osmicated,  dehydrated  and  embedded  in 
Durcupan.  
4.2.5  Electron microscopy 
Sections containing  the dorsal region of the caudate putamen from AS (control) and 
the  AS/AGU  (mutant)  rats  were  rinsed  with  PB  and  placed  in  a  solution  of  1% 
Osmium tetroxide in PB for 20 minutes in an agitator. The sections were rinsed with Chapter 4                                                                                   Materials and Methods 
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distilled water (3 x 30 mins) and dehydrated through a series of graded concentrations 
of acetone from 70 to 100%, followed by a descending ratio of acetone to durcupan 
resin (3:1, 1:1, 1:3) and two changes of 100% durcupan resin. The sections were flat 
embedded  in  durcupan  resin  between  two  small  sheets  of  acetate,  sandwiched 
between  two  glass  slides,  weighted  down  with  metal  weights  and  heated  at  60ºC 
overnight in an oven (Appendix 6). The top acetate sheet was peeled off, and stock 
embedded sections were attached onto the end of a blank embedding block using RS 
adhesive and left for at least 30 min in an oven. The block containing the area of 
interest was trimmed. 
4.2.5.1  Ultrathin sections processing and staining 
Ultrathin sections (50 70nm thickness) from the dorsal region of the caudate putamen 
of  AS  (control)  and  AS/AGU  (mutant)  rats  were  cut  from  selected  blocks  using 
diamond knives (Drukker International, Netherlands) on a Reichert Jung Ultracut E 
ultramicrotome. Ultrathin sections were collected on 300 mesh coated copper grids 
(300 Mesh Thin Bar Copper 3.05 mm, G2720C, Agar Scientific, UK) and double 
stained with uranyl acetate and lead citrate (Reynolds, 1963). The grids containing 
sections were stained in lead citrate for 5 mins, placed in sodium hydroxide 7 times, 
washed in distilled water 7 times, stained in 12.5% methanolic uranyl acetate for 5 
mins, washed in distilled water 7 times, stained in lead citrate for 5 mins, placed in 
sodium hydroxide 7 times, washed in distilled water 7 times and left to dry for 20 
mins. 
Ultrathin sections were examined at a magnification of 10,000X and 50,000X using a 
transmission electron microscope (JEOL JEM 100S, No. IEM 100S 4, JEOL LTD, 
Tokyo, Japan). All areas of interest were photographed. 
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4.2.6  Data analysis 
 
4.2.6.1  The classification of neuronal elements 
Tyrosine  hydroxylase  +ve  neuronal  elements  can  be  positively  identified  with 
immunoperoxidase  DAB  reaction  when  they  showed  a  higher  electron  density  in 
comparison to neighbouring elements. Similarly, they were considered positive with 
immunogold when one or more gold particles were located in the labeling area. The 
classification of neuronal elements was made according to the descriptions of  Peters 
et al. (1976). Axon terminals were 0.25  m or larger in diameter and contained many  
small synaptic vesicles. A synapse can normally be defined as symmetric  when it has 
a thin postsynaptic density and asymmetric when it has a thick postsynaptic density. 
Dendrites  were  identified  by  their  large  diameter,  the  presence  of  postsynaptic 
densities and/or an abundance of microtubules and endoplasmic reticulum.   
 
4.2.6.2  Sampling of TH+ve and unlabelled terminals (Figure 4.1) 
To determine the proportions of  TH+ve terminals compared to unlabelled terminals 
in the dorsal caudate putamen, at least 180 electron micrographs from 12 animals (at 
least  10  electron  micrographs  per  animal)  were  photographed  randomly  at 
magnifications  of  x10,000  in  areas  (10.5  x  8.5   m)  in  which  immunogold  or 
immunoperoxidase DAB for TH were present.  For each animal (and stain) 10 squares 
from a 300 – square grid (G) were sampled in a manner which was uniform for all 
animals (see figure 4.1).  
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i.  the first square (i.e. the one at the left hand end) was photographed in the top 
left corner.  
ii.   Five grid squares were omitted and the sixth grid photographed in the top 
right corner.  
iii.   The third and fourth grids were photographed in the bottom left and bottom    
right corners respectively. In each case, 5 grid squares were omitted between 
sample grids.  
iv.  The sequence began again.  
v.  Once a horizontal row had been completed, the next row was omitted and 
counts began again on the following row. 
The aim was to cover as large an area on the grid as possible, but to sample in a 
standardised manner. 
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Figure 4.1 : A schematic diagram to show standard sampling 
methods  for  TEM  photography  and  analysis  (refer  also  to 
text).  
   
Top left 
Top right 
bottom left  bottom right 
10.5  m 
8.5  m 
8.5 m 
10.5  m 
8.5  m 
10.5  m 
8.5  m    1 
a 
b  c  d 
G 
1  2 
3  4  5 
6  7  8 
     (x5) 
     (x5)       (x5) 
     (x5)       (x5) 
75  m 
75  m 
10.5  m 
  2    3   4 Chapter 4                                                                                   Materials and Methods 
 
168 
4.2.6.3  Measurements of synaptic vesicle numbers  
Figure 4.2 shows schematically the method for counting the number of vesicles and is 
partially modified from a recent study by Tao Cheng (2006). This anther studied the 
distributions  of  seven  pre synaptic  proteins  in  the  active  zone  using  immunogold 
labelling. The active zone is a well defined area in the presynaptic terminal directly 
apposed to the post synaptic density (PSD) and a site of synaptic vesicle exocytosis 
and neurotransmitter release.  He measured the numbers of immunogold particles and 
vesicles in three zones:  
(i)  Zones I and II (each 33 nm wide) contain the two rows of synaptic vesicles 
immediately adjacent to the presynaptic membrane known as the proximal or 
“readily  releasable”  pool.  Active  zone  cytomatrix  materials  (pyramidal  in 
shape and 50 nm wide) extend through these two zones (I and II).  
(ii)  Zone III is twice as wide as zone I and II together, and contains almost all the 
remaining synapses known as the distal or reserve pool.  
In my study, vesicles were counted in  four zones if they lay between the two parallel 
lines perpendicular to the synaptic cleft. The visible synapse length (L) of the synapse 
(determined by the post synaptic density, PSD) was measured: 
a)  Zone I (0 41.7 nm).  
b)  Zone II (41.7 83.3 nm). 
c)  Zone III (83.3  166.7 nm).  
d)  Zone IV (166.7  300 nm). 
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Figure  4.2:  Schematic  diagram  of  synaptic  measurement 
zones. Two parallel lines (A + B) perpendicular to the segment of the 
presynaptic membrane define the two sides of the area of measurement; 
the distance between them is the index length (L). Three parallel bands 
with increasing distance from the presynaptic membrane were marked 
in dotted lines: Zone I, 0 41.7 nm; Zone II, 41.7 83.3 nm; Zone III, 83.3  
166.7 nm and Zone IV,  166.7  300 nm. The postsynaptic density (PSD) is 
shown  as  a  dark  gray  rectangle.  Partially  modified  from  Tao Cheng 
(2006). 
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Zone I (immediately adjacent to the presynaptic terminals) and Zone II are both 41.7 
nm in wide. I choose this width to reflect the average diameter of vesicles (35 45 nm)  
in each zone. Zone III is four times as wide as Zone I. In my study a few vesicles were  
present further than 200 nm from the presynaptic membrane, so I added Zone IV (up 
to 300 nm from the presynaptic membrane) to cover the remaining vesicles. 
The number of vesicles per synaptic length was calculated by dividing the number of 
vesicles in a zone by the length of the synapse (L). The number of synapses are at 
least 10 in each animal. 
 
4.2.7  Image analysis 
 Images were captured on plate film which was then developed. The films were put in 
a  working dilution of 500ml D19 Kodak developer (Kodak path, Paris) in 500ml of 
water for 3 mins, and then were rinsed in water for one minute before placing in 
Amfix (Amfix, Champion, UK) for 5mins rinsed in water for 20 mins and dried. The 
negatives  of  electron  micrographs  were  scanned  using  an  Epson  scanner  (Epson 
perfection 4990), and the contrast and exposure were adjusted using Paint Shop before 
printing. 
4.2.8  Statistical analysis 
The results were analysed by two sample t test using the Minitab statistics package 
(MINITAB Release 13.30). 
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4.3  Results 
 
4.3.1 Comparison of numbers and percentages of TH+ve nigrostriatal 
dopaminergic terminals in the dorsal caudate putamen (DCPU) with 
immunoperoxidase DAB  staining  for TH  in  AS  and  AS/AGU  rats 
aged 12 months 
 
The results show statistically significant differences between the two groups in the 
total number of TH+ve terminals, unlabeled terminals and total terminals in the dorsal 
caudate putamen (< 0.05).  The AS/AGU (mutant) rats had fewer terminals than the 
AS (control). The results are summarized in table 4.1. 
Despite  the  marked  difference  in  absolute  numbers  the  percentage  of  TH+ve 
nigrostriatal dopaminergic terminals as a proportion of the total number of terminals 
was approximately the same in both strains at this age (Table 4.4).  
The sampling methods used here led to the inclusion of 1 200 synaptic terminals per 
animal for analysis. Several feature emerged: 
(i)  There were simply fewer synaptic terminals per unit area in AS/AGU rats 
compared to the AS parent strain. 
(ii)  In both strain, about 15% of terminals were dopaminergic, as revealed by 
DAB staining. 
(iii)  The reduction in numbers of synapses in the AS/AGU rats included both 
the dopaminergic and non dopaminergic ones. 
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Number 
 
AS 
 
 
AS/AGU 
 
P 
 
TH+ve terminals 
 
 
35.7 ± 2.3 
 
19.3 ± 0.9 
 
< 0.05 
 
Unlabeled 
terminals 
(TH ve terminals) 
 
182.3 ± 0.9 
 
118 ± 5.3 
 
< 0.01 
 
Total terminals 
 
 
218 ± 2.6 
 
137.3 ± 6.1 
 
< 0.01 
 
Table 4.1: Number of terminals within the DCPU with immunoperoxidase DAB 
staining for TH in AS control and AS/AGU mutant rats aged 12 months (n=3 per 
group). All values are mean number of terminals ± SEM. All comparisons are 
two sample t tests. 
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4.3.2 Comparison of numbers and percentages of TH+ve nigrostriatal 
dopaminergic terminals in the DCPU with immunogold staining for 
TH in AS and AS/AGU rats aged 12 months 
 
As  with  DAB  staining,  immunogold  staining  results  show  statistically  significant 
differences between the two groups in the number of TH+ve terminals, unlabeled 
terminals and total terminals in the dorsal caudate putamen (< 0.05). The AS/AGU 
(mutant) rats had fewer terminals than the AS (control). The results are summarized in 
table 4.2. 
Despite  the  marked  difference  in  absolute  numbers  the  percentage  of  TH+ve 
nigrostriatal dopaminergic terminals as a proportion of the total number of terminals 
was only slightly less in AS/AGU (mutant) rats at this age (13%) than in AS controls 
(17%) (Table 4.4).  
It appears that DAB and immunogold staining give similar numbers of TH+ve and –
ve terminals. For 3 – month old animals, only immunogold staining was used. 
 
 
 
 
 
 
 
Number 
 
AS 
 
 
AS/AGU 
 
P 
 
TH+ve terminals 
 
 
43.7 ± 2 
 
23 ± 2.1 
 
< 0.01 
Unlabeled 
terminals 
(TH ve terminals) 
 
207.7 ± 9.3 
 
148.3 ± 10 
 
< 0.05 
 
Total terminals 
 
 
251.3 ± 11 
 
171.3 ± 12 
 
< 0.05 
Table 4.2: Number of terminals within the DCPU with immunogold staining for 
TH in AS control and AS/AGU mutant rats aged 12 months (n=3 per group). All 
values are mean number of terminals ± SEM. All comparisons are two sample t 
tests. 
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4.3.3 Comparison of numbers and percentages of TH+ve nigrostriatal 
dopaminergic terminals in the DCPU with immunogold staining for 
TH in AS and AS/AGU rats aged 3 months 
 
The results show statistically significant differences between the two groups in the 
number of TH+ve terminals in the dorsal caudate putamen (< 0.05). The AS/AGU 
(mutant) rats had significantly fewer dopaminergic terminals than the AS (control) 
strain.  The  results  are  summarized  in  table  4.3.    However,  unlike  the  12  month 
animals, the number of unlabelled terminals (and the total number of terminals) was 
similar in the two strains i.e. only the TH +ve terminals were reduced. 
The percentage of TH+ve nigrostriatal dopaminergic terminals as a proportion of the 
total number of terminals was reduced in AS/AGU (mutant) (Table 4.4).  A chi 
square (X
2) analysis of the percentage of TH+ve terminals (using absolute numbers) 
shows that the two strains are significantly different (X
2 =7.19, df = 1,  P<0.01). 
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AS 
 
 
AS/AGU 
 
P 
 
TH+ve terminals 
 
 
54.67 ± 2.8 
 
 
25.67 ± 0.33 
 
 
< 0.01 
Unlabeled 
terminals 
(TH ve terminals) 
 
254.3 ± 12 
 
 
245 ± 9.7 
 
 
NS 
 
Total terminals 
 
 
309 ± 15 
 
 
270.7 ± 9.5 
 
 
NS 
Table 4.3: Number of terminals within the DCPU with immunogold staining for 
TH in AS control and AS/AGU mutant rats aged 3 months (n=3 per group). All 
values are mean number of terminals ± SEM. All comparisons are two sample t 
tests (NS: not significant). 
 
 
 
Strains  AGE  Techniques  percentage 
AS  12 month  TH immunoperoxidase DAB  16.4% 
AS/AGU  12 month  TH immunoperoxidase DAB  14.1% 
AS  12 month  TH immunogold  17.4% 
AS/AGU  12 month  TH immunogold  13.4% 
AS  3 month  TH immunogold  17.7% 
AS/AGU  3 month  TH immunogold  9.5% 
Table  4.4:  percentages  of  TH+ve  terminals  within  the  DCPU  with 
immunoperoxidase  DAB  and  immunogold  staining  for TH  in  AS  control  and 
AS/AGU mutant rats aged 3 and 12 months (n=3 per group). 
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4.3.4  Comparisons  of  synaptic  vesicles  numbers  of  TH+ve 
nigrostriatal  dopaminergic  and  unlabelled  terminals  in  the  DCPU 
(identified by immunogold staining for TH) of AS and AS/AGU rats 
aged 12 months 
 
 
The results show statistically significant differences between the two groups in the 
number of synaptic vesicles in each zone and in the total numbers of vesicles and also 
in the number of vesicles per synaptic length in both TH+ve and unlabelled terminals 
of the DCPU at this age (< 0.05). The AS/AGU (mutant) rats had fewer vesicles than 
the AS (control) rats. The results are summarized in table 4.5. 
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Terminals 
 
AS 
 
 
AS/AGU 
 
P 
 
9.98 ± 0.94 
 
5.08 ± 0.17 
 
< 0.05 
TH +ve 
                    NV                               
 
                 NV/L 
 
36.15 ± 2.7 
 
14.2 ± 0.96 
 
< 0.05 
 
7.28 ± 0.39 
 
5 ± 0.1 
 
< 0.05 
 
Zone I               
(0 41.7 nm) 
Unlabeled            
   (TH ve)      NV 
 
                 NV/L 
 
29.59 ± 1.7 
 
18.31 ± 0.79 
 
< 0.05 
 
10.11 ± 0.78 
 
5.57 ± 0.6 
 
< 0.05 
TH +ve 
                        NV                               
 
                 NV/L 
 
36.61 ± 1.7 
 
15.64 ± 2.2 
 
< 0.01 
 
7.72 ± 0.81 
 
5.49 ± 0.003 
 
NS 
 
Zone II 
(41.7 83.3 nm) 
Unlabeled            
   (TH ve)      NV 
 
                 NV/L 
 
31.46 ± 3.7 
 
20.16 ± 0.002 
 
NS 
 
26.48 ± 3.3 
 
12.64 ± 2.6 
 
< 0.05 
TH +ve 
                    NV                               
 
                 NV/L 
 
95.7 ± 9.3 
 
35.7 ± 8.2 
 
< 0.05 
 
26.44 ± 1.5 
 
14.39 ± 0.92 
 
< 0.01 
 
Zone III 
(83.3  166.7 
nm) 
Unlabeled            
   (TH ve)       NV 
 
                 NV/L 
 
107.12 ± 1.5 
 
52.65 ± 3.7 
 
< 0.01 
 
16.63 ± 2.9 
 
2.72 ± 0.87 
 
< 0.05 
TH +ve 
                    NV                               
 
                 NV/L 
 
60.9 ± 12 
 
7.76 ± 2.6 
 
< 0.05 
 
20.67 ± 0.35 
 
6.28 ± 0.71 
 
< 0.01 
 
Zone IV 
(166.7  300 
nm) 
Unlabeled            
   (TH ve)       NV 
 
                 NV/L 
 
84.21 ± 5.1 
 
23.16 ± 3.5 
 
< 0.01 
 
63.20 ± 4.4 
 
26.01 ± 4.1 
 
< 0.01 
TH +ve 
                    NV                               
 
                 NV/L 
 
229.4 ± 13 
 
73.3 ± 14 
 
< 0.01 
 
62.11 ± 1.3 
 
31.17 ± 0.19 
 
< 0.01 
 
Total  
 
Unlabeled            
   (TH ve)      NV 
 
                 NV/L 
 
252.4 ± 7.3 
 
114.3 ± 6.1 
 
< 0.01 
Table  4.5:  Numbers  of  synaptic  vesicles  in  TH+ve  nigrostriatal  dopaminergic 
and unlabelled terminals within the DCPU (identified by immunogold staining 
for TH) in AS control and AS/AGU mutant rats aged 12 months (n=3 per group). 
All values are mean number of synaptic vesicles (NV) or numbers per synaptic 
length  (NV/L)  ±  SEM.  All  comparisons  are  two sample  t tests  (NS:  not 
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4.3.5  Comparison  of  synaptic  vesicles  numbers  in  TH+ve 
nigrostriatal  dopaminergic  and  unlabelled  terminals  in  the  DCPU 
(identified by immunogold staining for TH) of AS and AS/AGU rats 
aged 3 months 
 
 
The results show statistically significant differences between the two groups in the 
number of TH +ve synaptic vesicles in each zone and in the total number of vesicles 
and  also  in  the  number  of  vesicles  per  synaptic  length  in  TH+ve  nigrostriatal 
dopaminergic terminals of the DCPU.  The AS/AGU (mutant) rats had fewer vesicles 
than the AS (control). By contrast, there were no significant differences between the 
two strains in the number of vesicles in unlabelled (i.e. non dopaminergic) terminals. 
The results are summarized in table 4.6. 
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Terminals 
 
AS 
 
 
AS/AGU 
 
P 
 
7.89 ± 0.46 
 
3.44 ± 0.29 
 
< 0.01 
TH +ve 
                    NV                               
 
                 NV/L 
 
29.97 ± 1.5 
 
11.49 ± 0.51 
 
< 0.01 
 
7.39 ± 0.63 
 
6.72 ± 0.29 
 
NS 
 
Zone I               
(0 41.7 nm) 
Unlabeled            
   (TH ve)      NV 
 
                 NV/L 
 
30.23 ± 2.1 
 
29.4 ± 3 
 
NS 
 
8.83 ± 0.82 
 
3.67 ± 0.35 
 
< 0.05 
TH +ve 
                    NV                
 
                 NV/L 
 
33.43 ± 2.1 
 
12.23 ± 0.62 
 
< 0.01 
 
8.33 ± 1.1 
 
7.72 ± 0.2 
 
NS 
 
Zone II 
(41.7 83.3 nm) 
Unlabeled            
   (TH ve)      NV 
 
                 NV/L 
 
34.64 ± 2.8 
 
33.55 ± 1.7 
 
NS 
 
32.17 ± 2.7 
 
7.89 ± 1.9 
 
< 0.01 
TH +ve 
                    NV                               
 
                 NV/L 
 
122.5 ± 12 
 
26.2 ± 5.8 
 
< 0.05 
 
32.56 ± 2.6 
 
29.94 ± 2.1 
 
NS 
 
Zone III 
(83.3  166.7 
nm) 
Unlabeled            
   (TH ve)      NV 
 
                 NV/L 
 
133.6 ± 11 
 
129.33 ± 3.2 
 
NS 
 
18.83 ± 3.3 
 
2.95 ± 1.5 
 
< 0.05 
TH +ve 
                    NV                               
 
                 NV/L 
 
70.6 ± 8.1 
 
9.51 ± 4.5 
 
< 0.01 
 
13.89 ± 0.56 
 
10.94 ± 2.7 
 
NS 
 
Zone IV 
(166.7  300 
nm) 
Unlabeled            
   (TH ve)      NV 
 
                 NV/L 
 
57.21 ± 4.4 
 
46.1 ± 9.6 
 
NS 
 
67.72 ± 5 
 
17.95 ± 3.6 
 
< 0.01 
TH +ve 
                    NV                               
 
                 NV/L 
 
256.5 ± 8.8 
 
59.4 ± 9.8 
 
< 0.001 
 
62.5 ± 2.1 
 
55.33 ± 4.5 
 
NS 
 
Total  
 
Unlabeled            
   (TH ve)      NV 
 
                 NV/L 
 
256.3 ± 9.5 
 
238.42 ± 3.3 
 
NS 
Table  4.6:  Numbers  of  synaptic  vesicles  in  TH+ve  nigrostriatal  dopaminergic 
and unlabelled terminals within the DCPU (identified by immunogold staining 
for TH) in AS control and AS/AGU mutant rats aged 3 months (n=3 per group). 
All values are mean number of synaptic vesicles (NV) or numbers per synaptic 
length  (NV/L)  ±  SEM.  All  comparisons  are  two sample  t tests  (  NS:  not 
significant). Chapter 4                                                                                                              Results 
 
180 
4.3.6  Distributions  of  vesicles  and  average  length  of  synaptic 
terminals in AS and AS/AGU rats aged 3 and 12 months. 
 
 
 
The percentage zonal distribution of vesicles in TH+ve and unlabelled terminals are 
approximately the same in both strains at both ages (Figure 4.3 4.6). Zone III  often 
thought of as the “reserve pool” has the highest percentage of vesicles. The actual 
synapse length is significantly greater in AS/AGU mutants than AS controls at 12 
months, otherwise there are no strain differences (Figure 4.7). 
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Figure  4.3:  Distribution  of  vesicles  of  TH+ve  terminals  within  the  DCPU 
(identified  by  immunogold  staining  for  TH)  in  control  (AS)  and  mutant 
(AS/AGU) male rats aged 12 months. The figures are expressed as percentages 
(n=3 per group). 
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Figure  4.4:  Distribution  of  vesicles  of  unlabelled  terminals  within  the  DCPU 
(identified  by  immunogold  staining  for  TH)  in  control  (AS)  and  mutant 
(AS/AGU) male rats aged 12 months. The figures are expressed as percentages 
(n=3 per group).  
 
 
 
 
Distribution of vesicles in TH+ve terminals within the DCPU of 
3 month rats
0
10
20
30
40
50
60
70
80
90
100
Zone I Zone II Zone III Zone IV
P
e
r
c
e
n
t
a
g
e
AS
AS/AGU
 
Figure  4.5:  Distribution  of  vesicles  of  TH+ve  terminals  within  the  DCPU 
(identified  by  immunogold  staining  for  TH)  in  control  (AS)  and  mutant 
(AS/AGU) male rats aged 3 months. The figures are expressed as percentages 
(n=3 per group).  
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Figure  4.6:  Distribution  of  vesicles  of  unlabelled  terminals  within  the  DCPU 
(identified  by  immunogold  staining  for  TH)  in  control  (AS)  and  mutant 
(AS/AGU) male rats aged 3 months. The figures are expressed as percentages 
(n=3 per group).  
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Figure  4.7:  Synaptic  terminals  length  within  the  DCPU  (identified  by 
immunogold staining for TH) in control (AS) and mutant (AS/AGU) male rats 
aged 3 and 12 months.  Means ± SEM (n=3 per group). (* P < 0.05; NS: not 
significant). 
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4.3.7 Electron micrographs of nigrostriatal dopaminergic terminals 
in the AS and AS/AGU rat  
 
Figure 4.8 shows TH+ve  and TH ve terminals identified by DAB staining for TH. 
The quality of this figure reflects the small amount of glutaraldehyde  used in the 
fixative (1% : 4% paraformaldehyde). 
Figures  4.9 4.13  show  TH+ve  and  TH ve  terminals  identified  by  immunogold 
staining for TH in both AS and AS/AGU rats aged 3 and 12 months. 
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Figure 4.8: Electron micrograph (A,B,C and D) showing TH+ve terminals (red 
rectangular) stained with DAB for TH and TH ve terminals (yellow circle) of AS 
rats aged 12 months, (x20,000). In inset boxes (a,b,c and d) a high magnification 
of TH+ve terminals and there synapses (arrows) (x50,000).  
 
 
 
C
D
d Chapter 4                                                                                                              Results 
 
186 
 
 
 
 
 
 
 
Figure 4.9: Low magnification electron micrograph showing TH+ve terminals 
stained with immunogold and TH–ve terminals of an AS rat aged 12 months, 
(x10,000).  
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Figure 4.10: Electron micrograph showing TH+ve terminals (A and B) stained 
with immunogold for TH and TH –ve terminal (C), unlabelled dendrite (Ud) and 
synapses (arrows)  of AS rats aged 12 months, (x50,000). Scale bars = 0.2  m. 
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Figure 4.11: Electron micrograph showing TH+ve terminals (A and B) stained 
with immunogold for TH and TH –ve terminal (C), unlabelled dendrite (Ud) and 
synapses (arrows)  of AS/AGU (mutant) rats aged 12 months, (x50,000). Scale 
bars = 0.2  m. 
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Figure  4.12:  Electron  micrograph  showing  TH+ve  terminals  (A)  stained  with 
immunogold  for  TH  and  TH  –ve  terminal  (B),  unlabelled  dendrite  (Ud)  and 
synapses (arrows)  of AS (control) rats aged 3 months, (x50,000). Scale bars = 0.2 
 m. 
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Figure  4.13:  Electron  micrograph  showing  TH+ve  terminals  (A)  stained  with 
immunogold  for  TH  and  TH  –ve  terminal  (B),  unlabelled  dendrite  (Ud)  and 
synapses (arrows)  of  AS/AGU  (mutant)  rats aged 3  months, (x50,000). Scale 
bars = 0.2  m. 
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4.4  Discussion 
 
 
It is well established that the midbrain dopaminergic system is affected in AS/AGU 
rats (Payne et al., 2000). The levels of dopamine in the dorsal and lateral  caudate 
putamen are  reduced in both post mortem micropunches which measures intra   and 
extra cellular dopamine and by in vivo microdialysis which measures extra cellular, 
released, dopamine (Campbell et al., 1997, 1998). 
Terminals  were  considered  to  be  labeled  (a)  with  immunoperoxidase  when  they 
showed a higher electron density in comparison to neighboring elements (Mengual 
and Pickel, 2002) and (b) with immunogold silver when they contained one or more 
silver  particles  which  appear  as  small  black  aggregates  in  pre synaptic  terminals 
(Mengual and Pickel, 2002). Terminals were only included in the analysis if they 
showed pre synaptic, post synaptic membranes and ten or more vesicles.    
The first control used in this experiment were sections from the same region (dorsal 
striatum)  which  underwent  the  same  procedure  for  preembedding 
immunocytochemistry except for the omission of TH primary antibody. In this type of 
control, no gold particles were seen. The second control used in this experiment was 
the examination of the lumen of blood vessels in same sections. Sections had to reach 
the criterion that no gold particles were seen in the blood vessels lumen.    
This study can be improved by (a) decreasing the concentration of glutaraldehyde 
fixative to less than 1% but this may effect the good morphology of the tissue or (b) 
the use cryosections treated with immunogold with silver enhancement (Monaghan 
and Atherton, 1992).    
There are some limitations of using immunocytochemistry :  (a) TH protein is altered 
by  fixation,  dehydration  and  heating  which  lead  to  decreased  recognition  by  Chapter 4                                                                                                        Discussion   
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antibodies (Chan et al., 1990), (b) using glutaraldehyde in high concentration  leads 
to increased non specific staining and decreased antigenicity of some protein (Kosaka 
et  al.,  1986),  (c)  Avidin biotin peroxidase  labelling  is  diffuse  and  may  lead  to 
artifactual  labelling  (Beier,  1992)  and  (d)  immunogold silver  labelling  is  more 
localized but less deeply penetrating into the tissue (Chan et al., 1990).    
 
My results show firstly that the number of TH+ve terminals in the striatum of AS 
(control) rats aged 3 and 12 month (16 17%) are consistent with the figures obtained 
previously in human (approximately 16%) (Kung et al., 1998) and rat studies (9 
21%) (Hokfelt, 1968; Tennyson et al., 1974; Pickel et al., 1981; Descarries et al., 
1996).      Secondly,  AS/AGU  (mutant)  rats  aged  12  months  have  a  reduction  in 
numbers of TH+ve terminals and in unlabelled terminals and also in the number of 
synaptic  vesicles  compared  to  AS  (control)  rats.  However,  in  younger,  3 month 
animals, the reduction is in TH+ve terminals only; TH ve terminals are unaffected. 
Several issues are raised by this: 
(i)  Extracellular  dopamine  levels  are  reduced  in  AS/AGU  rats  by  80 90% 
compared to the control (AS) strain (Campbell et al., 1998). In 12 month 
animals studied in the present experiment, the arithmetic sum of a 40% 
reduction in TH+ve terminals, together with a 40% reduction in vesicle 
numbers in these TH+ve terminals which remain, could account entirely 
for  this  reduction  in  released  DA  within  the  striatum.  The  figures  are 
equally compelling for AS/AGU animals aged 3 months where there is a 
50% reduction in TH+ve terminals and a reduction in vesicles by three 
quarters. Chapter 4                                                                                                        Discussion   
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(ii)  The susceptibility of TH+ve terminals in both young and old AS/AGU rats 
(while TH ve terminals are only affected in old animals) suggests (a) that 
dopaminergic neurons are unusually vulnerable to the effect of the PKC γ 
mutation but that (b) the eventual reduction in all terminals suggests a very 
fundamental mechanism underlies terminal loss. 
(iii)  The  zonal  figures  for  synaptic  vesicle  numbers  suggest  that  the  loss  is 
general, is not linked particularly to the readily releasable in the storage 
pool,  and  is  probably  not  linked  to  a  molecularly  characteriseable 
population of vesicles. In particular, there is no evidence that the region 
closest to the synaptic cleft is devoid of vesicles.     
The loss of nigrostriatal dopaminergic neurons that results in a marked reduction of 
dopaminergic nerve terminals in the striatum is a characteristic post mortem feature of 
PD  (Frost  et  al.,  1993)  and  may  be  confirmable  in  living  Parkinson’s  patients 
(Leenders et al., 1990). The loss of dopaminergic terminals in the striatum occurred 
also in animal models such as MPTP treated monkeys and baboons (Herkenham et 
al.,  1991;  Hantray  et  al.,  1993)  and  in  rats  treated  with  6 OHDA (Pickel et  al., 
1992b; Ichitani et al., 1994). 
Reduced vesicle counts have been seen in mice treated with MPTP. Low doses cause 
axon  terminals  to  swell  and  show  reduced  vesicles;  with  high  doses,  terminals 
disappear  (Cochiolo  et  al.,  2000).  Paradoxically,  in  rats  treated  with  6 OHDA 
terminal size and vesicle numbers may increase (Pickel et al., 1992b; Stanic et al., 
2003) a finding very much at variance with the present study. 
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General Discussion  
Each of the three experiments reported in this thesis has its own Discussion section. 
This General Discussion seeks to place the findings in context by posing a series of 
questions. 
 
(1) Do the aminergic cells in the substantia nigra and midbrain raphe 
nuclei have a normal capacity to synthesise their neurotransmitters 
in the AS/AGU mutant ?  
 
 
This question arises because of an apparent paradox. It has been previously shown 
(using in vivo microdialysis of caudate putamen and HPLC/ECD) that, at all ages, the 
AS/ AGU rat only possesses 10 20% of the extracellular dopamine levels found in the 
AS  parent  strain  under  normal  physiological  conditions  (Campbell  et  al.,  1998; 
2000). Conversely, whole tissue micropunches of the caudate putamen (which will 
include  a  wide  and  heterogeneous  variety  of  cells  and  cell  parts)  show  no  strain 
differences in dopamine until six months of age, and relatively modest differences 
thereafter (Campbell et al., 1996; 1997). Since the strain difference in whole tissue 
dopamine  levels  is  of  order  of  20 30%,  whilst  the  strain  differences  in  released 
(extracellular) dopamine is of the order of 80 90%, this could suggest either 
(a) that there is a fundamental dysfunction of release (as has been proposed Payne 
et al. 2000) or 
(b) that  there  is  a  fundamental  deficiency  of  synthesis  such  that  the  relatively 
normal levels are built up over a lengthy period. 
It should be pointed out that these data were obtained from rats of an age where a 
major decrease in SNC cell numbers would not be expected (Clarke and Payne, 
1994)   and I used rats of this age range in my own experiments also. Chapter 5                                                                                         General Discussion 
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(a) Tyrosine hydroxylase 
My  results  (Experiment  1)  suggest  that  there  is  no  deficit  in  levels  of  tyrosine 
hydroxylase within the cell bodies of the substantia nigra pars compacta and, since 
TH is the rate limiting enzyme for catecholamine synthesis (Blanchard et al., 1995), 
it is difficult to conclude that there is any deficiency in dopamine synthesis in the 
mutant strain at the ages tested.  
Is the use of a quantitative immunofluorescent technique a suitable one to answer this 
question?  A widely used method of measuring TH activity would involve incubations 
of  homogenized  post  mortem  brain  with  radiolabelled  precursors  followed  by 
measurement of labeled catecholamines (Nagatsu et al., 1964; McGeer et al., 1971). 
However, this type of approach has drawbacks such as (a) a lack of knowledge of how 
many  catecholaminergic neurons are actually present in the micropunches / culture 
(and , therefore, the “dilution factors” of other tissue components) (b) ignorance of the 
possible contribution made by other neurons and glial cells to dopamine synthesis and 
(c)  ignorance  of  whether  these  are  marked  interneuronal  differences  in  synthetic 
capacity e.g. between healthy and senescent neurons. The method I have used enabled 
me to sample individual dopaminergic neurons only. The main conclusions are: 
i.  that, despite being unable to release dopamine at striatal terminals  (Campbell 
et al., 1998) dopaminergic cell bodies in the SNC of  the AS/AGU mutant did 
not show reduced TH activity. Rather, 
ii.  they exhibited enhanced TH activity compared to AS controls, suggesting that 
they were operating a feedback control mechanism and 
iii.  that, whilst there was variation in TH activity from cell to cell, this was no 
greater in AS/AGU mutants than in AS controls.  Chapter 5                                                                                         General Discussion 
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The fact that TH levels are actually increased in the SNC neurons of mutant rats also 
requires  some  discussion.  The  simplest  explanation  is  that  it  is  due  to  feedback 
inhibition by the enzymatic end products (Nagastu et al., 1964; Spector et al., 1967; 
Kumer and Vrana,1996).  In the light of this, it is interesting to note that a reduction 
in  dopamine  levels  in  the  striatum  increases  the  ability  of  pteridine  (which  is  a 
cofactor for TH) to bind to TH thus decreasing its ability to form a complex with 
ferric  iron  and  resulting  in  an  increase  in  TH  activity  (Okuno  and  Fujisawa, 
1985,1991; Andersson et al., 1988,1992; Haavik et al., 1991; Almas et al., 1992; 
Daubner et al., 1992; Ribeiro et al., 1992). 
The possible loss of transmission of dopaminergic neurons with age in rats or mice 
could be due to one or more of the following: a reduction in dopamine release, a 
change in dopamine synthesis or a loss of dopaminergic cells in the SNC and VTA; it 
could even be due to a loss of port synaptic receptor density (McNeill and Koek, 
1990; Tatton et al., 1991; Della et al., 1992; Hamdi et al., 1992). 
Unlike  the  cell  bodies  of  the  SNC,  TH  levels  in  the  striatum  (where  nigrostriatal 
terminals are located) are diminished in AS/AGU rats. This may reflect a decreased 
activity in dopaminergic terminals themselves, or a decreased activity in cells of the 
caudate putamen, some of which are TH +ve (Tashiro et al., 1989), or a decreased 
number  of  dopaminergic  terminals  per  unit  area  within  the  striatum:  the  results 
obtained in my third experiment (see below) suggest that the latter explanation is the 
correct one. 
In  the  caudate putamen,  the  sampling  area  is  a  large  rectangle  which  will  be 
heterogeneous in its content. In such circumstances, an immuno fluorescent approach 
is less beneficial than in the case of the mid brain where individual neurons could be 
sampled. However, I believe that the benefits of sampling cell bodies and striatum Chapter 5                                                                                         General Discussion 
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with the same methodology outweighs this disadvantage (which is, in any case, no 
greater than that occurring in other techniques such as tissue slice incubation). 
Moreover,  the  fact  that  a  statistically  significant  difference  could  be  found  is 
indicative of a very real effect, given the “dilution” provided by the vast mass of 
surrounding cells and neuropil in which the dopaminergic terminals are embedded. 
Previous studies have shown that reduced dopamine release in the striatum of the 
AS/AGU rat is accompanied by elevated dopamine metabolites such as DOPAC and 
HVA (Campbell et al., 1996; 1997; 1998; 2000). It has been suggested that this is 
due  to  an  underlying  dysfunction  of  vesicle  formation  and  packaging,  leaving 
dopamine  free  in  the  cytoplasm  to  be  acted  upon  by  mitochondrial  monoamine 
oxidase (Payne et al., 2000). An alternative explanation, that there is massive over 
production of dopamine at the terminal, which the vesicular packaging system cannot 
cope with, appears unlikely from my data. 
 
(b) Serotonin 
Like dopaminergic neurons, serotonergic neurons in the dorsal raphe are reduced in  
number (and striatal release greatly impaired) in the AS/AGU mutant (Al Fayez et 
al.,  2005).  A  loss  of  serotonergic  neurons  in  the  dorsal  raphe  nucleus  (Jellinger, 
2005) and a reduction in serotonin concentration in the striatum, substantia nigra and 
hippocampus have been documented in the brains of the Parkinson’s patient (Rinne et 
al., 1974; Scatton et al., 1983; Agid et al., 1987; Mizuno, 2005) as has a depletion of 
5 HT  and  its  metabolites  in  the  cerebrospinal  fluid  (CSF)  (Tohgi  et  al.,  1993). 
Nevertheless,  the  present  experiment  shows  that  (like  the  data  for  TH)  the  5 HT 
content of the cell bodies in the midbrain is higher in AS/AGU than in AS rats. This 
implies  continual  activity  and  (perhaps)  a  regulatory  feedback  mechanism.  Whilst Chapter 5                                                                                         General Discussion 
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end product inhibition can apply to TH in the synthesis of dopamine, it is not so 
certain that it applies to tryptophan hydroxylase (TPH) which is the rate limit enzyme 
of serotonin synthesis (Martinez et al., 2001; Wang et al., 2002). In assessing the 
activity of serotonergic neurons, it is more common to measure 5 HT directly, rather 
than  TPH  (Tappaz  and  Pujol,  1980;  Moret  and  Briley,  1992;  Martinez  et  al., 
2001; Wang et al., 2002).    
 
 
(2) Are typical Lewy body proteins elevated in the dopaminergic and 
serotonergic systems of PKC γ mutant rats? 
 
This question is important for two reasons: 
i.  in  general,  whilst  Lewy  bodies  are  a  major  feature  of  Parkinson’s  disease 
(Pollanen et al., 1993; Cornford et al., 1995; Forno, 1996; Galvin et al., 
1997;  Shults,  2006),  rodent  models  such  as  6 OHDA  do  not  show  them. 
Nevertheless, it may be possible to measure levels of  the molecules most 
commonly associated with Lewy bodies to see it if there are elevated. 
ii.  Because  it  remains  a  controversial  issue  whether  the  Lewy  body  and  its 
contents are a harmful, pathological feature of Parkinson’s disease, or whether 
they represent an attempt by the neuron to counteract the degenerative process 
(Alves Rodrigues  et  al.,  1998;  Bence  et  al.,  2001;  Chung  et  al.,  2001a; 
McNaught  et  al.,  2002;  Olanow  et  al.,  2004).  The  matter  is  made  more 
difficult by a lack of information on the normal physiological role of some 
molecules characteristic of Lewy bodies.  
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(A) Ubiquitin 
The immunofluorescence levels of ubiquitin are higher in the SNC (especially the 
lateral  region)  and  the  dorsal  raphe  nuclei  of  AS/AGU  mutants  compared  to  AS 
controls.  These are cell groups which are affected in AS/AGU mutant rats (loss of 
cell  numbers  in  the  midbrain  and  depletion  of  striatal  transmitters)  (Clarke  and 
Payne, 1994; Campbell et al., 1997; 1998; Al Fayez et al., 2005). Other regions 
such as SNR, SNL, VTA and MRN are less affected this suggest that, despite the lack 
of Lewy bodies in rats, elevated ubiquitin is associated with loss of function in very 
specific cell groups.  
Ubiquitin is present in the Lewy bodies in Parkinson’s disease (Lennox et al.,1989; 
Love and Nicoll, 1992).   
Lewy bodies (neuronal intracytoplasmic inclusion bodies) can be seen in the surviving 
dopaminergic neurons of the substantia nigra pars compacta in all most every case of 
PD (Jellinger, 1987; Hughes et al., 1993; Pollanen et al., 1993; Cornford et al., 
1995;  Forno,  1996)  and  isolated  Lewy  bodies  (presumably  the  remains  of  dead 
neurons) can be found in the neuropil (Jellinger, 1991; Mackenzie, 2001).  Lewy 
bodies  can  also  be  seen  in  other  non dopaminergic  neurons  such  as  cholinergic 
neurons  in  the  nucleus  basalis  of  Meynert,  noradrenergic  neurons  in  the  locus 
coeruleus,    serotonergic  neurons  in  the  raphe  nuclei,  the  motor  vagal  nuclei,  the 
pedunculopontine nucleus, the Edinger Westphal nucleus, in the intermediolateral cell 
column of the spinal cord, the hypothalamus and the autonomic ganglia (Jellinger, 
1991). They due therefore not restricted to a transmitter specific neuron population.  
The  mechanism  by  which  Lewy  bodies  are  formed  and  their  relationship  to 
neurodegenerative disease, or the ageing process,  remains unknown. One hypothesis 
is  that  Lewy  bodies  are  harmful.  Proteins  such  as  α synuclein  or  ubiquitin  will Chapter 5                                                                                         General Discussion 
 
203 
accumulate and aggregate if  the ability of cells to degradate these protein is exceeded 
or  if  proteasomal  function  is  impaired  (Sherman  and  Goldberg,  2001).  Further, 
aggregated proteins will  provide a nucleation center for the formation of inclusion 
bodies such as Lewy bodies (Chung et al., 2001a) and the accumulation of these 
inclusion bodies might in turn induce neuronal dysfunction and/or cell death (Alves 
Rodrigues et al., 1998; Bence et al., 2001; Chung et al., 2001a). A quite different 
hypothesis is that Lewy bodies are beneficial and protective for neurons because they 
behave structurally and functionally as aggresomes (McNaught et al., 2002; Olanow 
et al., 2004).  Aggresomes are cytoplasmic inclusion bodies formed at the centrosome 
(a  perinuclear  structure  linked  to  the  microtubular  system)  as  a  cytoprotective 
response to high levels of misfolded proteins (Johnston et al., 1998; Kopito, 2000).  
Ubiquitin  accumulation  may  suggest  a  failure  of  the  ubiquitin proteasome  system 
(UPS) leading to accumulated abnormal proteins as ubiquitin aggregates or inclusion 
bodies  associated  with  cell  degeneration  (Alves Rodrigues  et  al.,  1998).  Many 
investigators have assumed that the immunopositive ubiquitin staining in Lewy bodies 
must  represent  elevated  levels  of  intracellular  ubiquitin protein  conjugates  (e.g. 
Andersen,  2000)  in  both  sporadic  and  hereditary  neurodegenerative  diseases 
(Ciechanover et al., 2000).  However, it must be remembered that most forms of 
immunocytochemistry do not lend themselves to easy quantitative interpretation. If 
ubiquitin levels are indeed elevated (and if that elevation is injurious) then a cascade 
could follow in which a primary failure of UPS leads to aggregated proteins, which 
could further inhibit the UPS by direct interaction with the proteasome (Akopian et 
al., 1997; Bence et al., 2001) or by saturating the capacity of one or more molecular 
chaperones which are required for UPS function (Bercovich et al., 1997).  Chapter 5                                                                                         General Discussion 
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Many factors in the SNC in the midbrain of PD patients could potentially contribute 
to failure of the UPS these include:  
a)  high levels of protein oxidation (Alam et al., 1997),  
b)  high  levels  of  3 nitrotyrosine  in  the  SNC  which  may  indicate  excitoxicity 
(Good et al., 1998),  
c)  reduction in the levels of α subunits of 20S proteasome and levels of 26S 
proteasome enzyme activities (McNaught et al., 2001),  
d)  inhibition of complex 1 activity (Schapira et al., 1990a,b; DeMartino and 
Slaughter, 1999) since UPS is an ATP dependent system (Alves Rodrigues 
et al., 1998),  
e)  dopamine  itself  can  produce  free  radicals  by  auto oxidation  or  through 
metabolism by monoamine oxidase (Olanow, 1990; Jenner and Olanow, 
1998; Jenner, 1998) and  
f)   4 hydroxy 2 nonenal  (HNE)  is  a  product  of  lipid  peroxidation  present  in 
surviving dopaminergic  neurons in PD patients (Yoritaka et al., 1996); it 
leads  to  enhanced  cross linking  of  proteins  and  mediated  inhibition  of 
proteasomal function (Okada et al., 1999).  
In the present study,  elevated levels of ubiquitin can be found inside the cell bodies of 
the SNC and dorsal raphe – cell bodies which appear to remain viable and responsive 
in terms of their transmitter synthesising capacity (see above), but whose terminals are 
incapable of releasing physiological normal amounts of DA or 5 HT in the striatum 
(Campbell et al., 1997; 1998; Al Fayez et al., 2005). 
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(B) Parkin 
The immunofluorescence levels of parkin are higher in the cell bodies of both SNC 
and dorsal raphe neurons in the mutants compared to the controls. Other areas such as 
SNR, SNL, VTA and  MRN are less affected. The affected regions are also those 
which exhibit loss of neurons and depletion of their neurotransmitters (dopamine and 
serotonin)  in  the  striatum  in  AS/AGU  mutant  rats  (Clarke  and  Payne,  1994; 
Campbell et al., 1997; 1998; Al Fayez et al., 2005) and in PD (Bernheimer et al., 
1973; Hornykiewicz, 1998; Jellinger, 2005).  
 Parkin staining is characteristically found in the cytoplasm of neuronal cell bodies 
(Shimura et al., 1999; Gu et al., 2000; Horowitz et al., 2001), in rough endoplasmic 
reticulum (Imai et al., 2002), Golgi apparatus (Shimura et al., 1999) and also in the 
nucleus (Stichel et al., 2000; Horowitz et al., 2001). 
In  addition,  parkin  is  present  in  Lewy  bodies  in  the  brain  of  PD  patients 
(Schlossmacher et al., 2002) except in an autosomal recessive juvenile parkinsonism 
patients that, interestingly, have a mutation in the parkin gene and no Lewy bodies 
(Takahashi et al., 1994; Mori et al., 1998; Shimura et al., 1999; Hayashi et al., 
2000). The ubiquitin homology domain at the  N terminal of parkin is involved in 
substrate recognition (Shimura et al., 2000) and it has importance in multi ubiquitin 
formation (Finley and Chau, 1991). 
This correlation between ubiquitin and parkin is strengthened by examples of  the lack 
of parkin (e.g. by mutation) leading to accumulation and overexpression of substrate 
proteins such as Pael R and CDcrel 1 (Zhang et al., 2000; Imai et al., 2001) and to 
dysfunction of UPS and the death of dopaminergic neurons (Dong et al., 2003; Yang 
et al., 2003). Chapter 5                                                                                         General Discussion 
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Moreover, the overexpression of mutated forms of parkin causes oxidative stress and 
cell death via proteasomal inhibition (Hyun et al., 2002).  
Like ubiquitin (see above) there are diverse views on the significance of supra normal 
levels of parkin within neurons. Thus, overexpression of parkin has been associated 
with reduced ubiquitinated proteins levels (Hyun et al., 2002), parkin may be playing 
a protective role against apoptotic cell death by delaying mitochondrial swelling and 
reducing Cytochrome C release (Darios et al., 2003; Feany and Pallanck, 2003; 
Greene et al., 2003), parkin may mitigate α synuclein induced neuronal cell death 
(Yamada et al., 2005) and may have aggresome like properties (Ardley et al., 2003). 
These proposal would suggest that over expression of parkin (such as was found in 
my study) may have a protective role. 
 
(C) Alpha synuclein 
In my study, staining with alpha synuclein  was found in the neuropil of the SNC and 
striatum. This is to be expected, give that α synuclein normally has a pre synaptic 
distribution (Lee and Trojanowski, 2006) except in pathological conditions when it 
is  found  in  the  Lewy  bodies  (Spillantini  et  al.,  1997)  which  neither  occur  in 
conventional rat models of PD (e.g. 6 OHDA)  (Betarbet et al., 2002; Shimohama et 
al., 2003; Melrose et al., 2006) nor in the AS/AGU mutant (see chapter 2 and above).  
Alpha synuclein immunofluorescence levels were higher in the SNC neuropil of the 
AS/AGU mutants compared to the AS controls rats and levels progressively increase 
with age in the SNC of both strains. The neuropil of the SNC contains projections 
from several different regions such as GABAergic neurons from the striatum, globus 
pallidus and the adjacent SNR (Ribak et al., 1980; Smith and Bolam, 1989; Tepper 
et al., 1995), glutamatergic neurons from the prefrontal cortex, subthalamic nucleus Chapter 5                                                                                         General Discussion 
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and  the  pedunculopontine  tegmental  nucleus  (which  also  provides  cholinergic 
projections)  (Flaherty  and  Graybiel,  1994;  Naito  and  Kita,  1994;  Reese  et  al., 
1995;  Smith  et  al.,  1996;  Bezard  and  Gross,  1998;  Blandini  et  al.,  2000)  and 
serotonergic neurons from the dorsal raphe nucleus (Flaherty and Graybiel, 1994; 
Blandini et al., 2000).  
There  is  little  doubt  that  the  SNC  and  its  projections  are  particularly  affected  in 
Parkinson’s  disease  (Bernheimer  et  al.,  1973;  Spillantini  et  al.,  1997; 
Hornykiewicz, 1998; Sian et al., 1999) and in the AS/AGU mutant rat (Clarke and 
Payne, 1994; Campbell et al., 1997; 1998). 
However, the link between α synuclein, Lewy bodies and toxicity in rodents remains 
unclear.  Transgenic  mice  that  over express  α synuclein  show  remarkably  little 
neuropathology (Matsuoka et al., 2001). Although, Lewy bodies occur in rotenone 
treated mice, they do not seen to occur in rats, nor do they occur with other treatments 
designed to mimic PD (such as 6 OHDA) (Betarbet et al., 2002; Shimohama et al., 
2003; Melrose et al., 2006). The most parsimonious explanation is that α synuclein 
levels are not high enough to lead to Lewy body formation, but another factors could 
be increasing levels of parkin which may prevent the accumulation of α synuclein in 
dopaminergic cells in the SNC (Lo Bianco et al., 2004).  Recently, Periquet et al. 
(2007)  have  shown  that  some  truncated  forms  of  α synuclein  lead  reliably  to 
aggregate  formation,  whereas  others  do  not.  In  the  case  of  the  AS/AGU  rat, 
fluorescence  readings  show  that  α synuclein  is  not  present  in  the  cell  bodies  in 
detectable amounts, so no inclusions would be expected. 
As alpha synuclein is not present in cell bodies but in the neuropil of the SNC (with 
AS/AGU rats having higher levels), there are many possible explanations: Chapter 5                                                                                         General Discussion 
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a)  alpha synuclein  is  present  in  glial  cells  and  is  seen  in  the  form  of  glial 
cytoplasmic inclusions in PD (Arai et al., 1999; Piao et al., 2000; 2001; 
Hishikawa et al., 2001; Takahashi and Wakabayashi, 2001; Mori et al., 
2002) and MSA (Braak and Braak, 1999; Burn and Jaros, 2001; Wenning 
and Jellinger, 2005). 
b)  Alpha synuclein is present in dendrites or axons or blood vessels. 
c)  Alpha synuclein  is  present  in  the  terminals  as  it  is  a  pre synaptic  protein 
(Withers et al., 1997; Lee and Trojanowski, 2006). High levels of alpha 
synuclein in the terminals leads to:  
i.  toxicity  (Conway  et  al.,  2000  a,b;  Hegde  and  Jagannatha  Rao, 
2003; Yamada et al., 2004).  
ii.   Loss of the physiological function of alpha synuclein (Rajagopalan 
and Andersen, 2001). Both factors may affect the ability of terminals 
to  carry  out  their  functions  (such  as  the  packaging  and  release  of 
transmitters). 
 
 
(3). What are the possible mechanisms of death of SNC cells in PKC 
γ mutant rats?  
 
This question is discussed because, although my experiments did not examine cell 
death, they did examine:  
a)  Cell structure which may give insight into degenerative morphology. 
b)  Molecules associated with pathological change. 
 
The progressive loss of dopaminergic nigrostriatal neurons in the SNC is a major 
pathological feature of Parkinson’s disease. One of the degenerative mechanisms that Chapter 5                                                                                         General Discussion 
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occurs in human SNC cells is apoptosis (Mochizuki et al., 1996; Anglade et al., 
1997; Tompkins et al., 1997; Tatton, 2000). A similar mechanism also occurs in 
laboratory animal models such as treatment with MPTP (Tatton and Kish, 1997; 
Spooren et al., 1998; Serra et al., 2002), 6 OHDA (He et al., 2000; Marti et al., 
2002) or rotenone and MPP
+  (Lim et al., 2007). 
The  dopaminergic  cells  of  the  SNC  number  approximately  450,000  (Lang  and 
Lozano,  1998a).  The  process  of  apoptosis  in  general  takes  a  few  hours  to  a  day 
(Barret and  Preston, 1994) and post mortem studies on the SNC of PD patients 
suggest a timing of 8 hours (Anglade et al., 1997). Whilst it is highly likely  to find 
numerous  apoptotic  cells  in  the  immediate  aftermath  of  a  neurotoxic  treatment 
(MPTP, 6 OHDA), it is highly unlikely that significant numbers of such cells will be 
found  in  a  naturally occurring  model  of  cell  loss.  However,  it  is  possible  to  use 
stereological  techniques  to  identify  differences  in  ultrastructure  between  the 
dopaminergic cell bodies of mutant AS/AGU rats and the parent AS strain which may 
suggest  decreased  viability.    Regarding  cell  organelles,  the  volume  fraction  of 
mitochondria  and  rough  endoplasmic  reticulum  of  the  SNC  cells  is  higher  in  the 
AS/AGU mutants rats. There are many possible reasons for this observation:  
a)  The number of mitochondria and RER increase in AS/AGU or decrease in AS 
rats. 
b)   The number and size of mitochondria and RER stay the same, but the cell or 
its cytoplasm shrinks in AS/AGU rats or swells in AS rats.  
c)   The  number  of  mitochondria  and  RER  stay  the  same,  but  the  organelles 
change their size.  
Several studies indicate that the mitochondria and rough endoplasmic reticulum are  
affected in the SNC in neurodegenerative situations:  Chapter 5                                                                                         General Discussion 
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i.  endoplasmic reticulum stress occurs due to the accumulation of mis 
folded proteins that interferes with protein degradation (Friedlander 
et al., 2000), and occurs after treatment with MPTP, 6 OHDA and 
rotenone (Ryu et al., 2002). It is known that endoplasmic reticulum 
stress  may,  in  turn,  affect  different  components  of  mitochondrial 
Cytochrome C oxidase leading to mitochondrial dysfunction (Hori et 
al., 2002),  
ii.  mitochondrial dysfunction is an indication of apoptosis and leads to 
cell death (Deckwerth and Johnson, 1993; Vayssiere et al., 1994; 
Petit  et  al.,  1995;  Zamzami  et  al.,  1995  a,b;  Liu  et  al.,  1996; 
Schinder et al., 1996; Susin et al., 1996; White and Reynold, 1996; 
Ellerby  et  al.,  1997),  and  future  studies  could  profitably  examine 
mitochondrial  activity,  for  example,  how  oxidative  stress  due  to 
dopamine, plays an important role in sporadic PD (Mouradian, 2002) 
by  causing  a  degenerative  cascade    in  which  increasing  ROS 
production and an increase in mis folded proteins leads to  impairment 
of  the  ubiquitin proteasome  system,  endoplasmic  reticulum  stress, 
mitochondrial  dysfunction    and  cell  death  (Parker  et  al.,  1989; 
Schapira et al., 1990 a,b; Shoffiner et al., 1991; Mann et al., 1992; 
Martin  et  al.,  1996;  Sheehan  et  al.,  1997;  Bence  et  al.,  2001; 
Nishtoh et al., 2002).  
iii.  Furthermore, loss of parkin (which is an ubiquitin ligase) (Shimura et 
al.,  2000))  leads  to  accumulation  of  parkin  substrate  in  the 
endoplasmic reticulum,  endoplasmic reticulum stress and cell death 
(Imai et al., 2001).  Chapter 5                                                                                         General Discussion 
 
211 
iv.  Other  effects  of  dopamine  and  its  metabolites  lead  to  the  loss  of 
oxidative  phosphorylation  function  and  mitochondrial  swelling  that 
allow the opening of the mitochondrial transition pore (MTP) (Cohen 
et al., 1997; Kim et al., 1999; Berman and Hastings, 1999).  
AS/AGU rats have smaller neurons and less volume than AS (control) rats within the 
SNC (see chapter 3) which may indicate cell shrinkage. One example of cytoplasmic 
shrinkage, together with cell membrane budding and chromatin condensation at the 
nuclear  membrane  is  shown  in  figure  3.7  (page  151).  All  these  features  may  be 
morphological characteristics of apoptosis (Anglade et al., 1997; Jellinger, 2001). 
No signs of necrosis were found in AS/AGU rats. 
 
(4)  How can a mutation in PKC γ lead to a pathological dysfunction 
of dopaminergic and serotonergic systems? 
 
The  PKC  family  is  thought  to  be  involved  in  widely  diverse  functions  including 
modulation of ion channels (Baraban et al., 1985; Madison et al., 1986; Shearman 
et  al.,  1989),  the  desensitization  of  receptors  (Huganir  and  Greenyard,  1990), 
modification  of  neuronal  plasticity  (Routtenberg,  1985;  Akers  et  al.,  1986),  the 
enhancement  of  neurotransmitter  release  (Malenka  et  al.,  1986;  1987),  vesicle 
packaging and release (Tanaka and Nishizuka, 1994; Stevens and Sullivan, 1998) 
and cell surface signal transduction (for review see Nishizuka, 1984 a,b; 1986). 
The  mutation  in  PKC γ  in  the  AS/AGU  rat  must  underlie  dysfunction  of  both 
dopaminergic  and serotonergic systems, although it is unclear whether the mutation 
directly underlies dysfunction of both systems or whether one system is primarily 
affected and the other secondarily. 
Dopamine levels in the striatum are reduced in AS/AGU (mutant) compared to AS 
(control) rats as measured by micropunches and by  microdialysis (Campbell et al., Chapter 5                                                                                         General Discussion 
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1996;  1997;  1998).  The  reduction  of    extracellular  dopamine  (as  measured  using 
microdialysis)  is  greater  than  the  reduction  in  whole  tissue  dopamine  levels  (as 
measured by micropunch) suggesting that the main impairment is in the release rather 
than in synthesis and/or storage, a suggestion which is supported by pharmacological 
interventions (Campbell et al., 2000).  In addition, dopamine metabolites are greatly 
increased  in  the  AS/AGU  (mutant)  rats  (Campbell  et  al.,  1998;  2000).  One 
possibility is that dopamine may be free within the cytoplasm of the nerve terminal 
where it can be metabolized by mitochondrial enzymes such as monoamine oxidase. 
This is a strong possibility given (a) normal or increased TH activity for synthesising 
DA (b) greatly reduced numbers of vesicles in identified DA terminals in the striatum. 
Free dopamine can cause inhibition of the dopamine transporter system (Berman et 
al.,  1996)  as  well  as  being  cytotoxic  through  the  formation  of  dopa quinone 
(Graham,  1978;  Hastings  et  al.,  1996;  Stokes  et  al.,  1999)  or  reactive  oxygen 
species (Cohen et al., 1997).   Like dopamine, serotonin levels are reduced in several 
areas of the striatum as well as in the dorsal raphe nuclei. Extracellular levels in the 
striatum (as measured by microdialysis) are especially reduced, and there is also a 
reduction in serotonin neuron numbers in the DRN by age 12 months while the MRN 
is unaffected (Al Fayez et al., 2005). The level of 5 HT metabolites are also elevated 
in the striatum and midbrain of the AS/AGU (mutant) rats (Al Fayez et al., 2005). If 
this means that, like DA, 5 HT is free in the cytoplasm, it may also be toxic since it  
can be metabolized to toxic dimmers and quinone imines (Perez Reyes and Mason, 
1981). Moreover, the aberrant oxidation of 5 HT is known to occur in conditions such 
as Alzheimer’s disease (Wong et al., 1993).   
The reduction in the number of TH+ve terminals and synaptic vesicles in the caudate 
putamen of AS/AGU mutant rats as seen in Experiment 3 may explain the reduction Chapter 5                                                                                         General Discussion 
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in  the  levels  of  extracellular  dopamine.  This  reduction  is  greater  than  the  loss  of 
dopaminergic  cell  bodies  in  the  SNC  (Payne  et  al.,  2000)  and  suggests  that  the 
reduction in extracellular dopamine in the caudate putamen of AS/AGU mutant rats 
may be due to the failure in dopamine packaging and release. We hypothesize that the 
mutation of PKC γ interferes with this process, because the PKC family are involved 
in  vesicles  packaging  and  release  (Tanaka  and  Nishizuka,  1994;  Stevens  and 
Sullivan, 1998).  
 
Does the AS/AGU rat continue to be a useful model that give insight 
into conditions such as Parkinson’s disease?  
 
The AS/AGU rat  has been suggested as model that gives insight into conditions such 
as Parkinson’s disease (Petzinger and Jankowec, 2003; 2005; Dev et al., 2003b; 
Huang et al., 2004). It is a spontaneous animal model with progressive movement 
disorder and dysfunction of aminergic transmitters release which, together with the 
parent AS control strain, provides a useful model to investigate the factors that lead to 
(or  prevent)  reductions  in  both  dopaminergic  and  serotonergic  function.  Previous 
studies have shown that the agu mutation in the gene coding for PKCγ  affects both 
the dopaminergic and serotonergic nigro striatal systems. The major effects (reduction 
in striatal transmitter release, elevation in metabolite levels and loss of cell numbers in 
the  midbrain)  are  the  same  for  both  systems  and  mimic  characteristics  of  PD 
(Bernheimer  et  al.,  1973;  Jellinger,  1990;  2005;  Hornykiewicz,  1998;  Mizuno, 
2005). In the present study, I show that, whilst the terminals are clearly dysfunctional, 
the cell bodies of DA and 5 HT neurons remain relatively normal at these ages, and 
may well be responsive to depleted DA and 5 HT release. This suggest that the cell 
bodies may be capable of being rescued by an appropriate therapeutic treatment – Chapter 5                                                                                         General Discussion 
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unlike the situation with toxic treatments such as 6 OHDA or MPTP – which gives 
the  AS/AGU  rat  a  positive  advantage.    Nevertheless,  molecules  associated  with 
human Lewy bodies (ubiquitin, parkin and α synuclein) are elevated in the mutant   
even though  inclusion bodies do not occur. This confirms the similarity of the model 
to human PD, but may also give insight into the significance of raised levels.  The size 
of nigrostriatal dopaminergic neuron cell bodies are reduced in AS/AGU mutant rats.  
The number of TH+ve terminals and vesicles are reduced in AS/AGU mutant rats.  
This demonstrates that dysfunction can stem from a reduction in terminal numbers 
and/or  terminal  function  –  and  not  necessarily  from  a  reduction  in  midbrain  cell 
numbers. This is important because cell counts of nigral dopaminergic neurons can 
only be mode post mortem. It thus remains unclear what stage in the course of the 
Parkinson’s disease cell loss has occurred.                                                                                                                               Chapter 6 
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CONCLUSIONS 
Despite  being  unable  to  release  dopamine  and  serotonin  at  striatal  terminals  
(Campbell et al., 1998) dopaminergic cell bodies in the SNC and serotonergic cell 
bodies  in  the  DRN  of    the  AS/AGU  mutant  did  not  show  reduced  TH  or  5 HT 
activity.  Rather,  they  exhibited  enhanced  TH  and  5 HT  activity  compared  to  AS 
controls, suggesting that they were operating a feedback control mechanism.  Whilst 
there was variation in TH  and serotonin activity from cell to cell, this was no greater 
in AS/AGU mutants than in AS controls.   
Lewy body proteins, ubiquitin and parkin, are elevated in the cell bodies of the SNC 
and raphe nuclei of AS/AGU rats and increase with age within the SNC area of both 
AS and AS/AGU rats.  Control areas (such as  oculomotor and pontine nuclei) are 
unaffected. Alpha synuclein does not occur in the cell bodies of the midbrain nuclei, 
but in the surrounding extracellular tissue. It is elevated in the neuropil of the SNC of 
AS/AGU rats but other areas are unaffected.   
AS/AGU (mutant) rats have smaller SNC neurons than AS (control) rats and their 
volume  was  decreased.    However,  within  that  overall  decreased  size,  no  obvious 
ultrastructural morphological differences were seen between the two strains. 
Both the number of TH+ve terminals and the number of vesicles within them were 
decreased within the dorsal caudate putamen of AS/AGU mutant rats aged 3 and 12 
months compared to AS controls. In 12 month AS/AGU mutant rats, there are also 
reductions in the number of non dopaminergic terminals but there is no evidence of a 
reduction at 3 months. There is no evidence that the region closest to the synaptic cleft 
is devoid of vesicles.  
The AS/AGU rat provides a useful spontaneous experimental model for studying 
factors leading to the reduction in dopaminergic and serotonergic function, and for  Chapter 6                                                                                                    Conclusions 
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testing the capability of cell bodies of being rescued by appropriate therapeutic 
treatments. The elevation in levels of Lewy body associated molecules (ubiquitin, 
parkin and alpha synuclein), even without Lewy bodies being present, confirm the 
similarity of the model to human PD. 
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APPENDICES 
 
Appendix1 
 
 
Preparing paraformaldehyde fixative: 
To prepare 1000 ml of 4% paraformaldehyde in 0.1 M phosphate buffer (PB): 
1)  Heat 500 ml of distilled water in a conical flask until water temperature 
reaches 70º C. 
2)  Weigh 40 mg of paraformaldehyde then add to the flask. 
3)  Add concentrated 1% sodium hydroxide solution drop by drop until all is 
dissolved. 
4)  Add 500 ml of 0.2 M PB to make 1000 ml. 
5)  Filter the solution. 
 
Preparing glutaraldehyde fixative: 
To prepare 1000 ml of 3% glutaraldehyde in 0.1 M phosphate buffer (PB): 
1) Add 1000 ml distilled water to a conical flask. 
2)  Measure and add 120 ml of 25% glutaraldehyde to the flask. 
3)  Filter the solution. 
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Preparing a mixture of 1%glutaraldehyde and 4% 
paraformaldehyde fixative: 
 
To prepare 1000 ml of mixture of 1% glutaraldehyde and 4% paraformaldehyde 
1)  Prepare  4% paraformaldehyde using the same procedures as above. 
2)  Add to it  40 ml of 25% glutaraldehyde.  
 
Preparing mammalian  ringer : 
Add the following substances to 1000 ml distilled water: 
1)  Sodium Chloride                                  9g. 
2)  Potassium Chloride                              0.4 g 
3)  Calcium Chloride                                 0.25g 
4)  Magnesium Chloride                           0.005g 
5)  Sodium Hydrogen Carbonate              0.5g 
6)  Sodium Dihydrogen Phosphate           0.05g 
7)  D glucose                                             1g 
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Appendix 2 
 
Histokinette automatic tissue processor and Wax embedding 
1)  Remove the specimens from the fixative. 
2)  Rinse the specimens with 0.1 M PB. 
3)  Label and place the specimens into a Histokinette basket. 
4)  The sequence for the Histokinette is as follows: 
I.  70% ethanol                       (1x2 hours) 
II.  90% ethanol                       (1x2 hours) 
III.  Absolute alcohol                (3x2 hours) 
IV.  Amyl acetate                      (3x2 hours) 
V.  Wax bath                            (2x4 hours) 
5)  Place the specimens into a vacuum embedder for 20 minutes to get rid of air 
that may be present and allow further penetration of wax within the specimens. 
6)  Leave to cool for 30 min before sectioning at 7  m with microtome. 
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Appendix 3 
(A) Staining 
 Toluidine blue Staining 
1) Place slides in histoclear for 10 minutes. 
2) Hydration  
First Absolute Alcohol              1 min 
Second Absolute Alcohol          1 min 
90% Alcohol                              1 min 
70% Alcohol                              2 min 
3) Wash in water. 
4) Place slides in 1% aqueous toluidine blue for 30 seconds. 
5) Wash in water. 
6) Dehydration  
70% Alcohol                             1 min 
90% Alcohol                             1 min 
First Absolute Alcohol              1 min 
Second Absolute Alcohol          2 min 
7)  Place in Histoclear for 10 minutes. 
8)  Mount in Histomount. 
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Appendix 3 
 
(B) Immunocytochemistry on wax sections 
1)  Cut and mount the sections on slides coated with APES. 
2)  Place the slides into a 37º C oven overnight. 
3)  Place the slides into a 56º C oven for 2 hours. 
4)  Boil 1600 ml of 0.01 M sodium citrate buffer (pH 6.0) in a stainless steel 
pressure cooker. 
5)  Position the slides onto metal staining racks and lower into the pressure 
cooker, ensuring the slides are totally immersed in citrate buffer solution, and 
close the lid. 
6)  When the pressure cooker reaches its operating temperature (120º C) and 
pressure (103 kPa/ 15 PSI) (after about 4 minutes) start a timer for 1 minute. 
7)  Remove the pressure cooker from the heat source and run cold water until the 
pressure decreases. 
8)  Place the slides into distilled water. 
9)  Place the slides into PBS (1x5 min). 
10)  Place the sections into 1.5% H2O2 for 10 minutes. 
11)  Rinse the sections in distilled water (2x5 min), followed by PBS (2x5 min). 
12)  Circle the individual sections with a wax pen, cover sections with blocking 
serum for 60 minutes and incubate overnight in primary antibody diluted in 
blocking serum. 
13)  Rinse the sections in PBS (3x5 min).                                                                                                                        Appendices 
 
289 
14)  Incubate the sections in biotinylated secondary antibody for 60 mins. (For a  
fluorescent secondary antibody the sections were incubated for 24 hours, then 
rinsed in distilled water (3x5 mins). Proceed to step 21). 
15)  Rinse the sections in PBS (3x5 min). 
16)  Incubate the sections in ABC complex for 60 mins 
17)  Rinse the sections in PBS (3x5 mins). 
18)  Rinse the sections in 0.1M PB (1x5 mins). 
19)  Incubate in DAB solution for 2 5 mins. 
20)  Rinse the sections in 0.01M PB (2x5 mins). 
21)  Dehydrate, clear and mount. 
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Appendix 4 
Solutions 
1) 0.01M Sodium Citrate buffer (pH 6.0) 
Add 3.84g of Citric acid (anhydrous) to 1.8 L of distilled water. Adjust to pH 6.0 
using concentrated NaOH. Add 200 ml to make up 2 L. 
 
2) 0.01 M Phosphate Buffered Saline (PBS) 
Add 36g NaCl to 200 ml Phosphate buffer and  add 1800 ml distilled water. 
 
3) Phosphate buffer (PB) 
(A) To make 0.2 M PB, Add 17.47g Sodium Dihydrogen Phosphate and 40.75g di 
Sodium hydrogen Phosphate to two litres of distilled water. 
(B) To make 0.1 M PB, add one litre of distilled water to one litre of 0.2 phosphate 
buffer. 
 
4) Blocking serum 
Add 10 l of 1% normal goat serum ( NGS ) to 990  l of 0.3% Triton in PBS. 
 
5) 0.3%Triton X 100 in PBS 
Add 30 l Triton to 10 ml of PBS. 
 
6) Primary antibody in antiserum diluent 
1:500        Add 1 l of primary antibody to 0.5 ml blocking serum. 
1:1000      Add 1 l of primary antibody to 1ml blocking serum. 
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7) Biotinylated secondary antibody 
Add 5 l secondary antibody to 1ml blocking serum. 
 
8) Fluorescent secondary antibody 
Add 1 l secondary antibody to 0.1 ml PBS. 
 
9) ABC Reagent 
Add 20 l reagent A and 20 l reagent B to 1ml PBS. Mix well immediately and allow 
to  stand for at least 30 minutes. 
 
10) DAB Solution 
1) Add 2 drops of Buffer Stock Solution to 0.5 ml of distilled water. Mix well. 
2) Add 4 drops of DAB Stock Solution. Mix well. 
3) Add 2 drops of Hydrogen Peroxide Solution. Mix well. 
4) Add 2 drops of the Nickel Solution (to achieve a gray black staining). Mix well.  
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Appendix 5 
Fluorescence quantification  using Leitz Laborlux S Fluorescence 
microscope (Figure 2) 
 
1) Focus the square on specimen with UV light on. 
2) Press A, adjust display reading to zero with knob JO. 
3) Press I and record value from display.( Note, all values read negative). 
4) Press A once. This resets display. 
5) Press A again, zero should appear in the display. 
6) Focus the square again (Remember to take background readings). 
7) Press I and record new value. 
8) Repeat procedure. 
 
Points to note 
1)  If more sensitivity is required turn from 
                                                                   x1 to x10  
                                                                        or 
                                                                  x10 to x100 
2)  If increased sensitivity is used either (x10 or x100 which is very 
sensitive) than remember that the background reading will also be 
higher. Take new background reading. 
3)  If values are higher than 100 a blank reading shows in the display. 
It is then necessary to decrease sensitivity. 
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Appendix 6 
Processing tissue for Transmission electron microscopy 
1)  Rinse in 0.1 phosphate buffer    (3x5 mins). 
2)  Osmicate with 1% osmium tetroxide in agitator 20 mins . 
3)  Rinse in a distilled water (3x30 mins). 
4)  Dehydrate: 
70% Acetone 15 mins 
90% Acetone 15 mins 
100% Acetone (4x15 mins) 
5)  Mixture of 75% Acetone and 25% Durcupan 2 hours. 
6)  Mixture of 50% Acetone and 50% Durcupan 2 hours. 
7)  Mixture of 25% Acetone and 75% Durcupan 2 hours. 
8)  100% Durcupan overnight. 
9)  100% Durcupan 3 hours. 
10)  Embed in durcupan and leave overnight in oven at 70
oC. 
11)  Stick embedded tissue onto the end of blank embedding block and leave in 
oven at 70
oC for at least 30 mins. 
Durcupan resin 
                       
   1)   Add 10g of Durcupan (Durcupan, ACM Fluka, 44611, Netherlands). 
2)  Add 10g of DDSA (dodecenyl succinic anhydride, R1052, Agar Scientific 
LTD, UK). 
3)  Add 0.3g of DMP 30 (2,4,6 Tri dimethylaminomethyl phenol, R1065, Agar 
Scientific LTD, UK). 
4)  Add 0.3g of Bibutyl Pthalate (R1071, Agar Scientific LTD, UK). 
5)  Mixed and leave for at least 30 min in oven.                                                                                                                        Appendices 
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Appendix 7 
Pre embedding immunocytochemistry 
1) Incubate the sections in blocking solution for 30 minutes. 
2) Rinse the sections in washing buffer for 5 min. 
3) Incubate the sections overnight in primary antibody  in incubation buffer. 
4) Rinse the sections in washing buffer (3x10 min).  
5) Incubate the sections in 1nm goat anti mouse immunogold (1/50) in incubation    
    buffer for 4 hours.                    
6) Rinse the sections in washing buffer (3x15 min) and in PBS (3x5 min). 
7) Postfix the sections with 2% glutaraldehyde in PBS for 10 min. 
8) Rinse the sections in distilled water (2x5 min). 
9) Prepare the silver enhancement solution by mixing equal parts of Enhancer and                
    Initiator of the IntenSE M kit just before use. Apply at least 4 drops of silver  
    enhancement mixture on the sections for 10 15 min. 
10) Rinse the sections in distilled water (3x5 min). 
11) Dehydrate in acetone and embed in Durcupan. 
Solutions 
Blocking solution  
0.8 % Bovine Serum Albumin (BSA), 0.1% gelatin IGSS, 5% normal goat serum 
(NGS) and 2mM NaN3 in PBS (pH 7.4). 
Washing buffer 
0.8 % BSA , 0.1% gelatin IGSS and 2mM NaN3 in PBS (pH 7.4). 
Incubation buffer 
0.8 % BSA , 0.1% gelatin IGSS, 1% NGS and 2mM NaN3 in PBS (pH 7.4).                                                                                                                        Appendices 
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Appendix 8 
The primary antibodies used in immunocytochemistry 
 
Molecules 
 
 
Primary antibody 
 
Types 
 
Concentration 
 
Manufacturer 
 
α synuclein (ASN) 
 
 
Rabbit anti ASN 
 
Polyclonal 
 
1: 100 
* Kind gift from 
Dr.Poul Henning 
 
Parkin 
 
 
Rabbit anti parkin 
 
Polyclonal 
 
       1: 100 
* Kind gift from 
Dr.Poul Henning 
 
Serotonin (5HT) 
 
 
Rabbit anti 5HT 
 
Polyclonal 
 
1: 500 
AFFINITI, 
UK 
 
Tyrosine  hydroxylase 
(TH) 
 
Mouse anti TH 
 
Monoclonal 
 
1:500 
Chemicon 
Europe Ltd 
 
Ubiquitin (Ub) 
 
 
Rabbit anti Ub 
 
Polyclonal 
 
1:500 
 
DAKO Ltd 
* Dr.Poul Henning. Institute of Medical Biochemistry, University of Aarhus, Denmark. 
The secondary antibodies used in immunocytochemistry 
(A) Fluorescence 
 
Secondary antibody 
 
 
Concentration 
 
Fluorescence 
 
Manufacturer 
 
Anti mouse 
 
 
1: 100 
 
Fluorescein (green) 
 
Jackson 
ImmunoResearch 
 
Anti mouse 
 
 
1: 100 
 
Rhodamine (Red) 
 
Jackson 
ImmunoResearch 
 
Anti rabbit 
 
 
1: 100 
 
Fluorescein (green) 
 
Jackson 
ImmunoResearch 
 
Anti rabbit 
 
 
1: 100 
 
Rhodamine (Red) 
 
Jackson 
ImmunoResearch 
(b) Biotinylated 
Secondary antibody 
 
Concentration  Manufacturer 
 
Anti mouse 
 
 
1: 200 
 
Vector Laboratories 
 
Anti rabbit 
 
 
1: 200 
 
Jackson ImmunoResearch 
 